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Abstract 
Children in areas of highly seasonal malaria transmission in the Sahel should receive SMC 
with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ). These drugs retain their efficacy 
in the areas where SMC is recommended, but alternative regimens are needed if SMC is used 
in other areas or if these drugs start to lose efficacy. The aim of this study was to investigate 
the suitability of dihydroartemisin-piperaquine (DHAPQ) for SMC, using a non-inferiority 
trial design. 1500 children randomized to receive SPAQ or DHAPQ monthly from August to 
October, and a cohort of untreated children outside the trial, were followed-up for malaria. 
SPAQ was more efficacious than DHAPQ, but the difference was within the margin set for 
non-inferiority. Both regimens gave a very high level of protection lasting 4 weeks. 
Protection was related to dosage. Both regimens were well tolerated, incidence of mild 
adverse events decreased in successive months, consistent with toleration to study drugs.  In 
malaria cases, the frequency of the CVIET haplotype of pfcrt, the 86Y polymorphism of 
pfmdr1, and pfdhfr59 and dhps437 mutations, was greater among children who received 
SPAQ than in untreated children. However the number of cases, and the prevalence of 
parasitaemia, was much lower in treated children, reducing the scope for SMC to select for 
resistance. The frequency of the CVIET haplotype of PfCRT, thought to be associated with 
resistance to PQ, was not increased in children treated with DHAPQ. There was an enormous 
burden of malaria in the untreated children. SMC with SPAQ should be introduced for 
children in Burkina Faso without delay. DHAPQ is a potential alternative regimen in areas 
where SPAQ cannot be used but there are some drawbacks associated with its use. There is a 
need to develop alternative long-acting drugs with simple regimens that can be used for 
chemoprevention of malaria.  
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Chapter 1 Introduction 
Seasonal Malaria Chemoprevention (SMC) is now recommended by WHO, in areas of 
seasonal transmission in the Sahel children should receive sulfadoxine-pyrimethamine plus 
amodiaquine (SPAQ) each month, to protect them from malaria. These drugs remain effective 
in the areas where SMC is recommended, but other regimens may be required, both for use 
for SMC in other parts of Africa with seasonal malaria but where there is resistance to SP, 
and in the Sahel if SPAQ starts to lose efficacy due to resistance. The relatively long half-life 
of piperaquine makes dihydroartemsinin-piperaquine (DHAPQ), a potentially good choice for 
SMC.The purpose of this study was to investigate the suitability of DHAPQ for SMC.  
 
1.1 Malaria in Sub Saharan Africa 
Despite more than 100 years of research since the discovery of the malaria parasite in human 
blood by Charles Laveran in 1880 and the establishment of the mosquito’s role in the 
transmission of malaria by Sir Ronald Ross in 1898, malaria continues to be a threat for the 
Sub-Saharan Africa population (Raghavendra et al., 2011). A precise estimation of the burden 
of the disease cannot be made but according to the world malaria report for 2012 there were 
216 million (95% credible interval 149-274) cases of clinical malaria in 2011 of whom 81% 
or 174 million cases occurred in the African region. Approximately 655 000 malaria deaths 
occurred in 2011 of which 91% or 596 050 were in the African region; deaths in children less 
than 5 years old accounted for 86% of the estimated deaths. To face this unacceptably high 
burden of malaria in the world and mainly in Sub Saharan Africa, more attention has been 
paid to the disease in the 21st century than previously, with much more political and social 
support. Different approaches have been proposed and the best strategy has been subject to 
debate. It has been argued that malaria could be defeated through progressive and integrative 
activities including health infrastructure strengthening, training of qualified staff, improved 
access to diagnosis and treatment, environmental management, and improvement of 
economic conditions. Those opposed to this approach argue that it is too slow and that larger-
scale more aggressive and formal programmes are required in order to quickly prevent and 
eradicate malaria from the world. 
 
1.2 The historical malaria eradication program 
Eradication is defined as the permanent reduction to zero of the worldwide incidence of an 
infectious organism as a result of deliberate efforts (Enayati and Hemingway, 2010). The 
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commitment seen in the 20
th
 century nourished the hope that malaria could be eradicated 
through a comprehensive program. This program relied heavily on the use of 
DichloroDiphenylTrichloroethane (DDT) for Indoor Residual Spraying (IRS) between 1957 
and 1969, and Mass Drug Administration (MDA). Substantial progress was made with IRS: a 
reduction by 50% of the total population at risk by 1975 and a dramatic decrease in the 
mortality rate from 19.4 per 10 000 in 1900 to 1.61 per 10 000 in 1975. Despite these initial 
successes, serious technical, financial and logistic issues led to the failure of this strategy, and 
prevented it ever reaching tropical Africa.  
MDA is defined as the administration of a full therapeutic dose of an antimalarial regimen to 
an entire population or well defined sub-population at the same time. The strategy was 
initiated in the 1930’s and endorsed by the World Health Organization in the 1950’s as an 
additional tool to replace failing strategies (WHO, 1951). MDA in conjunction with other 
control measures was successful in a number of situations: MDA with sulfalene-
pyrimethamine combined with IRS achieved high level of efficacy in the Garki project in the 
Northern Nigeria in 1969 (Molineaux, 1980), but did not interrupt transmission. MDA works 
through the reduction of the prevalence of peripheral parasitaemia and the reduction of 
transmission via the inhibition of the liver or asexual intra erythrocytic stages of the parasite, 
the direct action on the gametocytes or a sporonticidal effect and the inhibition of the 
sporogonic cycle in the mosquitoes. Considering the short-lasting benefit of MDA one 
modification has been to repeat drug administration, the precursor to the development of 
Intermittent Preventive Therapy. More than four decades later, malaria eradication is back on 
the global health agenda, and was discussed at the 2007 Malaria Forum. Recently large and 
rapid scale-up of effective malaria control interventions has led to a consequent reduction in 
the number of malaria cases and deaths in some areas. It is hoped that with this encouraging 
evidence, with currently available tools, malaria can be better controlled, and even eliminated 
at least in some countries and regions. However, a broad consensus also exists that new tools 
focused specifically on the interruption of transmission need to be developed if malaria 
eradication is to be eventually achieved. While investigating new tools and exploring new 
strategies, in areas where the disease is still of high burden the most realistic approach 
probably relies on programs that aim to control rather than eliminate malaria. 
 
1.3 Malaria control programmes 
Malaria control has three main components: vector control, which aims to prevent contact 
with mosquitoes; chemotherapy if infectious contact happens and results in a clinical case; 
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and finally chemoprevention to prevent new cases and to contain current infection from 
further development to a clinical case. 
 
1.3.1 Vector control 
Vector control is a key part of the strategies to prevent and reduce the burden of malaria in 
endemic countries, by reducing transmission. It has been endorsed by WHO and the RBM 
partnership. The WHO Study Group on Vector Control for Malaria and other Mosquito-borne 
Diseases defined selective vector control as the application of targeted, site-specific control 
activities that are cost-effective (WHO, 1995). Vector control measures aim to prevent 
physical contact with the vectors and include Insecticide Treated Nets (ITNs) or Long Lasting 
Insecticide-Treated Nets (LLINs), and Indoor Residual Spraying (IRS). 
1.3.1.1 Insecticide Treated Bed Nets (ITNs) 
The Roll Back Malaria strategy relies mainly on the use of the ITNs which has shown to 
reduce all causes mortality in children less than 5 years old by a mean of 17% in the first year 
of their implementation (Reyburn et al., 2005). Studies on the efficacy of ITNs have showed a 
positive impact on entomological parameters (Lengeler, 2000). Report from key studies 
(Bradley et al., 1986) in the Gambia and in 1991 by Alonso and colleagues (Alonso et al., 
1991) showing a negative association of ITN use with mortality placed a real hope in the use 
the insecticide treated bed nets. Despite this proven efficacy, the achievement of widespread 
use has been difficult because of sociologic or financial barriers or insufficiency of the 
provision. Recent considerable effort has been made to make the ITNs – LLINs available to 
those who need it: The ITNs were distributed free of charge to pregnant women and children 
less than 5 years old during the antenatal care and during the EPI vaccination and large 
campaign of distribution free of charge by the national malaria control program or at a 
subsidized price by other donors like NGOs has permitted a high level of ITNs ownership 
(more than 80% of household in 2011) in Burkina Faso according the world malaria report in 
2011.The treated bed nets are effective on the female mosquitoes attracted by the human 
seeking for blood while those resting on the walls are better captured through the treatment of 
these surfaces. 
1.3.1.2 Indoor Residual Spraying (IRS) 
IRS is one of the operational interventions which are effective in reducing the transmission of 
malaria. A stable formulation of insecticide is applied to the insides of houses to kill the 
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female resting adult mosquitoes (Enayati and Hemingway, 2010). IRS with DDT was used in 
the 1940’s by several national malaria control programmes during the global malaria 
elimination period from 1957 to 1969 (Erlanger et al., 2004). IRS with propoxur was used 
effectively in the Nigerian Garki project, complemented by MDA (Molineaux, 1980). IRS 
requires well-known epidemiology of malaria in the area, requires good logistics and a well 
trained staff, rendering this strategy unlikely to achieve sustainable results on a large scale. 
Other innovative vector control strategies are therefore needed to complement the ITNs use 
and the IRS. Innovative vector control strategies include the development of transgenic 
mosquitoes those are refractory to malaria infection, the use of Wolbachia strains to shorten 
the life span of mosquitoes, and the use of repellents and attractants. 
 
1.3.2 Chemotherapy 
1.3.2.1 Treatment of clinical malaria 
The prompt diagnosis and rapid treatment of clinical malaria is a keystone of malaria control 
strategies.  Different classes of drug have been synthesised. For decades, chemotherapy and 
prevention of malaria relied on chloroquine (CQ) which as the other amino-4-quinoleines 
targets the food vacuole of the parasite and blocks the heme metabolism. Chloroquine has the 
advantage of easy use and is well accepted despite the bitter taste of the tablets. However, 
resistant strains which appeared spread quickly rendering chloroquine no longer effective to 
treat malaria (Sirima et al., 2003, Tinto et al., 2002, Guiguemde et al., 1994, SO:, 2000, 
Gansané A, 2005); Amodiaquine was considered as a replacement for CQ in cases of poor 
tolerability to CQ (cutaneous side effects were less common), but seems to be less well-
tolerated. At the same time, sulfadoxine-pyrimethamine the second line treatment of 
uncomplicated falciparum malaria remains effective but its routine use as monotherapy has 
accelerated the spread of resistance. The global consequence is the widespread of the 
resistance to these “old” well-tolerated drugs (Sirima et al., 2003, Tinto et al., 2002, 
Guiguemde et al., 1994, SO:, 2000, Gansané A, 2005 , Korenromp et al., 2003, EANMAT, 
2003). In the face of the failing drugs, the malaria community sought viable alternatives. The 
idea of combination therapy has emerged arguing the same rationale behind the treatment of 
conditions like the tuberculosis and the HIV aids (Attaran et al., 2004). In the 1990’s 
combination therapy using artemisinin derivatives was advocated by the World Health 
Organization, which pushed national malaria control programmes to adopt these new 
combinations in their treatment policy (Attaran et al., 2004). The management of clinical 
malaria should be based on one of the recommended artemisinin combinations: Artemether-
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Lumefantrine, Artesunate-Amodiaquine, Artesunate-Mefloquine, Artesunate-Sulfadoxine-
Pyrimethamine and more recently Dihydroartemisinin-Piperaquine (WHO, 
http://www.who.int/malaria/publications/atoz/who_apt_position.pdf (accessed 11 Jan 2013)). 
These drug combinations have been extensively evaluated in Africa (Abdulla et al., 2008, 
Adjuik et al., 2004, Agomo et al., 2008, Arinaitwe et al., 2009, Ashley et al., 2005, Bassat et 
al., 2009, Bukirwa et al., 2006, Zongo et al., 2007b, Karema et al., 2006, Faye et al., 2012, 
Abuaku et al., 2012) and Asia (Karunajeewa et al., 2004, De la Hoz Restrepo et al., 2012, 
Myint et al., 2007, Karunajeewa et al., 2008b, Hasugian et al., 2007) where they achieved a 
high level of efficacy with a good tolerability profile. However the hope born with this new 
class of drugs for the control of malaria is waning with the detection of foci in the Thai-
Cambodian borders where parasites have become tolerant and less sensitive and even 
resistant to the artemisinin derivatives (Lim et al., 2009, Na-Bangchang et al., 2010, Noedl et 
al., 2010, Yeung et al., 2009). The way forward that has been proposed is the containment of 
the foci of resistance while investigating additional strategies including innovative vector 
control strategies, the development of a malaria vaccine, and chemoprevention. 
 
1.3.3 Chemoprevention of malaria 
Anti-malarial drugs have been used in different ways to prevent the occurrence of malaria in 
the populations living in the endemic countries for nearly 100 years. The objective of the use 
of drugs for prevention was originally to interrupt transmission, this has failed but the 
administration of anti-malarial drugs has often resulted in a marked reduction in the 
prevalence of malaria and the incidence of clinical attacks (Greenwood, 2004). As a result of 
lessons learnt about the difficulties of sustainability, strong drug pressure, impairment of 
natural immunity, the cost and safety issues of the use of drugs for prevention, the strategy 
has evolved from the MDA, targeting a whole population at one point in time, to 
chemoprophylaxis, and then to Intermittent Preventive Treatment protect vulnerable groups 
from clinical malaria. Intermittent Preventive Treatment (IPT) of malaria involves 
administration of full therapeutic doses of drug at specified points in time to persons at risk 
irrespective of their parasitological status. As with chemoprophylaxis, IPT was initially 
investigated in pregnant women (IPTp), and subsequently in infants (IPTi) and in older 
children. 
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1.3.3.1 Intermittent preventive treatment in pregnancy (IPTp) 
The difficulty of sustaining chemoprophylaxis in pregnant women led Schultz and colleagues 
to initiate the first Intermittent Preventive Treatment trial in pregnant women in Malawi 
(Schultz et al., 1994). This study compared the efficacy of weekly chemoprophylaxis with 
chloroquine with intermittent administration of sulfadoxine-pyrimethamine, given twice 
during the pregnancy. They reported a reduced proportion of low birth weight babies in the 
group who received the SP twice during the pregnancy, results which were subsequently 
confirmed in large trials in Malawi (Rogerson et al., 2000) and Kenya (Shulman et al., 1999). 
Based on this somewhat limited evidence, the World Health Organization recommended the 
use of two doses of SP during pregnancy (one dose after quickening and one dose in the third 
trimester). Further studies demonstrated the efficacy of SP twice during pregnancy in 
reducing the incidence of malaria episodes, the incidence of malaria-related anaemia and the 
frequency of low birth weight (Kayentao et al., 2005, Diakite et al., 2011). Subsequently the 
concept has been applied to infancy who like pregnancy women represent a particularly 
vulnerable group that bears a high burden of malaria clinical episodes and mortality 
especially in areas where the transmission of malaria is intense and year-round.  
1.3.3.2 Intermittent preventive treatment in infant (IPTi) 
The first of these studies were undertaken in Tanzania where full doses of sulfadoxine-
pyrimethamine (Schellenberg et al., 2001) or amodiaquine (Massaga et al., 2003) were given 
during the first year of life. These studies reported a reduction in the incidence of clinical 
attacks of malaria and of severe anaemia, and no rebound effect was seen in the infants who 
received the SP the year following the discontinuation of the intervention. The findings of 
these preliminary studies were consolidated by trials in Gabon (Grobusch et al., 2007), Ghana 
(Chandramohan et al., 2005, Mockenhaupt et al., 2007, Kobbe et al., 2007a, Kobbe et al., 
2007b) and Mozambique (Macete et al., 2006). A consortium was established to address the 
outstanding issues surrounding the use of Intermittent Preventive Treatment of malaria in 
infants and to advocate for its recommendation by the World Health Organisation as a tool for 
malaria control in endemic areas where SP is still effective. IPTi eventually became a WHO 
recommendation (WHO, 2010), although it has yet to be implemented on a large scale. The 
delivery of IPTi is achieved through the Expanded Program of Immunisation (EPI), when 
children come for their routine vaccinations, a consequence of this is that the interval between 
successive treatments is not consistent with the known half-life (28 days) of sulfadoxine-
pyrimethamine, so protection lapses. To optimize the protective benefit a different method of 
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delivery is required.  This strategy targeting infants is justified in areas of high and year-
round transmission, where the burden of malaria in term of incidence of clinical malaria, 
proportion of deaths and severe anaemia, is borne by this age group. In areas where the 
epidemiology of malaria is different, the picture is not similar. Epidemiological data support 
that in areas of short intense seasonal transmission of malaria, the weight of the disease is 
borne by age groups extending beyond infancy (Becher et al., 2008), IPTi in these settings 
can make only a limited impact on the overall burden of children. Extending the age range up 
to 5 years to cover all those at high risk during the childhood in these areas, termed as  
Intermittent Preventive Treatment of malaria in children (IPTc), was subsequently proposed, 
and its restriction to the high transmission period in areas of seasonal transmission led to the 
term Seasonal Intermittent Preventive Treatment of malaria in children, sIPTc. 
 
1.3.3.3 Seasonal Intermittent preventive treatment of malaria in children sIPTc 
A randomized trial was conducted in Senegal to explore if the IPTi concept could be applied 
to older children (Cisse et al., 2006). This preliminary study and subsequent studies will be  
reviewed in the first part of the literature review section in chapter 2. sIPTc was developed  
specifically for the epidemiology characteristics of malaria transmission in the countries of 
the Sahel and Sub-Sahel located mainly in West Africa. sIPTc was later renamed Seasonal 
Chemoprevention of Malaria (SMC), in order to make a clear distinction between the use of 
drugs for prevention and for treatment, the latter being always based on a positive 
parasitological diagnosis. Burkina Faso is one of the countries of the Sahel suited to the SMC 
strategy.  
 
1.4 Burkina Faso and the study site 
1.4.1 Geography 
Burkina Faso is a Sahelian country located in the heart of Western Africa and covering a 
surface of 274400 km
2
. The country is located between 3° longitude East, 6° longitude West, 
the parallel 9° and 15° of latitude North.  Burkina Faso shares borders in the North and West 
with Mali, in the North East with Niger, in the South East with Benin and the South with 
Ghana, Ivory Coast and Togo. The capital city is Ouagadougou.  
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1.4.2 Demography 
The latest census of the population of Burkina Faso reported 14 017 262 inhabitants in 2006 
(RGPH 2006). One third of the population in Burkina Faso is less than 10 years old and 
almost half of the population is 15 years old or less (figure 1.1). 
 
Figure 1-1: Age structure of the population in Burkina Faso from 1975 to 2006 
 
1.4.3 Climate 
The country is characterised by a tropical climate, Sahelian in the North and Sudanese in the 
South. There are two distinct seasons: The rainy season lasts 5-6 months (May to October) 
and the dry season over 6 months from November to April. Rainfall varies from 1200 mm per 
year in the South to 600 mm per year in the North. The highest temperatures (40°-45°) are 
recorded between March and June while the lowest are seen in December and January. Based 
on these factors, the country is approximately divided into three different zones: 
- The Sudanese zone in the South, the rainy season lasts 6 months 
- The Sudano – Sahelian zone in the central region with 4-5 months of rain 
- And the Sahel zone where the rainy season lasts only 2 months. 
 
1.4.4 Economy 
The economy of Burkina Faso relies on farming and agriculture; more than 85% of the 
population lives on cultivation and livestock farming. Cotton is the main crop. According to 
the latest report of the UNDP (for the year 2012), Burkina Faso is classified as the 183 less 
developed country over 187 countries. 
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1.4.5 Malaria in Burkina Faso 
1.4.5.1 Epidemiology and the burden of malaria in Burkina Faso 
 
Figure 1.2 Percentage of consultations, hospital admissions and hospital deaths attributed to 
malaria in Burkina Faso 2006-2010. 
 
Over the five years 2006-2010, reported malaria remained a significant cause of consultation 
in the health districts. In 2010 reported malaria accounted for almost half of the reasons for 
care seeking in health centres. The same trend was observed for hospital admissions; more 
than one admission in two was attributed to malaria between 2008 and 2010 (figure 1.2). 
More recently, in 2012, 46% of causes of care seeking were attributed to malaria with 52% of 
hospital admissions and 37% of deaths. 
 
1.4.5.2 Malaria transmission in Burkina Faso 
Burkina Faso, as many countries of the Sahel, is characterised by high seasonality of malaria 
transmission (figure 1.3); the conjunction of the climate and temperature conditions 
determine different durations of the transmission season through the country. Thompson and 
colleagues developed a tool which estimates the suitability for malaria transmission based on 
climatic variables (temperature and humidity and rainfall), and using 50 years of climatic data 
determines the probability that transmission could occur in each calendar month. Using this 
tool, maps of the country based on the seasonal climatological suitability for malaria 
transmission in Burkina Faso were produced (Fig 1.3). 
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Figure 1.3: Percent occurrence of climate conditions suitable for malaria transmission 
in Burkina Faso 
 
1.4.5.3 Malaria species, vectors and entomological inoculation rate 
The main malaria species are Plasmodium falciparum, responsible for over 90% of malaria 
cases, Plasmodium ovalae (0.5-2%) and Plasmodium malaria (3-8%). Anopheles gambiae s.l. 
and An. funestus are the common malaria transmission vectors. An exophilic abundant 
subgroup of Anopheles gambiae highly susceptible to infection with wild Plasmodium 
falciparum has been recently described (Riehle et al., 2011). Estimates of the annual 
entomological inoculation rate range from 7.7 infective bites per person per year in 
Ouagadougou (the capital city) and 113 in the rural area in 1984, to up to 697 infective bites 
per man per year in Bama in 1999 (Baldet et al., 2003). A more sensitive method was used in 
1999 but the rainfall and practices favourable to the vector in Bama area helped to explain the 
large difference in the estimates.  
 
1.4.5.4 Malaria control in Burkina Faso 
Early diagnosis and prompt treatment of malaria with effective antimalarial drugs is the main 
strategy for malaria control in Burkina Faso. Since 2005, artemether-lumefantrine and 
artesunate-amodiaquine over three days have been the first-line therapies for uncomplicated 
Source: http://iridl.ldeo.columbia.edu/maproom/.Health/.Regional/.Africa/.Malaria/.CSMT/  
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malaria; severe cases are treated with either intravenous quinine or arthemether. Other 
strategies include insecticide treated bed-nets distributed free of charge to pregnant women 
alongside antenatal care, and Intermittent Preventive Treatment of malaria in pregnancy with 
two doses of SP in the second and third trimester. IPTi has been adopted as policy but is not 
yet implemented.  
 
1.4.5.5 Use of antimalarial drugs and antimalarial drug resistance in Burkina Faso 
Chloroquine (CQ) was introduced for malaria chemoprophylaxis in the 1970s for children 
under 5 years old and pregnant women. In 1979, chloroquine was used at 10 mg per kg body 
weight to treat presumptive cases of malaria (NMCP, 2011). The detection of the first cases 
of resistance prompted the National Malaria Control Program (NMCP) to increase the dose of 
chloroquine for malaria management to 25 mg per kg. Following the detection of the first 
case of CQ resistant Plasmodium falciparum, sulfadoxine-pyrimethamine (SP) was 
introduced as an alternative to CQ, and amodiaquine (AQ) was used in cases of poor 
tolerability to CQ. Despite its bitter taste, CQ was universally used while the use of SP 
remained limited. The prevalence of resistance to CQ increased to 16% in-vivo in 1990. 
Surprisingly this resistance remained low at 14% in the region of Bobo-Dioulasso between 
1988 and 1991 and only two cases of in-vivo resistance to SP were recorded (Guiguemde et 
al., 1994). Subsequent monitoring data from the NMCP have reported a significant increase 
in the CQ failure rate from 27% to 63% in 2003 and that of SP to 10% (NMCP, 2011). 
Clinical trial data reported 9.1% failure with SP and 18% with AQ in 2005 from Bobo-
Dioulasso (Zongo et al., 2005). At a consensus meeting held in February 2005, mono 
therapies with CQ, AQ and SP were removed from clinical malaria treatment and replaced 
with the more effective ACT drugs (NMCP, 2005). This meeting adopted IPTp with two 
doses of SP in pregnancy. Despite the implementation of several strategies (diagnosis and 
treatment, use of insecticide treated bed-nets), the prevalence and incidence of malaria 
remains high according to the latest statistics reported from the Ministry of Health (Ministère 
de la Santé, 2012). In this context, it is anticipated that the new strategy of SMC could have a 
substantial impact. An estimation of the population likely to benefit and the magnitude of the 
reduction of the cases (clinical cases, deaths, severe anaemia) was made in order to contribute 
to the evidence considered by policy makers that SMC is relevant for malaria burden 
reduction among Burkina Faso’s population. 
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1.4.5.6 Areas where SMC might be of benefit: Population at risk 
The estimate of the population in Burkina Faso by the National Demographic and Statistics 
Institute in the middle of 2009 and reported in the annual health statistics for 2009 released by 
the Ministry of Health was 15,224,780 inhabitants of whom 19% were children under five 
years old (Ministry of Health, 2010). Based on these statistics and the approximate 
delimitation of the country into three transmission zones, we estimated that 16% of the under 
5 years population live in the short transmission zone, 61% in the moderate long transmission 
zone and 23% in long transmission area (rural and urban areas combined). This gives an 
indication of the number of children that might benefit from IPTc (table 1.1).  
Table 1.1: Population at risk in different malaria transmission zones 
Malaria transmission pattern < 5 years old General population 
Short transmission season (< 3 months) 470,733 2,321,619 
Moderate length transmission season (3 – 4 months) 1,786,641 9,330,125 
Long transmission season (> 6 months) 656,981 3,573,036 
Total 2,914,355 15,224,780 
 
1.4.5.7 Potential impact of SMC 
In the statistics provided by the Ministry of Health in 2011 malaria (uncomplicated and 
severe malaria) was the leading cause of morbidity and mortality, accounting for 48% of all 
oupatient attendances, 63% of hospital admissions and 71% of hospital deaths in children 
under five years old (Ministère de la Santé, 2010). However, almost all malaria cases are 
unconfirmed despite recent improvements in diagnostic services. The only reliable 
information about the malaria burden comes from research studies. The incidence of malaria 
in the control group of the IPTc trial in Bousse, in the Sahelian zone (Konate et al., 2011) was 
1232 episodes (of which 982 episodes were with a parasite density of 5000/µL or more) 
among 1500 children under 5 years of age who were followed for one transmission season 
and all of whom were using an insecticide treated bed-net (ITN). With a total population of 
about 3 million children under 5yrs in the country, if only 50% of these are exposed to this 
level of malaria risk, this would be a total of 982,000 cases with high parasite density and 
1,232,000 cases with any parasitaemia each year among children under 5 yrs. If even 60% 
coverage of seasonal IPT could be achieved at each monthly round, with an efficacy of 85% 
for one month after each dose, then half of these cases (0.6x0.85=0.51) could be prevented. 
Burkina Faso appears therefore to be suitable for a seasonally targeted form of malaria 
control. 
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Chapter 2 Literature review 
The concept of seasonal chemoprevention of malaria (SMC) was developed to retain the 
advantages of chemoprophylaxis while minimising some potential drawbacks. It is limited to 
a short period of transmission each year, thereby limiting intake of drugs, and is restricted to a 
particular age range (children under 5 years of age), which may limit the scope for selection 
for drug resistance. The first section of this review focuses on the efficacy and clinical 
tolerability of the drugs used, next evidence relating to safety and tolerability is considered, 
followed by pharmacokinetic data and the duration of protection with different regimens 
based on data are from therapeutic studies (treatment of clinical cases), which give an 
indication of the duration of protection when these drugs are used in the context of the SMC. 
Finally the key known molecular markers mediating the resistance to the anti-folate drugs and 
amodiaquine are reviewed. At the end of each section, a brief summary of the research 
questions that this thesis aims to address is presented. 
 
2.1 Overall efficacy and tolerability of SMC 
A review and meta-analysis (Wilson, 2011) from a series of studies evaluating the efficacy, 
safety and tolerability of different drug regimens for SMC showed that the strategy is safe and 
has the potential to avert a substantial proportion of incident cases of malaria and of severe 
anaemia and death: the pooled estimate of the efficacy of monthly SMC against 
uncomplicated malaria was 80%. Evidence for an effect on mortality is less clear, the studies 
were not designed to estimate such effects, but the results did not rule out a substantial 
benefit. Subsequently a WHO GRADES assessment found that monthly SMC can avert 75% 
of malaria cases both uncomplicated and severe, and found that a reduction in the risk of 
death would be consistent with the high quality evidence of a reduction in severe malaria but 
there were too few deaths in these trials to evaluate effects of SMC on mortality. 
The first of the trials was conducted in Mali (Dicko et al., 2008). Two hundred and sixty two 
children 6 months to 10 years were randomized in Kambila to receive SP (monotherapy 
twice) or a placebo eight weeks apart in the 2002 malaria transmission season and followed 
up for 12 months and the subsequent transmission season of 2003. Over 12 months follow up, 
the age-adjusted protective efficacy was 43%; [95% CI 29% to 54%] and 68%; [95% CI 
55%-77%] when the follow up was restricted to 16 weeks. In the subsequent year (2003 
transmission season), when no intervention was given, the incidence of malaria was similar in 
the two groups. The intervention was safe and there was no evidence of a rebound effect after 
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one year of intervention. The benefit was moderate and the contribution of this intervention to 
the growth of SP related molecular markers (which could wane the clinical benefit) was not 
assessed; the protective efficacy could potentially be improved by a more effective drug 
regimen given on more frequent basis, it would also be important to assess the impact on drug 
resistance assessed at the end of the transmission season. To address these issues, in Senegal 
in 2002 one dose of artesunate plus one dose of SP or two placebos were given monthly to 
1136 children aged 2 to 59 months over three months, the children were then followed up for 
13 weeks. The primary outcome was the incidence of malaria in the cohorts (Cisse et al., 
2006). The intervention achieved a very high level of protection, 86% [95% CI 80%-90%] 
and the treatment was well tolerated. This study reported evidence of a high degree of 
selection of resistant parasites, carrying mutations associated with resistance to SP, although 
the authors stated the study was not designed to assess this effect. At the end of the 
intervention, there was a significant increase in the prevalence of pfdhfr mutations +20% 
[95% CI 10%-30%] and in the pfdhps mutations +42% [95% CI 25%-58%] among children 
who were parasitaemic at the end of the transmission season. This was a worrying finding and 
may reflect the fact that the combination of SP+AS exposes parasites to monotherapy with SP 
as AS is eliminated within a few hours. While the authors stated that firm conclusions could 
not be drawn, the trend of selection for resistance if confirmed would make SP alone or SP 
combined with artesunate not suitable for SMC and more suitable regimens should be 
investigated. 
 
In 2005 Kweku et al. (Kweku et al., 2008) compared the efficacy in Ghanaian children of 
SMC with either artesunate+amodiaquine monthly or bimonthly, or SP bimonthly, with a 
placebo. The incidence of clinical malaria and anaemia were the main endpoints. A total of 
2451 children 3-59 months from 30 villages were recruited and followed up for a 6 months 
period. The protective efficacy was low, 17% [95% CI 6.3%-27%] and 24% [95% CI 14%-
33%] in the bimonthly AS+AQ and bimonthly SP groups respectively and up to 69% [95% 
CI 63%-74%] in the monthly AS+AQ group. The protection from malaria anaemia was 
significantly better in the monthly AS+AQ group 82% [95% CI 54%-93%]. Adverse drug 
reactions were similar in the intervention groups. In this report, no formal assessment was 
done for the selection of resistant parasite which would be particularly relevant in view of the 
low protective efficacy. Furthermore, the limited efficacy in the bimonthly and short-acting 
combination regimens might be improved by using more frequent or longer-acting drug 
regimens.   
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Following the lessons learnt from the first study experience, scientists from Senegal repeated 
in 2008 a similar design of trial with more drug regimen options (Sokhna et al., 2008). One 
dose of SP was associated with either one dose of artesunate (1AS+SP), three doses of 
artesunate (3AS+SP), three doses of amodiaquine (3AQ+SP) or one combination without SP, 
(3AQ+3AS). A total of 2102 children were randomly allocated to one of these four 
combinations, and treated for three consecutive months over one transmission season. The 
primary outcome was the incidence of clinical malaria. Three daily doses of artesunate 
combined with SP were more effective than one dose of artesunate combined with SP, 
incidence of clinical malaria was 10% with 1AS+SP and 9% with 3AS+SP, but combining 
three doses of amodiaquine to three doses of artesunate was less effective (11%) in 
preventing clinical malaria and in reducing the prevalence of parasitemia at the end of the 
transmission season. The combination of three doses of amodiaquine with SP outperformed 
the three other regimens, with only 5% of incidence of clinical malaria, hazard ratio 0.50 
[95% CI 0.30-0.81]. The outstanding clinical efficacy of SPAQ was offset by two other 
findings: 
- The report of adverse events. A substantial number of children experienced at least one 
adverse event, 32% [95% CI 28-36%], more than for the other regimens; over 10% of these 
children vomited or presented with fever. Tolerability is of particular relevance in the context 
of chemoprevention where drugs will be given to healthy children, poor tolerability may limit 
adherence and such regimens may be poorly accepted by mothers and the community. 
- The prevalence of molecular markers associated with resistance to sulfadoxine and 
pyrimethamine among parasitaemic children was higher at the end of the transmission season 
than at the beginning. It is important to consider this finding in relation to the overall 
prevalence of parasitaemia. The prevalence of parasitaemia at the end of the transmission 
season was reduced by SMC with SPAQ, so that although all the positive children in the 
SPAQ group carried the triple mutation associated with resistance to SP, the overall 
prevalence of resistant parasites was lower in children who received SPAQ than in the 
placebo group. Nevertheless, in terms of transmission of the resistant parasites, even though 
fewer children carried resistant strains, the probability of recombination with sensitive strains 
is reduced by the elimination of sensitive strains within infected children.  
Two further studies were conducted in 2007 in Senegal and in The Gambia. The design was 
different in the two studies, individually randomized in the Gambia and cluster randomized in 
Senegal. 1893 children 3-59 months were enrolled in Senegal (Cisse et al., 2009) and 1008 
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children 6-59 months in the Gambia (Bojang et al., 2010). The children were treated with 
either SPAQ, or SP+piperaquine (SP+PQ), or dihydroartemisinin-piperaquine (DHAPQ). 
Three courses of treatment were given over three months and the follow up lasted for one 
transmission season. All regimens were highly effective. In The Gambia, the overall 
incidence of malaria was 0.22 per child per year [95% CI 0.15-0.28] and no child experienced 
more than one episode. The incidence rate of malaria (any parasitemia) was respectively 0.79 
[95% CI 0.57-1.07], 0.06 [95% CI 0.02-0.15], 0.10 [95% CI 0.04-0.21] and 0.06 [95% CI 
0.02-0.15] in the control, the SPAQ, the DHAPQ and the SP+PQ groups. The overall 
tolerability profile was excellent. In Senegal the incidence rate of malaria (intention to treat) 
of any parasitemia was 5.4%, 5.3% and 3.4% respectively for SPAQ, DHAPQ and SP+PQ 
treatment regimens. No serious adverse event was reported, but vomiting was more common 
in the children treated with SPAQ. While the report in The Gambia study did not assess the 
carriage of drug-resistant parasites (due to the very low prevalence of parasitemia), Cisse et 
al. reported 4.4% of positive slides at the December survey. Among children with 
parasitaemia, 53% of the genotyped samples were positive for the triple mutation in the pfdhfr 
gene and 38% for the pfdhps gene. The studies in the Gambia and Senegal were carried out in 
areas with very low incidence of malaria and were certainly under powered to assess the 
effect of the treatment on the selection of the resistant parasite, and were underpowered for 
demonstrating non-inferiority of DHAPQ compared to SPAQ. An unexpected increase in the 
prevalence of anaemia was found in the DHAPQ treated group and it was unclear what the 
reason was.  
 
Further studies exploring the impact of chemoprevention on the incidence of clinical malaria 
were undertaken in school children in Uganda and in adult population in South East Asia. In 
Uganda, school children were recruited, given SP alone or SPAQ or DHAPQ and followed up 
for 42 days to assess their efficacy safety and tolerability in the context of prevention malaria 
(Nankabirwa et al., 2010). By the end of the follow up 98.6% of the participants were 
assigned an outcome. DHAPQ was the most effective; the risk of parasitaemia was 
significantly lower in DHAPQ treated children 12% [95% CI 7.9%-17%] than that in the 
SPAQ 44% [95% CI 38%-52%] and the SP 80% [95% CI 74%-85%]. The risk in the placebo 
group was 85% [95% CI 79%-89%], p=0.022.  No serious adverse event was recorded but 
vomiting was more frequent in the SPAQ group. An efficacy trial design does not seem 
adequate to investigate the suitability of a drug regimen to be used for the prevention of 
malaria even if a post-therapeutic prophylactic effect may be demonstrated. The safety profile 
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in repeated courses may differ from a single course; furthermore, the age group studied in this 
area of intense transmission is less likely to be the most vulnerable group.  
 
At the Northwest border of Thailand, healthy volunteers male were randomised to receive 
bimonthly or monthly DHAPQ to prevent clinical malaria. They received three days 
treatment and were followed up weekly for 9 months. The protective efficacy was 98% [95% 
CI 96%-99%] in the monthly DHAPQ treatment and 86% [95% CI 81%-90%] in the 
bimonthly treatment arm. In Africa the target of chemoprevention strategy is pregnant women 
and children up to 5 or 10 years old; the figure is different in this part of Asia where the 
occupation of the adults puts them at high risk of acquiring malaria. The report from Thailand 
(Lwin et al., 2012) showed a high protective efficacy in adults; however the study is unique 
of its kind and no previous data is available to allow any comparison. It is also an indication 
that ultimately, chemoprevention could target adults in Africa when effective strategies will 
tend to contain the infection in children and when the adult population becomes the most 
potent reservoir. 
 
Considering the use of seasonal chemoprevention of malaria as a tool for malaria control, an 
important question is whether SMC may add benefit to the other interventions. Previous trials 
had been done in areas with low ITN coverage. To determine whether there is an additional 
benefit of SMC in children using ITNs, two studies were completed, in Burkina Faso (Konate 
et al., 2011) and in Mali (Dicko et al., 2011). The two studies have the same design with a 
similar primary objective. In Burkina Faso, 3014 children aged 3-59 months were given long 
lasting insecticide-treated bednets and randomized to receive either three days treatment of 
SPAQ (1509 children) or a placebo (1,505 children). The incidence rate (per person years at 
risk) of clinical malaria (parasitemia >5000 per µl) was 2.88 [95% CI 2.70-3.06]) per child 
during the intervention period in the control arm against 0.87 [95% CI 0.78-0.97] in the 
intervention arm, yielding a protective efficacy of 70% [95% CI 66%-74%] (p<0.001). There 
was a 69% [95% CI 6%-90%] reduction in incidence of severe malaria (p = 0.04); the 
reduction in the incidence of all-cause hospital admissions was 46% [95% CI 7%-69%] (p = 
0.03).  In Mali, 1,508 children were enrolled in the control and 1,509 in the intervention arm, 
all of them received a LLIN. In both trials, during the intervention period, the reported 
number of children sleeping under a LLIN was very high, over 99% in Burkina Faso and in 
Mali. In Mali, the incidence rate of malaria in episodes per person year (parasitemia>5000 per 
µl) in the control group was 1.90 [95% CI 1.76-2.05] against 0.34 [95% CI 0.29-0.41] in 
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those receiving SPAQ in addition to the bed-nets indicating a protective effect of 82% [95% 
CI 78%-85%] (p<0.001). The protective efficacy against episodes of severe malaria 87% 
[95% CI 42%-99%] (p = 0.001). In both trials the intervention was safe and well tolerated. 
 
Unlike IPTi which uses the EPI as the delivery channel, there is no established delivery 
mechanism for SMC; new routes of delivery were needed to ensure high coverage and good 
adherence. Several studies investigated SMC delivery through community participation, 
involving training of community health workers or volunteers, and engagement of the local 
communities through community sensitization, based on positive experiences with 
community case management of childhood illnesses, and home management of malaria 
(Haines et al., 2007). 
 
In The Gambia in 2006 (Bojang et al., 2011) two strategies of delivery were compared 
through a cluster randomised clinical trial. Twenty-six reproductive and child health (RCH) 
trekking clinics each serving a population that included about 400 to 500 children aged up to 
6 years of age, were randomly allocated to receive monthly chemoprevention of malaria 
either from the trained Village Health Workers (VHWs) or from the RCH trekking teams. In 
The Gambia the RCH trekking teams provide most of the health care to children less than 5 
years old in rural areas. VHWs are trained by the Ministry of Health to recognise and treat 
common illness including malaria. The study reported two important conclusions: delivery of 
the chemoprevention of malaria was feasible outside the formal health facilities, and delivery 
through the VHW was more effective, at a much reduced cost. The VHWs achieved a high 
coverage compared to the RCH trekking teams over three courses of treatment, 74% versus 
48%, risk difference of 27% [95% CI 16%-38%]. The VHWs channel was in place before the 
onset of the trial and just needed a short period of training to be operational; the VHWs 
interacted with the local population with whom they may be already more familiar, so the 
level of coverage (or adherence to the VHWs) could be different in settings where this system 
did not exist before.  
 
A further study to explore the use of the community to deliver SMC was  carried out in the 
Gambia to evaluate the potential benefits of combining the seasonal chemoprevention of 
malaria with  the home management of malaria (Sesay et al., 2011) and delivered through the 
VHWs. In the 2008 malaria transmission season, 1277 Gambian children aged 3-59 months 
living within the rural Farafenni demographic surveillance system were randomized to 
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receive monthly SMC with either SPAQ or placebo. The intervention was given by VHWs on 
three occasions in September, October and November 2008 in a double blinded manner. The 
VHWs were previously trained to manage the clinical cases of malaria with artemether-
lumefantrine (Coartem®). Ninety-four percent of children received all three treatments during 
the intervention period confirming the ability of the community to successfully deliver SMC 
in combination with Home Management of Malaria. Similar results were obtained in Ghana 
(Kweku et al., 2009): twelve villages were randomised to deliver the SMC through either the 
community based volunteers or through health workers. In this study four rounds of treatment 
were administrated in May, June, September and October 2006. The district management 
supervised delivery by the community volunteers. The results showed that the proportion of 
children who received at least the first of three or more courses of SMC was slightly higher in 
the community-based arm (90.5% versus 86.6% p=0.059; however for the completion of 
three doses, the proportion was similar in the two groups. This study also demonstrated the 
feasibility of the community delivery channel; a high coverage level can be achieved through 
the communities after a short period of training.  
 
Seasonal chemoprevention of malaria in children using SP+AQ is highly effective in these 
areas of the Sahel. However, there is little evidence about the best alternative regimen that 
could be used in areas where amodiaquine is already in use combined with the artesunate as 
first line treatment of uncomplicated malaria in settings like Burkina Faso, and regimens that 
could be used if resistance to SP and AQ starts to limit the effectiveness of SMC with these 
drugs, or in areas where there is already resistance to SP in parts of south-east Africa where 
transmission is seasonal and SMC could potentially be used.  
 
Summary of the research questions  
1) What is the safety, tolerability and efficacy of DHAPQ compared with SPAQ when used 
for SMC?  
2) What is the incidence of malaria episodes in untreated children in the study area and hence 
what is the potential burden preventable by SMC?  
3) What is the pharmacokinetic profile of PQ and of SPAQ when used for SMC in children? 
(in order to check if dosing is optimal and to use this data to interpret the duration of 
protection and understand the drug levels required for clinical protection) 
4) What is the effect of SMC in selecting for drug-resistant parasites? 
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2.2 Safety and tolerability of DHAPQ and SPAQ 
The safety and tolerability of drugs used for SMC has been referred to above, in this section 
further data on safety and tolerability of DHAPQ and SPAQ from malaria treatment studies is 
reviewed to have a more complete picture of possible adverse event with the use of drugs 
studied in this project.  
 
2.2.1 Dihydroartemisinin-piperaquine:  
 
Artemisinin derivatives have now been extensively studied, and they are remarkable for a 
lack of serious toxicity when used for the treatment of malaria (Meshnick et al., 1996). In 
addition to formal studies, artemisinins have now been widely used, with millions of 
treatments administered, mostly of artesunate, in Southeast Asia and Africa. The artemisinin 
derivatives are remarkably well-tolerated in humans. In a clinical safety review, no serious 
adverse events or significant toxicity was reported (Ribeiro and Olliaro, 1998, McIntosh and 
Olliaro, 2000).  
 
Dihydroartemisinin-piperaquine is an artemisinin-containing fixed-combination drug 
developed in China. Recent randomized efficacy clinical trials in Cambodia, Vietnam, and 
Thailand indicated excellent tolerability and high cure rates against multi-drug resistant 
falciparum malaria. Piperaquine has been widely used in China, and has been a standard 
antimalarial drug in China since the 1970s. The main side effects are: mild headache, 
listlessness, nausea, and dizziness (Chen et al., 1982). DHAPQ is now in routine use in 
Vietnam with no reports of serious adverse events although limited resources are available for 
pharmacovigilance. In recent efficacy trials from all parts of Africa, DHAPQ has shown a 
good tolerance but cardio toxicity has to be evaluated. The regimen was well tolerated with 
mild to moderate side effects including headache, diarrhea, dizziness, abdominal pain. Five 
serious side effects were seen with 5 patients over 215 who were treated (Yeka et al., 2005) 
but were unlikely to have been drug-related. An SMC trial comparing DHAPQ with other 
regimens has been completed in Senegal in 2008 and reported a good tolerability profile of 
the drug although there was a slight but statistically significant increase in the prevalence of 
anemia in children who received DHAPQ and it was unclear if this was a true effect of the 
drug.  
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2.2.2 Amodiaquine (AQ):  
AQ has been described as “very well tolerated” for routine use, (Luzzi and Peto, 1993) and it 
was widely used for chemoprophylaxis against malaria in the past. However, prophylactic use 
was discontinued due to rare instances of agranulocytosis, aplastic anemia, and 
hepatotoxicity, principally associated with use for malarial chemoprophylaxis in travellers 
(Luzzi and Peto, 1993, Olliaro et al., 1996). In Uganda and Burkina Faso, no serious toxicities 
were observed with AQ monotherapy (Staedke et al., 2001, Zongo et al., 2005). In SMC 
trials, the most common adverse event noted were cough, diarrhoea, with the vomiting being 
more frequent in the treatment with SPAQ (these studies used tablets)  (Sokhna et al., 2008, 
Cisse et al., 2009, Bojang et al., 2010). 
 
2.2.3 Sulfadoxine-pyrimethamine (SP):  
SP has generally been the preferred replacement for CQ for the treatment of uncomplicated 
malaria in Africa.  SP is no longer recommended for chemoprophylaxis due to rare, but 
serious toxicity. Adverse reactions listed on the SP package insert (Roche, USA) are blood 
dyscrasias (agranulocytosis, aplastic anaemia, thrombocytopenia), allergic reactions 
(erythema multiforme and other dermatological conditions), gastrointestinal reactions 
(glossitis, stomatitis, nausea, emesis, abdominal pain, hepatitis, diarrhoea), central nervous 
system reactions (headache, peripheral neuritis, convulsions, ataxia, hallucinations), 
respiratory reactions (pulmonary infiltrates), and miscellaneous reactions (fever, chills, 
nephrosis); based on widespread experience with the drug, all of these reactions appear to be 
uncommon or rare with short-term therapeutic use.  
 
2.2.4 Sulfadoxine-pyrimethamine plus Amodiaquine (SPAQ): 
A systematic review of 3 older studies that included SPAQ reported no serious adverse events 
(McIntosh, 2000). In five published studies from Kampala, Uganda, and Bobo-Dioulasso 
Burkina Faso a total of 1441 SPAQ treatments were administered without the occurrence of 
severe adverse events (Gasasira et al., 2003, Staedke et al., 2001, Zongo et al., 2005, Zongo et 
al., 2007a, Zongo et al., 2007b). SPAQ was also studied in 59 children with malaria in 
Tanzania and adverse events other than those expected for acute malaria were not identified 
(Schellenberg et al., 2002). In a study from Kampala, which compared three antimalarial 
combination therapies (Staedke et al., 2004), rigorous surveillance for adverse events, 
including laboratory testing, was done to evaluate drug safety and tolerability. Of the patients 
treated with SPAQ, six (6) experienced serious adverse events (defined as events that resulted 
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in hospitalization, required medical intervention, or were life-threatening).  Four of the events 
were attributable to severe malaria and included convulsions (3 patients) and vomiting (1 
patient). Three hematologic events that were not associated with severe malaria or other 
illnesses occurred in a single patient.  Further laboratory results reported in the SPAQ group 
included transient asymptomatic neutropenia (1 patient), and elevation of ALT associated 
with clinical hepatitis (1 patient), which resolved spontaneously by Day 28. The combination 
SPAQ was used in the SMC studies in The Gambia (Bojang et al., 2010), Senegal (Cisse et 
al., 2009) and Burkina Faso (Konate et al., 2011). 
This review shows that the clinical tolerability of the DHAPQ and SPAQ deserves a further 
investigation; the reviewed studies used the drug as tablets; in the present project, a paediatric 
formulation (syrup) was used, and it is unclear whether the adverse effect seen with the 
tablets will occur in similar proportion.  
 
2.3 Pharmacokinetics of piperaquine and sulfadoxine-pyrimethamine 
In SMC the prophylactic effect after the treatment is a key to the success of the strategy, we 
aimed to understand how this is achieved and the investigation of relevant pharmacokinetic 
(PK) parameters will be the most appropriate approach. We will first define these key 
parameters: population versus rich pharmacokinetic approach, the steady state, the 
bioavailability of the drug after single or multiple administration and the time taken to 
eliminate the drug (the terminal half-life, t1/2) and the area under the curve; then we will 
explore in the relevant pharmacokinetics studies the information gathered about these 
parameters. 
 
2.3.1 Definition of the key pharmacokinetics parameters 
The rich PK studies involve an intensive sampling (high number of samples) of an individual 
at different point in time (possibly with a short interval of time between samples); the analysis 
of such data is done on an individual basis.  
The population sparse PK studies are an approach where individuals are less frequently 
sampled and each individual will contribute with a limited number of samples; the analysis is 
done on pooled data of all participants.  
The steady state of a drug: As repeated doses of a drug are administered its plasma 
concentration builds up and reaches what is known as a steady state. This is when the amount 
of drug in the plasma has built up to a concentration level that is therapeutically effective and 
as long as regular doses are administered to balance the amount of drug being cleared the 
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drug will continue to be active. The time taken to reach the steady state is about five times the 
half-life of a drug. Sometimes a loading dose may be administered so that a steady state is 
reached more quickly. 
The bioavailability is the proportion of the administered dose that reaches the systemic 
circulation. 
The terminal half-life t1/2: this is the time required to halve the plasma concentration after the 
point of pseudo-equilibrium has been reached. 
The area under the curve (AUC), the area under the plot of plasma concentration of drug (not 
logarithm of the concentration) against time after drug administration is conveniently 
determined by the “trapezoidal rule”: the data points are connected by straight line segments, 
perpendiculars are erected from the abscissa to each data point, and the sum of the areas of 
the triangles and trapezoids so constructed is computed. When the last measured 
concentration (Cn, at time tn) is not zero, the AUC from tn to infinite time is estimated by 
Cn/kel. The AUC is of particular use in estimating bioavailability of drugs, and in estimating 
total clearance of drugs (ClT). 
 
2.3.2 Pharmacokinetics of piperaquine studies 
4-aminoquinoline piperaquine 1,3-bis-[4-(7-chloroquinolyl-4-piperazinyl-1]-propane is an 
anti-malarial drug synthesized in China and in Rhone Poulenc in the 1960s (Hung et al., 
2003). The development of the resistance to the “old” drugs and the recent advocacy of  
combination therapy with artemisinin derivatives (Nosten and White, 2007, White, 2006) has 
placed PQ in the centre of malaria treatment reorientation, piperaquine (PQ) is therefore 
referred to as a resurgent antimalarial (Davis et al., 2005). For its second “life” in 
combination of an artemisinin derivative, dihydroartemisinin, close attention has been paid to 
how to maximize the efficacy of the combination while protecting the drugs from the 
development of resistance. Extensive efficacy and tolerability evaluations of the regimen 
have been performed in South East Asia (Ashley et al., 2004, Denis et al., 2002, Song et al., 
2011, Tjitra et al., 2012) and in Africa (Arinaitwe et al., 2009, Bassat et al., 2009, Nambozi et 
al., 2011, Yavo et al., 2011, Zongo et al., 2007a); all studies reported high cure rate for the 
treatment of uncomplicated falciparum malaria (Keating, 2012).  
Despite extensive clinical evaluation, few studies have been published on the 
pharmacokinetics of PQ in malaria patients (Annerberg et al., 2011, Karunajeewa et al., 
2008a, Nguyen et al., 2009, Tarning et al., 2008, Tarning et al., 2012, Hung et al., 2004) and 
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in healthy volunteers (Roshammar et al., 2006, Ahmed et al., 2008, Nguyen et al., 2008, 
Chinh et al., 2009, Sim et al., 2005). 
2.3.2.1 Pharmacokinetic of Piperaquine in healthy volunteers 
Earlier studies on the pharmacokinetics of piperaquine were published in 2006 by 
Roshammar et al. (Roshammar et al., 2006). CV8®, a co-formulation of 320 mg of 
piperaquine, 32 mg of dihydroartemisinin, 5 mg of primaquine and 90 mg of trimetoprim was 
given to 12 fasted Vietnamese healthy volunteers over three days and followed up for 29 
days. An intensive approach was used to obtain 468 piperaquine concentration-time points. 
Piperaquine was characterised by multiple peaks during the absorption and the elimination 
phases. This study was seen as a pilot; however the drug content including primaquine, 
trimethoprim, and a different dosage of dihydroartemisinin than currently used (40 mg),may 
have affected the pharmacological properties of the piperaquine and this study is therefore 
less relevant for the purpose of this report. Further trials were conducted in Asia to better 
evaluate the pharmacokinetic profile of the piperaquine. In 2008, seventy-two male Caucasian 
volunteers (40 aged 20-45 y and 32 aged 18-45 y) were enrolled in a complex 
pharmacokinetic study. Rising single oral (RSD) and rising multiple doses  (RMD) in adults 
were administered in order to determine the safety, tolerability and pharmacokinetics of 
piperaquine alone. In the RSD study, 5 escalating single oral doses (500, 750, 1000, 1250 and 
1500 mg) of PQ were given to 40 volunteers. In the RMD, 4 escalating doses (500, 750, 1000 
and 1500 mg) of PQ were given to 32 volunteers. All volunteers underwent intensive blood 
sampling and were followed up to 60 days. In the RSD cohort, the reported maximum 
concentration Cmax ranged from 41.6±29.5 ng/ml with 500 mg of PQ to 147±110 ng/ml with 
1500 mg of PQ, a maximum time Tmax  to reach the maximum concentration from 4.0 h to 
2.5h (500mg-1500mg) and a terminal half-life from 11.2 days to 12.7 days. In this report the 
escalating of the doses improves the  Cmax  and the  Tmax decreased but the terminal half-life 
remained constant. In the RMD, the Tmax was shorter with the 1500 mg of PQ 3 h and 
maximal with 750 mg. This approach indicated that a single rising dose of PQ (even high 
dosage) has no benefit for SMC as it does not improve the half-life of piperaquine. 
 
Chinh et al. measured the pharmacokinetic profile of piperaquine in 24 healthy Vietnamese 
adults taking three tablets of Arterakin® or Artekin®, all of them containing piperaquine 320 
mg and 40mg of dihydroartemisinin but manufactured respectively in Vietnam (Central 
Pharmaceutical Factory No.1 Hanoi) and China (Holleykin Pharmaceutical Co. Ltd, 
Guangdong). After a single dose (tablets containing 120 mg Dihydroartemisinine, 960 mg 
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piperaquine), the participants were followed up for 28 days (Chinh et al., 2009). The Cmax was 
higher in the drug manufactured locally compared to the Artekin® (232 ng/ml versus 204 
ng/ml) and they had similar time to reach the maximum concentration (3 hours). The terminal 
half-life of 25 days was similar in the two groups. This result from a single dose of three 
tablets doses could be an interesting option for SMC in term of adherence to the strategy in a 
long term perspective. However, clinical tolerability and biological safety should be carefully 
evaluated after repeated doses (over three to four months) in these adult populations and 
especially in children (Hung et al., 2004). 
 
2.3.2.2 Pharmacokinetic of Piperaquine in patients with uncomplicated malaria 
Eighty-five Cambodian patients (38 adults and 47 children 2-10 years) presenting with 
clinical malaria due to P. falciparum or P.vivax were given Artekin orally at 0, 6, 24 and 32 
hours with a total piperaquine dose of 32-35 mg base per kg  and followed up to 35 days for 
efficacy. The adults received Artekin
®
 tablets (320 mg piperaquine 40 mg 
dihydroartemisinin) while children received either tablets or granules (120 mg piperaquine 15 
mg dihydroartemisinin) over three days. Participants underwent rich and sparse sampling 
schemes and plasma PQ concentration was measured using a validated high-performance 
liquid chromatographic assay with ultra violet detection at 340 nm(Hung et al., 2003). The 
findings with regard to the main pharmacokinetic parameters showed a bigger volume of 
distribution in children 614l/kg, 95% CI [332-1205] compared to adults, 574l/kg, 95% CI 
[371-711]. The oral clearance time was longer in the children 1.8 liters per hour per kg (1.29-
2.3 liters per hour per kg) with a shorter terminal half-life 14 days (10-18 days); the treatment 
success rate was 98% over 28 days follow up. In this study, mixing the sampling approach 
and the drug formulation may have ignored variability in bioavailability between the two 
formulations. Subsequently, studies with more sensitive approaches with a much lower limit 
of quantification (Tarning et al., 2005, Ahmed et al., 2008) indicated that the terminal half-
life had been under-estimated. More recently in 2012, a population approach was used to 
characterise the pharmacokinetic profile of PQ in African children 2-10 years old in Burkina 
Faso presenting with clinical malaria (Tarning et al., 2012). This is the largest study in term 
of sample size ever published on the clinical pharmacokinetics properties of Piperaquine in 
sick children from Africa. Standard doses of DHAPQ were given to 236 children who were 
followed up for 42 days in Bobo-Dioulasso, Burkina Faso. In this study, the time to  
maximum concentration was 3.84 hours  (1.52-12.4) and the terminal half-life was 23.2 days 
(14.8-31.3).The mean day-7 capillary concentration was 64.0 (16.8-130ng/ml).  Younger 
37 
 
children (2-5 y) had lower day-7 plasma concentrations compared to the older even though 
they received higher normalized per-body-weight doses of the drug. In this study, day-7 
plasma concentration of piperaquine predicted treatment outcome at the end of the 42 d-
follow up. Children whose day 7 piperaquine concentrations on capillary sample were below 
57ng/ml were more likely to fail the treatment; the cut-off for venous blood sampling was 
30ng/ml. This study contributed to the accumulating data on PK of PQ in children but does 
not address the issue of the pharmacokinetic characteristics of piperaquine when given to 
healthy children.  
 
The population pharmacokinetics profile was studied in Thailand in a randomised study 
aiming at preventing malaria in adult. Healthy male volunteers whose occupation puts them at 
risk in the Northwest border of Thailand were randomized to a 3-day treatment dose of 
dihydroartemisinin-piperaquine monthly (DPm) or every 2 months (DPalt) or an identical 
placebo with or without fat (6.4 g/dose) over a 9-month period (Lwin et al., 2012). All 
volunteers were monitored weekly. They reported 114 episodes of malaria (49 P. falciparum, 
63 P. vivax, and 2 P. ovale). The protective efficacy against all malaria at 36 weeks was 98% 
(95% CI, 96% to 99%) in the DHAPQ monthly group and 86% (95% CI, 81% to 90%) in the 
DHAPQ two monthly groups (for both, P < 0.0001 compared to the placebo group). All 
regimens were well tolerated. There was no case of malaria in volunteers with plasma 
concentration above 31ng/ml. The administration of fat did not influence the main results. 
 
The lower limit of detection (LoD) is the lowest specimen concentration which is likely to be 
reliably distinguished from the Lower Blank (LoB) and at which detection is possible. The 
LoB is the highest apparent specimen concentration expected to be found when replicates of 
a blank sample containing no specimen are tested. 
The lower limit of Quantification (LoQ) is the lowest concentration at which the specimen 
can be reliably detected and at which some predefined goals for bias and imprecision are met. 
The LoQ may be equivalent to the LoD or it could be at a much higher concentration. 
 
In general pharmacokinetic evaluations are done in adult volunteers and only recently in 
children with uncomplicated falciparum malaria; most of these results are from Asia. Clinical 
pharmacological evaluation of the drugs has been limited in the African continent and no 
pharmacokinetic data are available on healthy children.  
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Population pharmacokinetic studies, possible due to the development of more efficient 
techniques when analysing the data, are preferred to intense studies due to the difficulty of 
sampling more often in young participants, furthermore, the parameters reported are 
dependent on the sensitivity of the experiment. There is substantial inter-individual variability 
and the terminal half-life is a function of the duration of follow up (appears to be longer in 
long follow up trials). In sick children, the terminal half-life is longer but the steady state 
maximum concentration in the plasma is much lower in these children. 
 
2.3.2 Pharmacokinetics of sulfadoxine-pyrimethamine plus Amodiaquine 
SPAQ is the most effective regimen for SMC in children, but there is little information about 
the pharmacokinetics of these drugs in children. Although this combination has been used for 
many years for treatment of clinical malaria there have been no studies of the 
pharmacokinetics of this combination. A recent study described the pharmacokinetics of 
amodiaquine when used in combination with artesunate to treat children with clinical malaria 
(Stepniewska et al., 2009), and another recent study described the pharmacokinetics of SP in 
children with malaria (Barnes et al., 2006), and a further study of SP in children with 
uncomplicated malaria demonstrated a low plasma level of the drug in children who failed the 
treatment (Obua et al., 2008), but there are no studies of these drugs given together or in 
healthy children. 
 
This section has reviewed the key pharmacokinetics parameters sustaining the efficacy of the 
DHAPQ and SPAQ: the maximum concentration Cmax, the terminal half-life T1/2, the time 
taken to reach the Cmax. Except in the preventive study conducted in Thai adults, all the 
reviewed studies were done either in healthy adults or in patients with acute malaria; 
therefore some important aspects remain unexplored.  
 
- What is the relationship between PQ dose in mg/kg and the PQ plasma concentration, and 
the relationship between the plasma concentration and the incidence of clinical malaria, and 
are these associations modified by age?  
- Does the duration of protection reported in this trial support the current monthly interval for 
the drug administration? 
These research questions will be investigated in chapter 5.  
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2.4 Selection of molecular markers 
2.4.1 Molecular basis of de novo selection of drug resistance 
The molecular basis of drug resistance has been well established for chloroquine (CQ), the 
anti-folate fixed combination antimalarial sulfadoxine-pyrimethamine (SP) and the 
cytochrome b inhibitor atovaquone (Djimde et al., 2001, Schwobel et al., 2003, Korsinczky et 
al., 2000, Wellems, 1991, Wellems and Plowe, 2001, Basco et al., 1998, Brooks et al., 1994, 
Hyde, 1990, Triglia and Cowman, 1994). Following the large-scale deployment of ACTs in 
the 1990s, molecular studies have reported a link between the PfMDR1 gene and the most 
advocated ACT, artmether-lumefantrine (Sisowath et al., 2005, Humphreys et al., 2007, 
Sisowath et al., 2007, Gadalla et al., 2011, Sidhu et al., 2005). 
 
 2.4.2 Emergence of drug resistance 
The genetic events leading to drug resistance are spontaneous and rare; these are thought to 
be independent of the drug used; the event maybe a mutation or a change in the copy number 
of genes encoding for the parasite target (White, 2004). A single mutation or change of amino 
acids may lead the establishment of resistance (as it is the case with the cyt b for atovaquone) 
or a gradual increase (mefloquine resistance) or finally in a stepwise process (resistance to 
pyrimethamine) (Hastings et al., 2002).  
 
2.4.2.1 Spread of drug resistance 
The spread of drug resistance depends on the transmission of resistant gametocytes; in 
mathematical terms the ratio (gametocyte density of resistant strain/gametocytes density of 
the sensitive strain) drives the spread of resistance. Resistant strains have survival advantages 
as they are more likely to recrudesce and show a slow response to antimalarial treatments 
(White, 2004), and thus also are more likely to produce infective gametocytes (Hallett et al., 
2006, Sutherland CJ, 2002). Factors which are likely to limit or increase the spread of 
resistant parasites include  (i) host immunity and pressure, (ii) intensity of transmission, (iii) 
terminal half-life and (iv) population movement and transmission of resistant parasites. 
 
2.4.2.1.1 Host immunity and treatment pressure 
Host immunity plays an important role in the spread of drug resistance (Hastings et al., 2002). 
In high transmission settings, host immunity is continuously boosted by repeated exposure to 
infective bites, thus while children are susceptible to severe infections, adults have varying 
levels of acquired immunity and are often asymptomatic, and thus remain untreated. In low 
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transmission settings, individuals are less frequently exposed to malaria infection, and 
consequently a higher proportion of infected individuals become sick and seek treatment with 
antimalarial drugs (Hastings et al., 2002, White, 2004). This difference in drug pressure 
pattern may contribute to the spread of antimalarial drug resistance. Host immunity has the 
ability to eliminate parasites resistant to antimalarial drugs and there may contribute to 
limiting the spread of these strains (Diakite et al., 2010). 
 
2.4.2.1.2 Intensity of transmission  
As well its role in determining the community level of acquired immunity, transmission 
intensity also plays a role in the spread of resistant parasite as a result of its relationship with 
clone multiplicity. In settings where the entomological inoculation rate (EIR) is low, 
monoclonal infections are common (Hill et al., 1995). The phenomenon of self-fertilization 
within the same parasite will more often occur, resulting in resistant parasites being more 
likely to be transmitted to the next generation of parasites, particularly under sustained drug 
pressure (Curtis and Otoo, 1986). In high transmission settings, the frequent rate of new 
entomological inoculation could result in a multiplicity of clones of parasites infecting people 
and this may facilitate the colonisation of the space by the resistant parasite after an effective 
treatment which killed the susceptible ones (Hastings, 1997). This selection of particular sub-
populations has recently been shown for submicroscopic parasites in western Kenya (Beshir 
et al., 2013). 
 
2.4.2.1.3 Drug elimination parameter – Terminal half-life   
There is renewing interest in the role of drug pharmacokinetics in the spread of resistance 
(Barnes et al., 2007) and completed studies in Africa have indicated that the use of ACTs can 
lead to the selection of resistance to the partner drug (Holmgren et al., 2006, Djimde et al., 
2008, Martensson et al., 2005). In malaria endemic settings, where the intensity of malaria 
transmission is very high, several genotypes of P. falciparum may infect a subject although 
certain of these may remain undetected. If an antimalarial drug was given to a subject 
harbouring such a genetically complex population of parasites, it will encounter not only the 
circulating parasites but also any recently inoculated sub-populations emerging from the liver. 
This may occur during the drug’s elimination phase (expressed as the terminal half-life). 
Particularly when the new parasites emerge during this time window when the drug may be at 
sub-therapeutic concentration, there is a higher probability that partially resistant parasites 
may be selected (Hastings et al., 2002, Watkins and Mosobo, 1993).  
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2.4.2.1.4 Population movement and transmission of resistant parasites 
Population movement has contributed to the spread of infectious disease (Prothero, 1977). 
The migration of an infected person (e.g. worker or trader) from a malaria endemic country to 
a region where the disease has been eradicated can lead to the resurgence of malaria 
transmission in the latter area (Martens and Hall, 2000). Populations migrating from an area 
of low transmission to a high transmission area are at high risk of infection and evidence from 
large resettlement of populations in Ethiopia, Indonesia and Brazil showed a significant 
increase in morbidity and mortality in all age groups in migrants from low to high 
transmission settings. In the same way, displaced human populations are likely to introduce 
resistant parasites from their place of origin into new places. Indeed intercontinental travel 
may have played a major role in the widespread pattern of antimalarial drug resistance (Roper 
et al., 2004) and explained the introduction of chloroquine and sulfadoxine-pyrimethamine 
resistance in Africa through South East Asia between the 1970s and 1990s (Anderson and 
Roper, 2005, Lynch C, 2011). 
 
2.4.3 Molecular markers of drug resistance. 
2.4.3.1 P. falciparum chloroquine –resistance transporter (PfCRT)   
Chloroquine acts by interfering with heme metabolism in the digestive vacuole of 
Plasmodium falciparum; in resistant parasites, the accumulation of chloroquine in the food 
vacuole is diminished (Bray et al., 1998, Fitch, 1970, Krogstad et al., 1985, Sullivan et al., 
1996, Yayon et al., 1984). The pfcrt is a gene of 13 exons located on the chromosome 7 
(Fidock et al., 2000b). This gene encodes for a transmembrane protein in the food vacuole of 
the parasite.  Among several point mutations in pfcrt associated with resistance to CQ in vitro 
in laboratory lines of P falciparum from Africa, South America and South East Asia, the 
substitution of threonine (T76) for lysine (K76) at position 76 (K76T), was present in all 
resistant isolates and absent from all sensitive isolates tested in vitro and pointed out the key 
role of this gene in in vitro resistance to CQ. The K76T change mostly confers resistance to 
CQ in association with other mutations in the same gene (Carlton et al., 2001, Djimde et al., 
2001, Bray et al., 2005). These data along with direct genetic evidence from studies of 
transgenic P. falciparum (Fidock et al., 2000a, Fidock et al., 2000b) strongly support the role 
of pfcrt in CQ treatment failures, and this has been subsequently confirmed in further clinical 
studies (Abruquah et al., 2010, Mockenhaupt et al., 2005, Sarr et al., 2005, Talisuna et al., 
2002). The prevalence of treatment failures to CQ had significantly increased since it was 
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first reported in the 1980-90s (Guiguemde et al., 1994, Sirima et al., 2003, NMCP, 2011, 
Tinto et al., 2006) and CQ is no longer considered useful for treatment of P. falciparum 
infections in Africa.  
 
Clinical resistance to piperaquine emerged in China following extensive use in mono therapy 
(Chen, 1982, Davis et al., 2005). There is an active search for molecular markers determining 
the resistance to piperaquine a resurgent antimalarial in combination with dihydroartemisinin. 
The structural similarities of piperaquine and chloroquine suggests possible cross-resistance 
between these drugs, so that pfcrt can be seen as a possible marker of piperaquine resistance. 
Using genetically modified pfcrt and pfmdr-1, San et al. reported the first evidence of 
evidence that resistance to piperaquine is conferred by mutations in pfcrt that are most 
commonly associated with resistance to CQ (Muangnoicharoen et al., 2009). However a 
recent study reported another independent relationship between the IC50 of piperaquine and 
dihydroartemisinin and mutations in pfcrt and pfmdr-1(Briolant et al., 2010).  
Nonetheless in this section we will investigate possible association of pfcrt CVIET and 
pfmdr-1 mutations with clinical resistance to piperaquine. Any other comparison of selection 
by piperaquine (for the antifolate resistance marker) is of limited interest.  
 
2.4.3.2 The P. falciparum multidrug resistance gene (PfMDR-1) 
This gene encodes an ortholog of the P-glycoprotein found in mammals mediating the 
multidrug resistance to cancer cells. The protein located on the food digestive vacuole plays a 
key role in the traffic regulation across the membrane (Valderramos and Fidock, 2006, 
Rohrbach et al., 2006);  N86Y modulates but is not essential in chloroquine resistance and the 
presence of the SNP Y86 in clinical studies was not associated with chloroquine failure 
(Duah et al., 2007). The simultaneous presence of pfcrt (T76) and PfMDR mutation in the 
position 86 (Y86) was associated with in vitro resistance to chloroquine but the relationship 
disappears when the analysis was adjusted for the presence of the pfcrt (Tinto et al., 2003); 
this confirm that pfmdr-1 is essential but not sufficient on its own to determine the resistance 
of CQ; however these two mutations together can be used to monitor the resistance to 
amodiaquine (AQ), another amino-4-quinolone and sharing some structural similarities with 
chloroquine (Tinto et al., 2008). The mutations in Y86 of the PfMDR was also linked to 
different susceptibility to other antimalarial drugs, for example the mutant 86Y was linked to 
mefloquine hypersensitivity while the N86 was found after treatment with artemether-
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lumefantrine (Sidhu et al., 2005, Sisowath et al., 2005, Sidhu et al., 2006, Sisowath et al., 
2007, Baliraine and Rosenthal, 2011). In vitro studies have reported a correlation between 
IC50 estimates for CQ and AQ (Ochong et al., 2003), which is suggestive of cross resistance 
in vitro (Childs et al., 1989, Basco and Le Bras, 1993). However, cross resistance between 
CQ and AQ has not been confirmed in vivo (Bloland and Ruebush, 1996, Sowunmi et al., 
2001, Schellenberg et al., 2002).  
 
2.4.3.3 P. falciparum Dihydrofolate reductase (PfDHFR) and dihydropteroate 
synthetase (PfDHPS) 
The synthesis of folate is essential for parasite P. falciparum survival; antifolate drugs 
prevent the completion of this process through the inhibition of dihydrofolate reductase (dhfr) 
(by pyrimethamine and proguanil), and inhibition of dihydropteroate synthetase (dhps) (by 
sulfadoxine) (Biswas et al., 2000, Bzik et al., 1987, Triglia and Cowman, 1994). Although the 
molecular basis of pyrimethamine in vitro resistance is well established (Aubouy et al., 2003, 
Foote et al., 1990, Peterson et al., 1990), the relationship between the identified markers and 
clinical failure is not linear. dhfr  and dhps mutations which appear in a stepwise process, 
have been associated with an enhanced transmission of gametocytes to mosquitoes despite a 
low level of in vivo treatment failure (Hallett et al., 2006, Méndez F., 2002). The presence of 
the I164L mutation in pfdhfr signified an established high level resistance to pyrimethamine 
in SE Asia (Plowe, 1998), but this mutation is extremely rare in Africa (Nzila A, 2005, 
Ochong et al., 2008). P. falciparum with different levels of sensitivity to sulfadoxine have 
sequence variation in the dhps gene (Brooks et al., 1994, Triglia and Cowman, 1994), and the 
pfdhps mutations A437G, K540E and A581G are particularly associated with established 
sulfadoxine-pyrimethamine failure in vivo (Dunyo et al., 2006, Hallett et al., 2006) . Of these, 
only the A437G mutation has been reported in Burkina Faso and in most other parts of West 
Africa. 
 
 In East Africa sulfadoxine-pyrimethamine clinical failure is common (Talisuna et al., 2004, 
Iriemenam et al., 2012, Karema et al., 2010, Eriksen et al., 2008) and is consistent with high 
frequency of the quintuple mutations in dhfr (51I/59R/108N) and the double mutation in dhps 
(S437G /K540E) along with the emergence of A581G mutation in Tanzania (Gesase et al., 
2009), in Kenya (Iriemenam et al., 2012) and in Uganda (Sendagire et al., 2005). The use of 
sulfadoxine-pyrimethamine for Intermittent Preventive Treatment of malaria in pregnancy 
and the recent recommendation by the World Health Organization for SMC in the Sahel and 
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sub-Sahel regions warrant a continued monitoring of pfdhfr and pfdhps for the emergence of 
mutations which might signify the establishment of high-level SP resistance in West Africa. 
 
 The aim of our study is to identify any evidence of selection by SMC on known markers of 
resistance for SP and AQ. The following objectives will be evaluated successively for the 
baseline and end of transmission season surveys, as well as in incident episodes over the 
period of follow up. 
 
 The specific objectives were: 
(i) Determine the prevalence of mutations in pfdhfr and pfdhps.  
(iii) Determine the prevalence of the triple mutations in Dhfr (51/59/108). 
(iv) Determine the prevalence of the quadruple mutations. 
(v) Test whether early episodes (week 1) following SMC have different marker profiles 
(vi) Perform exploratory analysis on the association of combination of mutations, and 
haplotypes of interest, and the role of some markers seen elsewhere but recently identified in 
the study area. 
Detailed findings addressing these specific objectives will be presented in the chapter 6. 
 
Summary 
 This chapter has presented a review of four main aspects: the efficacy and clinical tolerability 
of the DHAPQ and SPAQ; clinical tolerability and biological safety in efficacy studies; the 
key pharmacokinetics parameters of Piperaquine, Sulfadoxine-Pyrimethamine and 
Amodiaquine summarised in population PK studies; selection of drug resistance and SMC. 
Each section has a brief summary of the research question (or presented as objectives). The 
following chapter presents the methods used in the clinical trials. 
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Chapter 3: Methods  
 
3.1 Overall design 
An individually opened randomised trial of seasonal chemoprevention of malaria was 
conducted during the peak of the transmission in the 2009 transmission season with 
dihydroartemisinin-piperaquine or sulfadoxine-pyrimethamine plus Amodiaquine given on 
three occasions to children 3 to 59 months of age. The treatment was administrated monthly 
at the beginning of August, September and October. An untreated group to serve as a 
comparator was recruited one month after the first cohort in the middle of September 2009.  
A randomized placebo group was not included because at the time of the study, there was 
evidence of the benefits of SMC, rendering unethical the recruitment of proper randomised 
group of untreated children. All cohorts were monitored for adverse events after each round at 
home and for malaria morbidity at the health facilities. A sub-study was undertaken within 
the dihydroartemisinin-piperaquine cohort to characterise the pharmacokinetic profile of 
piperaquine; full pharmacokinetic analysis of these data was outside the scope of this thesis, 
for the purpose of this thesis, day-7 concentration of piperaquine was used to determine the 
relationship between piperaquine concentration and the duration of protection provided by the 
SMC. Another subset of children within the two cohorts was randomised to have additional 
sampling for biological safety evaluation. A cross-sectional survey took place at the end of 
transmission season in November for the treated children and December for the untreated 
cohort (figure 3.1). Blood samples were taken at the indicated periods for assessment of 
parasitemia, haemoglobin concentration and for molecular studies. 
 
A separate study was planned during the low transmission period in 2011 in Lamarame, 
Senegal, in which a cohort of children aged 3-59 months was enrolled and treated with 
sulfadoxine-pyrimethamine plus amodiaquine, and followed for 28 days in order to 
characterise the pharmakinetic profile of sulfadoxine-pyrimethamine and amodiaquine 
(desethylamodiaquine). Blood samples were collected onto filter paper to measure the level of 
sulfadoxine-pyrimethamine and desethylamodiaquine. These studies in Burkina Faso and 
Senegal are successively presented in the sections 3.2 and 3.3 of this chapter.  
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  August                   September                    October                   November          December 
Rains 
Clinic visit 
Finger prick, check for malaria, 
IPT  
Clinic visit check for 
malaria, IPT  
SPAQ 
DHAPQ 
Untreated controls 
Finger prick  
 15 children sampled before and after each IPT dose in each group for biochemistry and haematology 
                
Clinic visit check for 
malaria, IPT  
Finger prick, check for malaria 
Clinic check for  
malaria 
Clinic check for 
malaria Finger prick 
Visit for 
adverse events 
Visit for 
adverse events 
Visit for 
adverse events 
Home visit 
day 14  
Home visit 
day 14  
Home visit 
day 14  
Home visit day 
14  
Home visit 
day 14  
Census & 
screening 
June-july 
N=749 
N=750 
N=250 
Figure 3.1 Study plan 
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3. 2 Randomised clinical trial in Burkina Faso 
3.2.1 Study sites 
The study was conducted in region to the west of Bobo-Dioulasso, the main capital city of the 
region. The study sites were three peripheral health facilities of one of the six health districts of 
the region, the health district of Lena: 
- Satiri (CSPS), the largest centre with 3540 inhabitants of whom 701 were under 5 years old.  
- Balla, distant of 2 miles from the centre of Satiri had 3028 inhabitants of whom 748 were 
children under 5 years old. 
These two centres are regular government health centres and staffed by two trained nurses, a 
midwife or an assistant mid-wife and a local pharmacist to manage the essential generic drug 
shop. 
- Kadomba, the third centre did not have a public health centre, the study was the first to provide 
direct care to the population in this site; the estimated population was 2831 inhabitants and 560 
children under 5 years old. Each of the sites was surrounded by a small dam which remains a 
factor for malaria transmission. 
In the study areas, the diagnosis of malaria is mainly presumptive (rapid diagnostic tests were 
provided by the National Malaria Control Program for a short period between 2008 and 2009). 
The infrastructure was basic comprising an outpatient department, a small hospitalisation room 
with 3 to 4 beds, and the essential drug shop. The national hospital at Souro Sanou in Bobo-
Dioulasso served as the reference hospital in case of any serious condition (severe or 
complicated malaria) to be treated in emergency.  
 
3. 2.2 Preliminary census and recruitment of participants 
Before the start of the study, community meetings were held in the villages to explain the 
objectives, the procedures and the duration of the project; these meetings targeted the mothers, 
the local community leaders and broadly all community members. These meetings facilitated by 
local community workers provided village members with information about the study. An 
enumeration of children less than five years old was then conducted, at the beginning of August, 
then screening and enrolment took place after an individual informed consent was given by the 
children’s parents or legal guardians (Appendix 1). 
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3. 2. 3 Inclusion and exclusion criteria 
3. 2. 3 .1 Inclusion criteria 
Children 3-59 months were screened (appendix 2) and enrolled in the cohort if they fulfilled the 
following criteria (appendix 3): 
- Ability to respect the follow-up schedule.  
- No intention to move outside the study site during the trial.  
- Residency within the peripheral health facility catchment area.  
- Agreement to come to the study clinic for any febrile episode or other illness and avoid 
medications given outside the study protocol.  
- Acceptance of home visits and  
- The provision of informed consent by the parent/guardian. 
In this study, the presence of a clinical attack of malaria at the time of enrolment was not an 
exclusion criteria; the patient was randomized to a treatment at entry but received the treatment 
for acute malaria with artemether-lumefantrine (Coartem® tablet 20mg artemether 120 mg 
lumefantrine) over three days and then received the intervention drug at the subsequent round of 
SMC. 
 
3. 2. 3.2 Exclusion criteria 
Children were not enrolled if one of the following criteria was found: 
- History of allergy or sensitivity to SP, AQ, or DHAPQ 
- Active medical problem requiring in-patient evaluation at the time of screening  
- Intention to move outside the three health facilities vicinity during the follow-up. 
- Chronic medical condition, i.e. malignancy requiring frequent medical attention 
- Known HIV infected infant and children or children from HIV infected mother. We did not 
formally test the children for HIV. 
 
3.2 4 Procedure of randomization 
All children who fulfilled the inclusion criteria were referred to the study nurse responsible for 
randomization. The randomization list was computer-generated at LSHTM by a person not 
involved in the day to day management of the study, and ID numbers including one check-digit 
number to control for transcription errors. This list and sealed opaque envelopes, bearing the 
study number and containing a card with the treatment allocation, were prepared at the London 
School of Hygiene and Tropical Medicine (LSHTM) and sent to the study site in Bobo-
Dioulasso, Burkina Faso. Each enrolled child was assigned the next available envelope as the 
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randomisation progressed; the child’s identity was then recorded next to his/her randomisation 
number in a register. A small number of randomization errors occurred. Children who 
consistently switched from a regimen to another over all rounds were considered as valid at the 
end of follow up and therefore included in the intention to treat analysis; those who mixed the 
treatment from a round to another were excluded from the according to protocol analysis. 
 
3.2.5 Description of the intervention 
3.2.5 .1 Dihydroartemisinin-Piperaquine: DHAPQ 
Dihydroartemisinin-Piperaquine was provided by Holley Cotec Beijing Limited Ltd China as 
(Duocotexcin®) tablets of 320 mg of piperaquine phosphate and 40 mg dihydroartemisinin in 
package of 8 tablets.  The drug was provided with a quality test certificate and was not 
subsequently tested during the course of the study (table 4). 
3.2.5.2 Amodiaquine: AQ 
This drug was bought from the local market; at the start of the study, the tablet presentation 
(Flavoquin® tablet 200 mg containing 153 mg base) was chosen, but an earlier shortage of this 
presentation prompted the team to use the syrup formulation for all rounds of the study; 
therefore the drug was in bottles of 60 ml (Camoquine® syrup 5ml/mg) (table 3.1). 
3.2.5.3 Sulfadoxine-pyrimethamine: SP  
Sulfadoxine-pyrimethamine manufactured by Roche (Fansidar® tablet) was bought from the 
local market and presented as tablet of 500 mg sulfadoxine and 1.25 mg pyrimethamine and 
contained in boxes of 3 tablets. 
Likewise the dihydroartemisinin-piperaquine, the amodiaquine and sulfadoxine-pyrimethamine 
did not undergo a quality testing during the study. We relied only on the certificate of GMP 
provided by the local pharmacist. 
 
Table 3.1: Summary of the intervention drugs 
Study drug Manufacturer Drug formulation Dosing schedule per month 
Sulfadoxine-pyrimethamine (Fansidar®) Roche Tablet 500 mg + 25 mg Single dose  
Amodiaquine (Camoquin®) Pfizer Syrup 5ml/mg Daily for 3 days  
Amodiaquine (Flavoquine®) Rhone Poulenc Tablet 200 mg Daily for 3 days  
Dihydroartemisinin-piperaquine (Duocotexcin®) Holley Cotec Tablet 40 mg + 320 mg Daily for 3 days  
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3.2.6 Drug administration 
The study drugs were dispensed by the nurse in charge of the randomization; all drugs were 
administered according to the child’s weight at enrolment and the same dosage was used for the 
subsequent administrations in September and October (appendix 7). The first dose was given at 
the clinic by the study nurse and all subsequent doses were given to the mothers for home 
administration directly supervised by trained field workers during home visits. In case a child 
vomited a dose within 30 minutes following the drug administration, a half dose was given 
again; if vomiting occurred again, no further replacement was administered. Children were 
weighted at entry and the dose of drug given accordingly. At home or at the clinics, the time of 
drug administration was recorded and the time of repeated dose administration in case a child 
vomited the first dose. 
The tablets were rounded to the nearest quarter and the syrup to the nearest 5 ml. 
 
3.2.7 Additional medication 
3.2.7.1 Treatment of clinical episode of malaria: Artemether-Lumefantrine (Coartem®) 
Artemether-Lumefantrine (Coartem ®) is one of the first line treatments of uncomplicated 
falciparum malaria in Burkina Faso, and was the treatment for all clinical cases of malaria 
occurring during the trial period. The drug was presented as tablet 20 mg artemether and 120 mg 
of lumefantrine, this regimen was chosen to avoid using a regimen containing amodiaquine 
(artesunate-amodiaquine is also adopted as the first line therapy of malaria in Burkina Faso). 
Coartem® was given as per the National Malaria Control Program guidelines over three days 
without fat. The drug was also bought from local pharmacists. 
3.2.7.2 Antipyretics: Paracetamol syrup 120 mg 
The management of clinical cases of malaria included the prescription of oral antipyretics,  
paracetamol syrup over three days or up to the relief of any axillary temperature over 38.0°C 
3.2.7.3 Antibiotics: Amoxicillin syrup 250 mg  
Generic amoxicillin from the national generic drug manufacturer was purchased; this is a broad-
spectrum antibiotic used for all febrile cases where the malaria is not the cause of the fever or in 
case of suspected associated bacterial infection, prescribed without any laboratory confirmation 
of infection. The drug was given over 7 days based on 25 mg/kilogram body weight. 
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3.2.7.4 Metopimazine (Vogalene
®
) 
This dopamine D2 receptor antagonist was used in the study to treat vomiting arising after 
children entered the study, whether or not they have recently received the study drug. It was used 
to treat any vomiting suspected to be drug-related. 
3.2.7.5 Diosmectite (SMECTA®, powder for oral suspension 1g) 
This was used to treat diarrhoea occurring after drug administration; the total quantity per day 
did not exceed 2 grams. 
 
3.2.8 Schedule for the intervention administration 
The most studied schedule for SMC was three rounds of treatment corresponding in general to 
the highest peak of malaria transmission in the area. In the present study, the intervention was 
given over three months from August to October 2009. The first round in August commenced 
from 11 to 18 august, then the second from 10 to 17 September and finally the third round from 
10 to 17 October 2009. This represented approximately seven days per round with an intensive 
workload examining all recruited patients, administrating the treatments, supervising the home 
doses, while preparing for the day 4 visits to ask about adverse reactions. Meanwhile, passive 
surveillance was maintained, children in need of care were received at the clinic by the study 
physicians.  Additional staff were employed during this peak period in each SMC round.  
In the untreated cohort, the children were followed in the same fashion; after their recruitment 
from 17 to 19 September, they were asked to return to the clinic for clinical check-up every 
month up to November 2009.  
 
3.2.9 End of transmission season epidemiological survey 
An epidemiological survey was conducted one month after the last dose of the intervention from 
10 to 17 November 2009 in each of the three sites for the intervention group and 17-19 
December 2009 for the untreated group. At this survey all children were evaluated by the study 
physicians; children were asked to provide finger-prick blood sample for blood smear and 
haemoglobin measurement. The randomized cohorts were sampled at the same time for the final 
survey, but the untreated group was sampled later, this may have led to some differences in the 
parameters measured. In this report, in order to compare malaria incidence between the SMC 
and untreated groups, this comparison period was limited to the period starting from 17 to 20 
September and ended during the epidemiological survey in November. For the comparison of the 
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two randomized groups, the time at risk started at randomization and ended at the November 
survey in November. 
 
3.2.10 Extended follow up  
The formal plan of the study was to implement three months of SMC followed by an end of 
transmission season survey. However, as the control group was recruited later than the main 
cohorts, follow-up of this group was continued, the team was kept on site to mid December 
2009. Passive follow up of all cohorts was maintained with passive detection of malaria for all 
subjects visiting the study clinics, until January 16, 2010. 
 
3.2.11 Active surveillance 
Upon enrolment and after the first dose children received at the clinic, a total of 21 well trained 
field workers visited them on a fixed time per month using active case detection forms (appendix 
5). 
3.2.11.1 On days 1 & 2 (day 0 being the first dose of the treatment)  
The field workers working in pairs went to the child’s home to supervise the administration of 
the daily treatment dose. All children from a given household were grouped in the same place to 
ease the supervision of the drug uptake and each child was observed after the drug 
administration for at least 30 minutes; a replacement dose was given in case of vomiting; in this 
case the time of the vomiting was recorded along with the time of the regular administration; 
then the field worker team could move to another household.  
3.2.11.2 On day 4 one day after the last dose of the treatment 
The field workers went back to the child’s home to check whether the child had any unusual 
symptom since the start of the treatment (Appendix 5); any signs or symptoms reported by the 
mothers or the guardians were carefully recorded and transmitted to the study physician. 
These records were part of the treatment regimen tolerability assessment tools (Appendix 4). 
3.2.11.3 On day 14 after the intervention  
The field-worker always worked in pairs to minimise errors, returned to enquire about any 
abnormality noted by the parents. At all visits, fieldworkers were urged to encourage the mother 
to bring back to the clinic any child who was unwell. Study personnel were available 24hours a 
week to take care of any presenting child. To ensure the best level of care for the children in the 
cohorts, for any symptom or sign found during the home visit, the field worker was instructed to 
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refer the child to the study clinic, the consequence being that no blood smear or rapid diagnostic 
test was done in the field. All referred children received prompt and effective care at the clinic 
but their records were not kept separately to build a passive case detection record which would 
allow a separate active surveillance analysis. 
 
3.2.12 Passive surveillance 
Beside the active follow up at the participant’s home, the study clinic was opened all day to 
receive any mother with a sick child. A full health check was done and the appropriate treatment 
given free of charge; a blood smear was always done when a fever (axillary temperature above 
37.5°c) or history of fever was associated with the complaints. 
 
3.2.13 Malaria diagnostics  
Unwell children who returned to the clinics were questioned (the parents or the guardians) and a 
full clinical examination was done. In case there was history of fever or a documented axillary 
temperature over 37.5°C a finger prick was undertaken, thick and thin blood smears were 
collected, dried and stained with 2% Giemsa for 30 minutes. The blood smears were double read 
by two independent senior laboratory technicians (none was aware of each other’s result). If the 
difference between the two readers was less than 30%, the final parasitemia was the mean of the 
two individual readings. In case the difference exceeded 30%, a third reader assessed the slides. 
The final parasitemia was calculated between the readers who had a difference less than 30%. 
Parasite densities was calculated by counting the number of asexual parasites per 200 leukocytes 
or per 500 leukocytes, if the count was <10 asexual parasites/200 leukocytes, assuming a 
leukocyte count of 8,000/µl. A blood smear was considered negative when the examination of 
100 high power fields does not reveal asexual parasites. Gametocytemia was also determined 
from thick smears by counting the number of gametocytes per 1000 leucocytes. The study was 
not blinded but microscopists were not aware of the study participants' treatment assignments.  
 
3.2.14 Management of the periods at risk 
Any episodes of malaria occurring within 7 days of a first episode were considered to be part of 
the initial episode and were not counted as separate episodes. All clinical episodes of malaria 
were treated according to the National Malaria Control Program policy using Artemether-
Lumefantrine (Coartem®) over three days. Children who were within 7 days of starting 
treatment with Coartem® at the time of the scheduled SMC round did not receive the SMC.  
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3.2.15 Sub-studies: laboratory procedures 
3.2.15.1 Samples on filter paper for parasite genotyping 
Two or three drops of blood were saved onto a filter paper at each presentation of a child for a 
clinical attack of malaria. These filter papers were air dried and packed into small plastic bags 
with a desiccant. Samples for the confirmed cases of malaria were brought to London (LSHTM), 
and samples from the cross-sectional surveys sent to San Francisco (UCSF), for the drug 
resistance genotyping.  
3.2.15.1.1 Baseline and end of the transmission season survey filter papers 
A random sample of 120 children’s filter papers was selected from the baseline and end of 
transmission sample to check the status of the key mutations prior and after the intervention. 
Mutations studied included the anti folates genes (dhfr 51/59/108, dhps436/437/613), the P.f 
multidrug resistant genes (Pfmdr1 86Y, 184F, 1246Y) and the P.f chloroquine resistant 
transporter (pfcrt CVIET) using protocols developed in the hosting laboratory of the Department 
of Medicine of the San Francisco General Hospital part of the University of California, San 
Francisco. The samples were processed by Mr Fabrice Somé (PhD student). 
3.2.15.1.2 Incident cases of clinical malaria during the follow up period 
Samples from the incident cases of clinical malaria were bought to reference laboratory of Dr 
Colin Sutherland at the London School of Hygiene and Tropical Medicine (LSHTM) for 
processing. We aimed at the beginning to genotype all incident clinical cases; however time and 
resources constraints restricted the genotyped samples to 720. The protocol for the genotyping 
and sequencing, and for the real time qPCR, was as previously described by Gadalla et al., 2010.  
3.2.15.2 Venous blood sampling for biological safety evaluation 
Ninety children were selected at randomization, forty five children per treatment regimen, for 
venous sampling before and after SMC doses, with 15 children sampled at each round.  
At each round, two mililiters of venous blood was collected from each child on day 0 pre-
treatment sample) and again on day 7 (post-treatment sample) for the selected children. The 
samples were collected into an EDTA tube and brought to the Centre Muraz Haematology and 
Biochemistry Laboratory for processing using an automated machine; then the results were 
printed out and recorded into a laboratory book and a copy of the print out was given to the 
study team.  
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3.2.15.3 Capillary blood collection for measurement of piperaquine concentration 
For the population pharmacokinetic study, a sub-sample of the children in the 
dihydroartemisinin-piperaquine arm of the main clinical trial was selected. The full analysis of 
these data is being done in Bangkok and for the purpose of our work day-7 concentration is to be 
analysed in relation to the incidence rate and the duration of protection from clinical attacks of 
malaria. The anticipated sample size was 210 children aged 3-59 months of age at the time of 
enrolment. The sample size was equally split into three groups; each group being sampled once 
either in August, September or October. Each child participant in this study was asked to give 
finger-prick blood samples collected into three capillary tubes for a total whole blood volume of 
200 µl and a 2.5 ml of venous blood. The blood collected was centrifuged and the plasma 
collected into 0.5 ml cryo-tube and stored immediately at -20 °C up to the end of the study and 
then sent to Bangkok. Three windows of sampling were selected: Between day 0 and day 6, a 
fixed sampling on day 7 and a third window between day 8 and day 30; the day 30 
corresponding to the beginning of the next round of the intervention. Within these windows, the 
exact time of sampling was generated randomly by collaborators in Thailand (Dr Joel Tarning). 
The objective was to get a higher density of the samples during the critical phases of the profile. 
Being a subset of the main trial, parents signed a separate informed consent form for this 
particular study. All samplings were made by well trained personnel. Because of the necessity to 
be sure the drug was given and at what time, particular attention was given to these patients; the 
field worker assisted to the drug administration and reported the time and waited for 30 minutes 
in case vomiting occurred. Adherence to the indicated time of sampling was facilitated by asking 
the parents to come back with the children 30 minutes before the time set for the sampling and in 
a few cases, the field worker had to pick the child and bring him/her to the clinic. Parents who 
were reluctant after the first sample was taken were visited to explained again about the study, 
and those who wished to leave the cohort were allowed to do so. After each blood collection, the 
child received a sweet and the mother received re-imbursement of cost of travel to the health 
clinic. The pharmacokinetic assays were done at the laboratory of clinical pharmacology of the 
University of Mahidol in Thailand. Piperaquine concentrations were determined using solid-
phase extraction and liquid chromatography with mass spectroscopy detection (Lindegardh et 
al., 2008). The low limit of quantification was 1.5 ng/ml and the lower limit of detection was 
0.375 ng/ml. For the purpose of this thesis, we evaluated how the day 7 concentrations related to 
the dose given in mg/kg, the age of the children and the incidence of clinical malaria expressed 
as the duration of protection following the administration of piperaquine combined with 
dihydroartemisinin-piperaquine. 
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3.2.16 Definition of the outcomes for the evaluation of the efficacy of SMC 
3.2.16.1 Clinical malaria 
The cumulative incidence of clinical malaria was the primary endpoint and defined as the 
presence of history of fever in the past 24 hours or an axillary temperature equal or greater than 
37.5°C associated with a parasitemia> 3000 parasites per µL 
3.2.16.2 Anaemia 
Anaemia in this study was defined as children with haemoglobin level less than 10g/dL. 
Children were assessed for the anaemia at the final survey, one month following the last round 
of the Intermittent Preventive Treatment of malaria. All children with haemoglobin less than 10 
g/dL were then treated with iron folate and Mebendazole.  
3.2.16.3 Adverse events 
The assessment of adverse events was one of the main endpoints of the study and made using the 
forms in Appendix 4. An adverse event was defined as "any untoward medical occurrence in a 
patient or clinical investigation subject administered a pharmaceutical product that does not 
necessarily have a causal relationship with this treatment" (ICH Guidelines E2A).  A serious 
adverse event was defined as an experience that results in any of the following outcomes: 1) 
death during the period of study follow-up, 2) life-threatening experience (one that puts a patient 
at immediate risk of death at the time of the event), 3) inpatient hospitalization during the period 
of study follow-up, 4) persistent or significant disability or incapacity, or 5) specific medical or 
surgical intervention to prevent one of the other serious outcomes listed in the definition. All 
recorded signs were coded according to a pre-specified guide (Appendix 6). 
 
3.2.17 Participant withdrawal 
Participants were withdrawn if they withdrew their informed consent or if they left the study 
area for good. 
 
3.2.18 Ethical approval 
The study conducted in Burkina Faso was submitted and approved by the London School of 
Hygiene and Tropical Medicine Ethics Committee, the Institutional Ethics Committee of Centre 
Muraz. 
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3.2.19 Data Safety and Monitoring Board 
A Data Safety and Monitoring Board was appointed to oversee the safety aspects of the trial. It 
comprised a statistician (Dr Neal Alexander, LSHTM, chair), a paediatrician (Dr Hassane 
Tamboura, National Hospital Souro Sanou, Burkina Faso) and an epidemiologist (Dr Corinne 
Merle, LSHTM). 
 
3.2.20 External quality control: the trial monitoring 
An external Clinical Research Organization led by Dr Raouf Ousseini monitored the study to 
check adherence to the protocol and to Good Clinical Practice guidelines and local regulatory 
requirements. 
3.2.21 Timing of field activities 
The study activities started late in July 2009. Formal contacts had been made with the local 
authorities to introduce the institutions in charge of the conduct of the study, and the study team. 
Local field workers were recruited and trained locally; just after the training sessions, a census of 
all children less than 5 years old present in the three sites targeted by the intervention was 
conducted. Meanwhile, the full team was set up and ready to enrol participants, and the first 
child was enrolled on 11 August 2009. The last follow up was the 16 January 2010. 
 
3.2.22 Statistical methods 
The primary endpoint was incidence of clinical malaria defined as fever or history of fever in the 
last 24 hours and P.falciparum density of at least 3000 parasites per microlitre. Secondary 
endpoints included: incidence of clinical malaria of any parasitemia, the prevalence of asexual 
parasitaemia and of gametocyte carriage, and of anaemia, at the end of the transmission season; 
the prevalence of molecular markers of resistance to study drugs among patients diagnosed with 
clinical malaria during the trial and in subjects with parasitaemia at the end of the transmission 
season. Sample size was chosen to give adequate power to demonstrate that SMC with DHAPQ 
was as effective as with SPAQ. SPAQ is highly effective for SMC in Burkina Faso (Konate et 
al., 2011) and in Mali (Dicko et al., 2011). Other regimens will be needed if SPAQ starts to lose 
its efficacy due to resistance. The aim of the study was to determine whether DHAPQ is as 
effective in preventing malaria as SPAQ, a non-inferiority design was therefore used. Since the 
aim of SMC is to completely protect children, the cumulative incidence (the proportion of 
children who had one or more attacks of malaria) was chosen as the primary endpoint. 
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To motivate the choice of non-inferiority margin we considered the cumulative incidence or risk 
(the proportion of children with malaria) by the end of the transmission period, if this was 7% in 
the SPAQ group, a difference not exceeding 4% would be required for non-inferiority of 
DHAPQ. This difference is equivalent to an odds ratio of 1.64. The odds ratio was used in order 
to define a fixed margin independent of the level of incidence in the comparison group, such that 
the trial would have approximately the same power regardless of the incidence in the comparator 
group. The size of the margin in relation to risks in the active and untreated groups is shown in 
the figure below, to show in perspective the size of the margin. The proportion of children with 
malaria, rather than the incidence rate, was chosen as the primary measure since the aim of SMC 
is to completely protect children. A sample size of 1500 children was needed for 80% power 
using a one-sided 2.5% significance level (corresponding to the use of 95% confidence 
intervals), allowing for 10% reduction in the number of subjects included in the according-to-
protocol analysis due to loss to follow-up or non-adherence to the protocol. The sample size 
required in each group is given by: 
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where π is the proportion (risk) in each group, assumed to be the same under the alternative 
hypothesis, and d is the risk difference. The z1-α is used instead of z1-α/2 because the test is one-
sided, so for a 5% significance level the value 1.64 is used, and for a significance level of 2.5%, 
a z value of 1.96 should be used. zβ is 0.84 for 80% power and 1.28 for 90% power. This 
formula is used by taking a value for π, computing d assuming an odds ratio of 1.64,  for 
example if π=0.07, the odd is 0.07/(1-0.07)=0.075269, the odds in the comparator group is 
1.64x0.075269=1.23441, which is a risk of 1.23441/(1+1.23441)=0.109877, so the risk 
difference is d=0.109877-0.07=0.039877. Substituting π=0.07 and d=0.04 into the formula gives 
a sample size of 642 for 80% power and a 2.5% significance level. With 10% loss to follow up 
this comes to 642/(1-0.1)=713. For 90% power and 5% significance we have 698: 
Table 3.2 Sample size calculation 
 
% significance 
(% confidence) z1-α 
Power 
zβ (z1-α+ zβ)
2 n n/0.9 
2.5% (95%) 1.96 90% 1.28 10.4976 859.4991 955 
5% (90%) 1.64 80% 0.84 6.1504 503.5687 560 
2.5% (95%) 1.96 80% 0.84 7.84 641.906 713 
5% (90%) 1.64 90% 1.28 8.5264 698.1055 776 
 
59 
 
This approach is conservative in that the power will be greater if the baseline risk is greater than 
is used in the calculation, but is an improvement on using a fixed margin, which could lead to 
much reduced power if the baseline risk is greater than was used in the sample size calculation. 
 
 
Figure 3.2 Illustration of size of the margin in relation to the risks in untreated and treated children. The expected 
proportion with malaria (y-axis) corresponding to a given incidence rate of malaria (x-axis)is shown. For a rate λ 
per child per season, the proportion in the untreated group was calculated assuming a Poisson distribution, as 1-
exp(-λ), and the proportion in the SPAQ group calculated assuming an efficacy of 84% (the efficacy of SPAQ in 
this study), as 1-exp(-λx0.16).  
 
The purpose of the untreated cohort was to estimate the incidence of the primary endpoint in 
untreated persons. So the sample size was based on the degree of precision we need on this 
estimate. The 95% confidence interval for the rate was (r/n)xEF where EF is the error factor 
exp(1.96xsqrt(1/r)), r was the number of events and n the number of child years. We estimated 
that with a rate of 1 episode per child year at risk, we needed 250 children with 95% [0.88 to 
1.13]. Data was entered using Access 2000 and analysed with Stata 11.0 following an analysis 
plan written before the end of the trial. For efficacy endpoints, both intention-to-treat and 
according-to-protocol analyses were done. The intention to treat population included all 
randomized children, analysed in the group to which they were assigned at randomization. For 
the ATP analysis, we excluded children who did not attend for an SMC treatment round. 
Children who attended, but did not receive SMC due to malaria, were included in the ATP. The 
WHO 2006 growth standard was used to determine nutritional status of the children. Malaria 
was defined as the presence of fever with an axillary temperature >37.5°c, or history of fever in 
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the last 24 hours, with a parasitemia of at least 3000 per µl of blood. Two episodes of malaria 
occurring at least seven days apart were considered as two different episodes. For the primary 
analysis, time at risk was assumed to start on the date the first child received SMC, and end one 
month after the last SMC round. For children who died or were known to have left the study 
areas, observations were censored on the date of death or emigration. Analysis of non-inferiority 
was based on the 95% confidence interval on the odds ratio for malaria, obtained from the 
Kaplan-Meier estimate of the proportion of children who had malaria and its standard error, 
using the delta method. This gives the standard error of the log odds ratio as  
s=√{V(p1)/[p1(1-p1)]
2
+V(p0)/[p0(1-p0)]
2
} where p1 and p0 are the Kaplan meier failure estimates 
and V(p1), V(p0) their variances estimated by Greenwood’s formula, and the odds ratio is 
OR=[p1/(1-p1)]/[p0/(1-p0)] and confidence limits OR.exp(1.96xs) to OR/exp(1.96s) (P Milligan 
personal communication).  
The cumulative hazard function, (an estimate of the average number of malaria episodes per 
child), was estimated using the Nelson-Aalen method including repeated events. Efficacy of 
SMC compared to the untreated group was defined as the percentage reduction in the number of 
episodes, which was estimated as 100x(1-R) where R is the hazard ratio from Cox regression, 
with confidence intervals calculated using a robust estimate of the standard error to account for 
repeated malaria episodes in the same child. For comparisons with the control group, time at risk 
started on the date of SMC round 2, or the date of enrolment for the untreated cohort, and ended 
one month after SMC round 3. Adjustment for covariates was critical because this was a non-
randomized comparison. The effects of age (age at entry in whole years), ITN use at baseline, 
village, and nutritional status at entry, were assessed by including these variables in the 
regression model, variables which did not contribute (no evidence of confounding and not 
associated with outcome) were removed from the model. Follow-up was continued until 16 
January 2010 and in a further analysis of duration of protection, time at risk was assumed to 
continue until this date, smoothed estimate of the hazard ratio was obtained using regression 
splines using the method of Lambert and Royston (Lambert, 2009), the efficacy (1-hazard ratio) 
with 95% confidence band was plotted against time since the final round of SMC. The logrank 
test for trend, stratified by month, was used to assess association of piperaquine concentration 
with protection. Analysis of covariance was used to estimate the difference between groups in 
the mean of each biochemical and haematological parameter, with the day 0 value included as a 
covariate, pooled across months. In the table below the link between the research question, the 
outcome and the statistical method used for its analysis is presented. 
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Table 3.2 a Link between research question, outcome and analysis method 
 
Research questions Study endpoints Statistical method 
1. What is the safety, 
tolerability and efficacy of 
DHAPQ compared with 
SPAQ when used for SMC? 
Protective efficacy of SMC 
with AQSP and DHAPQ 
Cox regression 
2. What is the incidence of 
malaria episodes? 
Incidence rate of malaria 
Number of episodes per child 
- Kaplan-Meier estimate 
- Nelson-Aalen method 
including repeated events 
3.What is the 
pharmacokinetic profile of 
PQ and of SPAQ when used 
for SMC in children? (in 
order to check if dosing is 
optimal and to use this data 
to interpret the duration of 
protection and understand the 
drug levels required for 
clinical protection) 
 
- Duration of protection 
 
- Correlation between day 7 
concentration of piperaquine 
and protection against 
clinical malaria 
 
- Regression splines using 
the method of Lambert and 
Royston 
- The logrank test for trend 
4 What is the effect of SMC 
in selecting for drug-resistant 
parasites? 
 
Selection of key molecular 
markers by SMC 
Chi square test 
 
 
 
3.3 Pharmacokinetics of SPAQ during the SMC in Lamarame, Senegal 
3.3.1 Study site 
The study was conducted in Lamarame, NDoffane District, Senegal. After holding community 
meetings to explain the study, boys and girls who did not have history of allergy to study drugs 
and whose parents agreed for them to participate were enrolled at the clinic.  
 
3.3.2 Screening and enrolment 
During the study organization phase, meetings were held at the health facilities, we explained, in 
local language, the aims of the study, the recruitment and follow up procedures, the total sample 
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size needed, and the duration of follow up as well as the detailed schedule for blood sampling. 
Subsequently we visited families at home to explain the study procedures and invite people to 
come to the clinic. Mothers or guardians were asked to bring the child to the clinic where, after 
signing the indicated consent. The child was weighed and had a clinical examination, a finger 
prick blood sample into a microtainer, from which 70µL of blood the laboratory technician 
pippetted onto filter paper.  
 
3.3.3 Drug administration 
After the first blood samples were collected, the children were given one course of treatment 
with sulfadoxine-pyrimethamine, and amodiaquine over three days, in April 2011, and were 
followed-up for one month. Each child was weighed, treated on day 1 with SP (25mg/kg 
sulfadoxine 1.25mg/kg pyrimethamine) and one dose of amodiaquine (10mg/kg amodiaquine 
base). Drugs were given according to the child’s weight and he was kept under observation for 
30 minutes before being allowed to return home. The remaining doses of amodiaquine (days 1 
and 2) was given to a field worker who visited the child at home to supervise drug 
administration. The exact date and time of the administration was recorded. Children who 
vomited a dose were given a repeat dose and the vomiting carefully recorded. Children with 
repeated vomiting were kept out of the PK cohort but followed for adverse event purpose and if 
necessary referred for appropriate care. 
 
3.3.4 Blood sampling for pharmacokinetics analysis 
Children were asked to provide a finger prick blood sample on three further occasions between 
day 1 and day 28, determined according to a pre-defined schedule. All enrolled children were 
asked to give blood before the first dose of the treatment; then they were randomly allocated in 
one of three different windows for the subsequent sampling, the timing of the samples within the 
indicated window was randomly allocated, with an even spread within the window. This scheme 
reflects the need to estimate PK parameters for two different drugs with different half-lives. 
Table 3.3 PK sampling windows per group 
 Sample 2     Sample 3      Sample 4 
Group 1:      Day 1-5        Day 6-14      Day 15-28 
Group 2:      Day 1-3        Day 4-10      Day 11-28 
Group 3:       Day 1-3       Day 4-6       Day 7-28 
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Finger-prick blood was collected into a microtainer containing EDTA or heparin, and then an 
exact amount of 70 µL of blood taken and stored onto a filter paper labelled with the child’s 
identification number, the time, date and day the sample was collected. The filter paper was 
dried at room temperature taking care that the blood spot does not have any contact with any 
surface while it was drying. 
 
3.3.5 Follow up and home visits 
Trained field staff visited each child on day 4, to ask about any adverse reactions to the drugs, 
and on day 14 and 28 to check the child was well. Children with signs of severe malaria, or any 
other severe illness were referred immediately to the health post. If a child had axillary 
temperature >=37.5°C or a history of fever in the last 48 hours a finger prick blood sample was 
taken for malaria diagnosis by rapid test and blood film. Children with a positive test were 
treated with Coartem.  
 
3.3.6 Pharmacokinetic experiment protocol 
The measurement of drug concentrations for pharmacokinetics parameters was performed at the 
London School of Hygiene and Tropical Medicine by Dr Kaur Harparkash between the end of 
July and August 2011. Individual filter paper was transferred into a small tube, then 50µL of 
Internal Standard added to each tube, followed by 250µL of CH3OH/CH3CHO in HCL, Somike 
for 2 minutes, then transfer the solution into the HPLC machine for procession. 
 
3.3.7 Statistical methods 
The sample size determination of 150 children aged 3-59 months was based on experience from 
other PK studies.  
 
3.3.8 Ethical approval 
The study was approved by the LSHTM Ethics Committee and the Conseil National de 
Recherche en Santé of the Senegalese Ministry of Health.  
 
3.3.9 Data safety and monitoring board 
A data safety and monitoring board was appointed within the University of Dakar to assess the 
safety aspect of the trial. They convened of regular meeting during the course of the trial and a 
final meeting upon the completion of the study. 
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3.3.10 Timeline of the field activities 
The study took place in Lamarame between May and July 2011 
 
3.3.11 Quality control 
The study benefited from an external clinical monitoring during the course of the trial and the 
tablets (SP & AQ) quality testing was undertaken in LSHTM, showing the drugs were of food 
quality. 
 
3.3.12 Pharmacokinetic modelling 
The full data analysis is specialised involving non-linear fitting, this was being done by Dr Neal 
Alexander, statistician at the London School of Hygiene and Tropical Medicine, London. For the 
purpose of the thesis, I performed simple descriptive analyses of the concentrations. 
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Chapter 4: Impact of SMC on malaria morbidity, clinical 
tolerability and biological safety 
 
4.1 Overview 
The preceding chapter 3 described the methods used in the clinical trial in Burkina Faso and in 
the pharmacokinetic study in Senegal which led to key findings presented in this chapter: the 
trial profile, the impact of SMC on malaria related morbidity, clinical tolerability and biological 
safety. The pharmacokinetic parameters resulted from the study in Senegal will be presented in 
the next chapter 5. 
 
4.2 The trial profile 
A total of 1519 children were screened in August 2009, 19 were not included due to recent use 
of antimalarial drugs (7), outside the age range (6), severe malnutrition (3) and other reasons (3). 
1499 children were randomized, 750 to DHAPQ and 749 to SPAQ. 12 allocation errors 
occurred, 7 children randomized to SPAQ received DHAPQ in error, 2 randomized to SPAQ 
received mixed treatments, and 3 randomized to DHAPQ received mixed treatments, leaving 
754 who received DHAPQ and 740 SPAQ, in the ATP analysis. 97% (1454/1499) of 
randomized children were seen at the survey at the end of the transmission season 
The distribution of the randomized and untreated children is summarised in figure 4.1. 
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Figure 4.1 Trial profile  
Screened: 1519 
Randomized: 1500 
DHAPQ: 757 SPAQ: 742 August 
December Seen: 247 
DHAPQ: 730 SPAQ: 724 November Seen: 249 
DHAPQ: 754 SPAQ: 737 October          Seen: 250 
DHAPQ: 756 SPAQ: 738 September Enrolled: 250 
Screened: 250 
Control group 
Up to 16/01/2010 
Not included: 19 
- Antimalarial use: 7 
- Malnutrition: 3 
- Age < 3 months: 6 
- Other reasons: 3 
1 death 
1 death 
2 absent 
1 death 
2 absent 
1 malnutrition 
1 absent 
12 absent 
1 withdrew consent 
1 death 
1 death 
1 absent 
2 deaths 
22 absent 
PASSIVE SURVEILLANCE OF ALL GROUPS 
IPT 
IPT 
IPT 
FS 
FS 
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4.3 Compliance with treatment doses 
During all rounds, the first dose of the drug was given and directly observed at the clinic by the 
study nurses. Subsequent doses were released to the mothers and the administration was done in 
the presence of the field worker who recorded the time of the drug uptake and the occurrence of 
any vomiting; a replacement dose was provided once if the child vomitted. 
 
Compliance with daily doses: One patient did not receive the third dose of amodiaquine in 
August 2009. Two patients did not receive the second and third dose of AQ in August. Two 
patients missed the second and third dose of DHAPQ in August and one patient missed his doses 
in October. 
 
Compliance with monthly doses: At enrolment, 9.5% (72.757) and 9.4% (70/742) respectively 
in the DHAPQ and SPAQ groups did not receive the SMC treatment due to clinical malaria. 
These proportions were respectively 8.1% (61/756), 7.5% (55/738) in September and 8.8% 
(66/754) and 8.3% (61/737) in October. 
 
4.4 Baseline characteristics of the participants 
Baseline characteristics of the three cohorts are shown in Table 4.1. The untreated cohort was 
not randomized, and was recruited later in the season.  
 
4.4.1 Age distribution 
Age distribution was similar across the groups, the mean age in month was 27.3±15.8 months in 
the DHAPQ treatment group, 28.5±15.8 months in children treated with SPAQ and 27.4±15.5 in 
the comparator group. When the age was categorised, the proportion of the children in each age 
group was comparable across the cohorts.  
 
4.4.2 Gender 
The proportion of females was the same in the SPAQ and the comparator group (49%) and 51% 
in the DHAPQ treatment group. 
 
4.4.3 The study villages 
The children were recruited from three villages: Satiri, Kadomba and Balla. They were 
approximately equidistant (3 miles) from each other. The comparator group was selected in the 
village of Balla. 
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4.4.4 Prevalence of clinical malaria 
The proportion of children with clinical malaria at enrolment was similar across the two groups 
16% in the DHAPQ and 15% in the SPAQ group. This proportion was higher in the comparator 
group 64%. 
 
4.4.5 Bed nets and ITNs use 
The ownership of bednets was very low and similar across the study area; the percentage of 
children who slept under a bed net the night preceding the survey was also low. 
 
4.4.6 Nutritional status 
The proportion of children who were stunted (height for age Z-score less than -2 SD), wasted 
(weight for height Z-score less than -2 SD) and underweight (weight for age Z-score less than -2 
SD) was similar in the two randomised groups. The comparator group recruited one month later 
had a higher proportion of wasted participants (42%). 
 
4.4.7 Prevalence of fever at enrolment 
Fever was defined as the measured axillary temperature equal to or greater than 37.5°C, the 
proportion of children with fever was exactly the same in the two SMC groups; a higher 
proportion of children in the comparator (untreated) group was febrile reflecting the timing of 
enrolment later in the malaria season. 
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Table 4.1: Baseline characteristics of the enrolled cohort 
 SMC randomized groups   
Variable SPAQ  
(n=742) 
DHAPQ  
(n=757) 
Untreated cohort  
(n=250) 
Date enrolled 11-20 Aug 11-20 Aug 17-19 Sep 
Study site     
Kadomba 323 325 0 
Balla 151 150 250 
Satiri 268 282 0 
Gender %Male:%Female 49%:51% 50%:50% 49%:51% 
Age group     
<12months 129 (17%) 153 (20%) 47 (19%) 
12-23months 155 (21%) 158 (22%) 63 (25%) 
24-35months 155 (21%) 152 (20%) 56 (22%) 
36-47months 147 (20%) 138 (18%) 45 (18%) 
48-59months 156 (21%) 156 (21%) 39 (16%) 
Mean weight kg (SD) 10.9 (3.22) 10.7 (3.13) 10.1 (2.72) 
Underweight 26% 25% 38% 
Stunting 25% 24% 14% 
Wasting 22% 22% 42% 
Use of bednets (%) 36% (267) 36%(273) 32% (79) 
Slept under ITN the night 
before (%) 
27% (204) 25% (186) 31% (77) 
Geometric mean parasite 
density/μL  
7893 8027 15068 
Number with fever*(%) 29% (213) 29% (216) 72% (179) 
Number with malaria** (%) 96 (13%) 98 (13%) 81 (32%) 
Number with parasites (%) 336 (45%) 323 (43%) 152 (61%) 
Number of gametocytes (%) 80 (11%) 80 (11%) 75 (30%) 
 
 
The children in the control group came from only one of the three villages. The age distribution 
was similar to the randomized groups, the proportion under-weight was greater, this may be 
because the children in the control group were assessed later in the transmission season, but 
there were also village differences. The prevalence and density of parasitaemia was greater, also 
reflecting that this cohort was recruited later. The two randomized groups were similar to each 
other in all the baseline characteristics.  
 
4.5 SMC and malaria-related morbidity parameters 
4.5.1 Overall impact of SMC on the incidence of malaria 
The primary outcome was the incidence of clinical malaria defined as fever with at least 3000 
parasites per microlitre; this incidence was respectively 119 and 161 cases in the SPAQ and 
* Axillary temperature >37.5°C or history of fever in the past 24 hours and ** Fever with any parasitaemia, 
measured in August for the randomized groups and a month later, in September, for the untreated cohort. 
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DHAPQ group yielding an incidence rate of 54.7 episodes per 1000 per month in the SPAQ 
group and 72.2 in the DHAPQ group (table 4.2) in the according-to-protocol analysis. The 
number of incident cases of malaria was similar in the intention-to-treat analysis (table 4.3).  
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Table 4.2: According To Protocol analysis of the incidence rate over three months of SMC 
Drug  N Cases Person months Rate /1000 /month 
Fever with any parasitaemia 
 SPAQ 740 156 2175.4 71.7 
DHAPQ 754 200 2228.9 89.7 
Fever with parasitemia ≥3000/μL 
 SPAQ 740 119 2175.4 54.7 
DHAPQ 754 161 2228.9 72.2 
 
Table 4.3: Intention To Treat analysis of the incidence rate over three months of SMC 
Drug  N Cases Person months Rate /1000 /month 
Fever with any parasitaemia 
 SPAQ 749 161 2202.5 73.1 
DHAPQ 750 199 2216.6 89.8 
Fever with parasitemia ≥3000/μL 
 SPAQ 749 122 2202.5 56.1 
DHAPQ 750 159 2216.6 71.3 
 
4.5.2 Analysis of non-inferiority 
142 children (70 in the SPAQ group and 72 in the DHAPQ group) had malaria prior SMC 
administration, and received artemether-lumefantrine (Coartem®) instead of SMC drugs during 
this round. These children were included but the cases on day 0 were not counted in the analyses 
of SMC efficacy. During three months from the first dose of SMC the Kaplan-Meier estimate of 
the proportion of children with an episode of malaria (≥3000/μL) was 0.15 in SPAQ group and 
0.19 in DHAPQ group, the odds ratio was 1.36 (95% CI 1.04,1.76; 90% CI 1.09,1.69). The 
cumulative hazard function (the mean number of malaria episodes per child) at three months was 
0.16 in the SPAQ arm and 0.21 in the DHAPQ arm, hazard ratio 1.31 (95% CI 0.99, 1.74, two-
sided P-value 0.059). When malaria with parasitemia at any density was considered, the odds 
ratio was 1.29 (1.02, 1.64) (Table 4.4). Similar results were obtained by ITT analysis (Table 
4.5). The Kaplan Meier estimates (Figure 6) of the cumulative incidence of malaria of any 
parasitemia showed an increase in the incident cases around the next round (before the 
intervention was given). 
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Table 4.4: According To Protocol (ATP) analysis of malaria incidence over 3 months from the first round of SMC 
 
N Cases Person 
Mths 
Rate 
/1000 
/month 
Proportion 
 with 
malaria 
 (K-M 
estimate) 
se OR 
(95%CI) 
Cum. 
Hazard 
se HR 
(95%CI) 
P-value 
Fever with any parasitaemia 
SPAQ 740 156 2175.4 71.7 0.193 0.014 1 0.213 0.017 1 - 
DHAPQ 754 200 2228.9 89.7 0.236 0.015 
 
1.29 
(1.02,1.64) 
0.266 0.019 
 
1.25 
(0.97,1.62) 
0.090 
Fever with parasitemia ≥3000/μL 
SPAQ 740 119 2175.4 54.7 0.149 0.013 1 0.161 0.015 1 - 
DHAPQ 754 161 2228.9 72.2 0.192 0.014 
 
1.36 
(1.04,1.76) 
0.212 0.017 
 
1.31 
(0.99,1.74) 
0.072 
 
 
Table 4.5: Intention To Treat (ITT) analysis of malaria incidence over 3 months from the first round of SMC 
 
  
 N Cases Person 
months 
Rate 
/1000 
/month 
Proportion 
with 
malaria 
(K-M 
estimate) 
se OR 
(95%CI) 
Cum. 
hazard 
se HR 
(95%CI) 
P 
value 
Fever with any parasitaemia 
SPAQ 749 161 2202.5 73.1 0.195 0.014 1 0.215 0.017 1 - 
DHAPQ 750 199 2216.6 89.8 0.234 0.015 
1.26 
(1.00, 1.59) 
0.264 0.019 
1.22 
(0.95,1.58) 
0.122 
Fever with parasitemia ≥3000/μL 
SPAQ 749 122 2202.5 56.1 0.151 0.013 1 0.163 0.015 
 
- 
DHAPQ 750 159 2216.6 71.3 0.191 0.014 
1.33 
(1.02,1.72) 
0.210 0.017 
1.29 
 (0.97,1.71) 
0.075 
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Figure 4.2a: Kaplan-Meier estimates of the proportion of children with an episode of malaria 
 
 
 
Figure 4.2b: Interpretation of the odds ratios and confidence intervals. The diagram show the 90% and 95% 
confidence intervals for the odds ratios for ATP and ITT analyses for the primary endpoint (malaria with 
parasitaemia above 3000/μL) and for the secondary endpoint (malaria with parasitaemia at any density). An odds 
ratio of 1.64 was specified as the non-inferiority margin. SMC with SPAQ is highly efficacious reducing the risk of 
malaria by about 80% compared to placebo. The non-inferiority margin is the amount of this protection that we 
would be prepared to give up in order to use an alternative drug regimen. DHA-PQ would be regarded as not 
inferior to SPAQ if it could be concluded that the odds of having malaria was not more than 1.64 times as great in 
children who received  DHA-PQ, as in children who received SPAQ. All the 95% confidence intervals for the odds 
ratio lie entirely above 1, indicating that SPAQ is superior to DHAPQ. For the primary endpoint, ATP and ITT 90% 
intervals just cross the non-inferiority margin, but for malaria defined as fever with parasitaemia at any density, 
the margin is not crossed by the 90% or by the 95% confidence intervals. The fact that the margin is not crossed 
for this endpoint, and just crossed for the other endpoint, suggests the difference is small and may not be 
regarded as a very important difference. In summary, the 90% and 95%CI’s do cross the margin for some analyses, 
but are entirely above 1, so we are confident SPAQ is superior to DHAPQ, but we are somewhat less confident in 
our conclusion that the DHAPQ is not inferior to SPAQ. 
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4.5.3 Comparison of the incidence of malaria in SMC and untreated groups 
Two hundred and fifty children 3-59 months were recruited in September when the second round 
of SMC was being administered to children in the trial. To estimate the efficacy of SMC, the 
incidence of malaria was compared between the SMC groups and the untreated group over 2 
months following the second round of SMC, adjusting for site, age group and insecticide treated 
bed-nets use. A total of 338 episodes of malaria were recorded in this period in the untreated 
children, a rate of 0.63 episodes per child per month. Efficacy against malaria (fever with any 
parasitaemia) was high in bothgroups, 74% (DHAPQ) and 80% (SPAQ), (table 4.6). For malaria 
defined as fever with parasite density ≥3000/μL, there were 229 episodes in the untreated cohort, 
a mean of 0.92 episodes per child, compared with 108 episodes in the DHA group and 78 in the 
SPAQ group over the same period, efficacy adjusted for the same covariates was 79% 
(70%,85%) and 84% (76%,90%) respectively.  To estimate duration of protection, incidence 
after the last round of SMC in each treatment group was compared with the incidence in controls 
over the same period, adjusted for the same covariates. In both groups protection persisted at a 
high level for 3-4 weeks in each group and decreased rapidly thereafter (Fig 4.2). 
 
Table 4.6 Protective efficacy of SMC 
Cox regression analysis of malaria incidence (fever with parasite density >0/μL) over two 
months from the second round of SMC showed a protective efficacy of 74% in DHAPQ and 
80% in the SPAQ group. 
 
No. of  
children 
Cumulative 
Hazard 
Crude 
hazard 
ratio 
Adjusted 
hazard ratio 
(95%CI) 
Efficacy 
(95%CI) 
Untreated 250 0.95 1 1 
 DHAPQ 753 0.18 0.19 0.26 (0.19,0.35) 74% (65%, 81%) 
SPAQ 735 0.14 0.15 0.20 (0.14,0.28) 80% (72%, 86%) 
Site: 
     Kadomba 644 0.18 1 1 
 Balla 549 0.55 3.01 1.12 (0.79,1.59) 
 Satiri 545 0.11 0.59 0.60 (0.42,0.85) 
 ITN use: 
     No 1279 0.29 1 1 
 Yes 464 0.24 0.84 0.82 (0.67,1.01) 
 Age 
     <12 months 328 0.22 1 1 
 12-23 months 374 0.37 1.68 1.54 (1.18,2.01) 
 24-35 months 360 0.44 2.01 1.91 (1.47,2.49) 
 36-47 months 328 0.20 0.90 0.91 (0.66,1.25) 
 48-59 months 347 0.12 0.55 0.58 (0.39,0.85) 
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A cohort of untreated children was recruited as a control group, at the time the main cohort 
received the second round of SMC. The y-axis shows the mean number of episodes per child 
since the start of surveillance. Malaria episodes were detected by passive detection, and at cross-
sectional survey performed just thirty days after the last round of SMC. Incidence of malaria was 
much higher in the comparator group who started just few days after the randomised group had 
received its second dose of SMC. The cumulative hazard was almost three times the hazard in 
the treated cohort where it remained under 0.40 (figure 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Cumulative hazard of malaria (fever or history of fever with any parasitemia) in children who 
received SMC with DHAPQ or SPAQ on three occasions in August, September and October. 
 
4.5.4 Incidence of severe malaria 
Four cases of severe malaria were recorded, two in the DHAPQ arm and one respectively in 
SPAQ and untreated groups. In the DHAPQ group, two female participants respectively 7 and 5 
months on admission presented with positive smear, neurologic signs (convulsions) and severe 
anemia (hb<5 g/dl). In the comparator group a female aged 9 months was admitted for severe 
anaemia and neurologic malaria. In the SPAQ group, a male, 19 months was admitted for 
haemoglobinuria.  All children received intravenous quinine and recovered. 
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4.5.5 Impact of SMC on the prevalence of Plasmodium falciparum infection and gametocyte 
carriage at the end of the transmission season survey 
The prevalence of parasitaemia and of gametocyte carriage was similar in both SMC groups, and 
substantially lower in the SMC groups than in the untreated controls (Table 4.7). In the control 
group, the prevalence of parasitaemia at the end of the transmission season was lower than when 
subjects were enrolled (36% compared to 61% at enrolment, Table 4.1), presumably reflecting 
the effect of antimalarial treatment received for clinical cases in this group.  
 
Table 4.7: Parasitemia and Gametocytemia at the end of the transmission season survey 
 
Prevalence of parasitaemia 
 
Prevalence of gametocytes 
 
No. 
sampled 
No. positive 
(%) 
Risk ratio 
(95%CI) 
No. 
sampled 
No. positive 
(%) 
Risk ratio 
(95%CI) 
Comparator 247 88 (36%) 1 247 18 (7%) 1 
DHAPQ 722 88 (12%) 
0.34 
(0.26,0.44) 721 6 (0.8%) 
0.11 
(0.05,0.28) 
SPAQ 731 89 (12%) 
0.34 
(0.26,0.44) 727 6 (0.8%) 
0.11 
(0.05,0.28) 
 
4.5.6 Impact of SMC on nutritional status 
At enrolment, severe malnutrition was an exclusion criterion; therefore any class of malnutrition 
found did not appear to influence the intervention outcome as tested in Cox regression. 
The proportion of underweighted and wasted decreased over the course of the trial but not the 
stunting stunted which in fact increased. In the treated groups, the proportion of wasted 
increased slightly 12%; other parameters improved. The treated and comparator groups were not 
comparable in regard to the differences in time of their recruitment (table 4.8). 
 
Table 4.8: Evolution of nutritional parameters over the follow up period 
 Underweight (%) Stunting (%) Wasting (%) 
 Pre Post Pre Post Pre Post 
Comparator 38% 23% 14% 24% 42% 16% 
DHAPQ 25% 20% 24% 13% 22% 25% 
SPAQ 26% 16% 25% 12% 22% 25% 
 
4.5.7 Prevalence of anemia at the end of the transmission season survey 
The prevalence of severe anaemia was similar in the two treated groups (both 9%). Prevalence 
was lower in the untreated group, possibly due to the fact that this group was surveyed one 
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month later, November in the intervention groups and December in the untreated group (table 
4.9). 
 
Table 4.9: Haemoglobin concentration at the end of season survey: 
 Heamoglobin (g/dL) 
 Number sampled <10 g/dL (%) < 5 g/dL (%) 
Control 243 114 (47%) 4 (2%) 
DHAPQ 719 253 (35%) 66 (9%) 
SPAQ 713 231 (32%) 64 (9%) 
 
 4.6 Clinical tolerability of the intervention 
4.6.1 Mild adverse events 
The incidence of mild adverse events was higher in the first round of SMC than in subsequent 
rounds, and in each round, the incidence was similar in both treatment groups (figure 8). The 
most commonly reported mild adverse events reported were cough, diarrhoea, vomiting, and 
fever (table 4.10). 
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Figure 4.4: Incidence of mild adverse events over the three rounds in the DHAPQ and SPAQ 
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Table 4.10: Incidence of mild adverse events 
Symptom/signs 
DHAPQ SPAQ 
 
Aug Sep Oct Aug Sep Oct 
N=707 N=726 N=735 N=685 N=713 N=709 August September October 
Proportion (%) with mild adverse events Risk difference % with (95%CI) 
At least one symptom 20 6.1 4.1 18 5.0 2.1 2.80 (1.20, 12.10) -1.00 (-3.40,1.40) -2.00 (-3.70,-0.20) 
Cough 11 2.8 1.2 12 2.2 0.80 1.80  (1.80, 8.50) -0.50 (-2.10,1.10) -0.40 (-1.40,0.70) 
Diarrhoea 7.9 1.8 1.8 8.5 1.7 0.60 1.00  (0.70,3.40) -0.10 (-1.50,1.20) -1.20 (-2.30,-0.10) 
Vomiting 4.2 1.0 0.70 3.4 0.60 0.60 1.70  (0.80,2.30) -0.40 (-1.30,0.50) -0.10 (-0.90,0.70) 
Fever 2.8 1.7 0.80 2.3 1.5 0.60 1.00 (0.30,1.80) -0.10 (-1.40,1.20) -0.30 (-1.10,0.60) 
Headache 1.3 1.0 0.30 1.8 0.30 0.10 0.30  (0.10,1.60) -0.70 (-1.50,0.10) -0.10 (-0.60,0.30) 
Abdominal pain 1.7 0.30 0.10 1.6 0.00 0.00 0.70 (0.10,1.50) -0.30 (-0.70,0.10) -0.10 (-0.40,0.10) 
Loss of appetite 1.0 0.70 0.10 1.5 0.10 0.10 0.60  (0.40,0.90) -0.50 (-1.20,0.10) 0.00 (-0.40,0.40) 
Pruritis 1.1 0.60 0.40 0.9 0.30 0.00 0.40 (0.10,0.60) -0.30 (-0.90,0.40) -0.40 (-0.90,0.10) 
Drowsiness 0.30 0.40 0.10 0.6 0.00 0.00 0.30 (0.70,0.40) -0.40 (-0.90,0.10) -0.10 (-0.40,0.10) 
Skin reaction 0.40 0.30 0.70 0.4 0.10 0.10 0.00 (0.10,0.30) -0.10 (-0.60,0.30) -0.50 (-1.20,0.10) 
Jaundice 0.10 0.00 0.10 0.3 0.10 0.00 0.40 (0.10,0.10) 0.10 (-0.10,0.40) -0.10 (-0.40,0.10) 
Dizziness 0.30 0.40 0.10 0.1 0.00 0.00 0.30% (0.10,0.10) -0.40 (-0.90,0.10) -0.10 (-0.40,0.10) 
Nausea 0.30 0.30 0.10 0.1 0.00 0.00 0.00 (0.00,0.00) -0.30 (-0.70,0.10) -0.10 (-0.40,0.10) 
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4.6.2 Serious adverse events 
Four children died in the DHAPQ group: a boy aged 20 months died in September, 24 days after 
the August round of SMC, with respiratory distress; a girl aged 5 months died in September, 14 
days after the September round of SMC, with gastro enteritis; a girl aged 1 year died in 
November, 34 days after the October round, with gastro-enteritis; and a girl aged 21 months died 
in October 8 days after the October round, with pneumonia. Two children died in the SPAQ 
group, a boy aged 2 years, died in September, 26 days after August round, with dehydration, and 
a boy aged 3 years died in October, 19 days after the September round,  with gastro-enteritis. In 
the untreated cohort, a girl aged 3 years died in November, with malnutrition. None of these 
deaths was considered related to SMC. 
 
4.7 Biological safety  
4.7.1 Pooled analysis 
To assess the impact of the SMC intervention on the haematological and biochemical parameters 
a subset of children in the treated cohort was selected to give 5 ml of venous blood on day 0 
before the round dose administration and again on day 7. 
A target of 45 children in each arm was calculated for the study (15 per arm and per round). To 
improve adherence, the sample size was split between the rounds and each participant child was 
sampled on a single round; the advantage being that children sampled on the last round may 
have accumulated the impact (positive or negative) of the intervention and this could be reflected 
in the parameters measured. Venous blood sampling was very challenging: despite repeated 
explanations and meetings with the mothers and local leaders, parents remained reluctant to 
attend for the remaining sampling; certain parents after the day 0 sampling collection refused to 
give the second sample; for some of the children, the amount withdrawn was not enough to be 
processed. In addition to these challenges in the field, haemolysis, breakage of a few tubes and 
insufficiency of plasma after centrifugation further limited the number of valid samples for 
analysis. For the purpose of the analysis, all data were pooled and all day 0 samples over the 
three rounds were analysed together. The results obtained indicated a decrease in the PVC and 
haemoglobin values in the children treated with DHAPQ between day 0 and day 7; the adjusted 
difference on day 7 was highly significant for the haemoglobin (1.03 95% CI [0.51,1.55], 
p=0.000) and for the PVC (2.31 95% CI [0.86,3.77], p=0.002) (table .4.11). 
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4.7.2 Parameters values outside the normal range 
In this section we examined each parameter to detect any value outside the adopted normal range 
for the haematological and biochemical values. 
4.7.2.1 White Blood Cell count 
High values: One participant treated with DHAPQ had a WBC 18900 cells per mm
3
 on day 0 
and 17200 cells per mm
3
 on day 7 in September. The participant R0648-7 treated with SPAQ on 
September round had 16300 cells per mm
3
 on day 0 and 12100 cells per mm
3
 on day 7 (fallen 
within the normal range). 
Low values: Seven (7) patients in the DHAPQ group and eight (8) patients had a day 0 WBC 
countless the normal value of 5300/mm
3
. By day 7 only one patient in the SPAQ group still had 
a low WBC count 3500 per mm
3
. 
4.7.2.2 Red Blood Cell count 
High values: Four (4) patients in the DHAPQ and two (2) patients in the SPAQ had a RBC count 
above the normal range (3.05 to 5.12x10
6
) on day 0. By day 7 two patients (2) in the DHAPQ 
and one (1) patient in the SPAQ group remain slightly above the normal range (5.41 for the 
patient in the SPAQ group, and 5.16 &5.20 for those in the DHAPQ group).  
Low values: Three patients (2 in the SPAQ and 1 in the DHAPQ) were below the normal range 
on day 0, by day 7 all of them fall into the normal range 
4.7.2.3 Haemoglobin 
On day 0 two (2) patients in the SPAQ group fell below the normal range (7.4 to 12.4 g/dl), their 
values were 4.6g/dl & 5.5 g/dl; in the DHAPQ group one patient was below the normal 7.3g/dl. 
By day 7 only one patient’s value in the SPAQ group remained low, even though it increased to 
4.8g/dl. In our context, a haemoglobin above 12.4g/dl is not abnormal, therefore only unusual 
two high values  were reported in patients treated with DHAPQ (17.7g/dl &19.8g/dl) on day 0 
but there fall into common range of values on day 11g/dl &12.8g/dl respectively, so these high 
values may be due to measurement errors. 
4.7.2.4 Creatinine 
On day 0, five (5) patients in the DHAPQ group and eight (8) in the SPAQ group had a 
creatinine values above the normal range (< 60 µmol/liter); only four (4) of them all in the 
SPAQ group accepted to be sampled again on day 7. Of the four, one patient had normal value 
and the three other had values slightly above 60 respectively 73.6, 60.8 & 64 µmol/liter. 
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4.7.2.5 TGOA 
Fifteen (15) patients in the DHAPQ and thirteen (13) in the SPAQ group had an absolute TGOA 
value above 60 UI/L on day 0. On day 7 ten (10) patients in the DHAPQ and six (6) in the SPAQ 
group refused further sampling. Of those who accepted the sampling, respectively one and three 
in the DHAPQ and SPAQ were still above the normal range on day 7.  
4.7.2.6 TGPA 
Seven (7) patients all in the SPAQ group had day 0 value above the normal range (<60 UI/l). On 
day 7 three (3) refused further sampling; of the four (4) only one had a normal value. 
4.7.2.7 Platelet count 
Three patients (3) all in the SPAQ group had day 0 platelets above the normal range (133-523 
000/mm
3
) and this trend was maintained upon day 7.  
4.7.2.8 The Lymphocytes 
Three patients in the SPAQ group had a proportion of lymphocytes outside the normal range 
(two above 70.7% and one less than 36.7%) but all of them come down within the normal range 
on day 7. 
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Table .4.11: Haematological and biochemical variables measured before and after SMC 
 
DHAPQ SPAQ Adjusted difference 
Variable Day 0 Day 7 N
#
 Day 0 Day 7 N
#
 
between groups  on day 7 
SPAQ-DHPQ (95%CI)*    P-value 
Haemoglobin g/dL 10.9 10.4 37 10.6 11.3 47 1.03 (0.51,1.55) 0.000 
PCV % 33.1 32.5 37 32.4 34.4 47 2.31 (0.86,3.77) 0.002 
Platelets10
3
/ mm
3
 234 319 37 276 304 47 -28 (-84,28) 0.316 
White blood cells10
3
/ mm
3
 8151 8714 37 7665 9035 48 599 (-767,1963) 0.386 
Red blood cells10
6
/mm
3
 4.284 4.242 37 4.082 4.370 48 230 (48,412) 0.014 
Neutrophils, cells/ mm
3
 3083 3474 32 2994 3505 41 53 (-925,1031) 0.914 
Eosinophils, cells/ mm
3
 233 173 32 194 223 41 54 (-42,151) 0.266 
Basophils, cells/ mm
3
 3.00 0.00 32 1.24 3.61 41 3.6 (-2.2,9.3) 0.219 
Lymphocytes, cells/ mm
3
 4752 4830 32 4283 4974 41 393 (-360,1147) 0.302 
Monocytes, cells/ mm
3
 129 118 32 118 129 41 15 (-38,69) 0.575 
Creatinine, µmol/litre 34.2 34.3 17 42.6 50.2 26 13 (-2.1,29) 0.089 
Tgoa, IU/litre 54.4 53.1 17 56.2 59.5 25 6.4 (-10,23) 0.449 
Tgpa, IU/litre 29.8 35.9 17 45.5 43.4 25 5.4 (-12,23) 0.534 
Vgm, Fl 77.6 77.1 37 78.6 79.0 47 1.3 (-0.81,3.3) 0.229 
Tcmh pg/GR 25.6 24.8 37 26.2 26.0 47 0.70 (-0.06,1.5) 0.069 
Ccmh g/dL 32.8 32.1 37 32.8 33.0 47 0.95 (0.03,1.9) 0.044 
#
No. of children sampled on both days, *difference between group means on day 7, adjusted for the day 0 value
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Summary 
SMC with SPAQ was highly effective, the protective efficacy was 74% & 80% respectively 
for DHAPQ and SPAQ for malaria of any parasitemia and 79% & 84% for malaria with 3000 
parasites per microliter). SPAQ was more efficacious than DHAPQ, but the difference was 
within the margin set for non-inferiority. Both regimens gave a very high level of protection 
lasting 4 weeks and the children were again at risk between two rounds. Both regimens were 
well tolerated, incidence of mild adverse events decreased in successive months, consistent 
with tolerance to study drugs. A limitation was that incidence of mild adverse events was not 
assessed in controls, some of these events may not have been drug-related. 
There was a very high burden of malaria in the untreated children.  
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Chapter 5: Association of piperaquine concentration with 
treatment dosage and incidence of malaria  
 
5.1 Overview of the chapter 
This chapter reported relevant results from the nested pharmacokinetics study undertaken in 
the cohort of children treated with DHAPQ (part of the main clinical trial) and described in 
the section 3.2 15 of the methods chapter (chapter 3). Drug efficacy is a function of multiple 
factors; one of them is directly related to the drug itself. Among other factors we can include 
the dose administrated orally (based on weight), the plasma concentration and the duration of 
action of the active metabolite. These factors play a central role in the growing SMC strategy, 
particularly plasma concentration and duration of protection are insufficiency explored. The 
following points are successively presented: 
- A brief review of the statistical methods used to analyse the data 
- The relationship between the drug administration in mg per kg and the age; 
- The relationship between the dose in mg per kg and the plasma concentration on day 7 
- The relationship between the age and the plasma concentration on day 7 
- The incidence of clinical malaria in relation with the plasma concentration on day 7  
In this paragraph, we estimated the duration of protection after one round of SMC. 
 
5.2 Statistics methods 
Day 7 piperaquine concentration has been predictive of treatment outcome with 
dihydroartemisinin-piperaquine. In this analysis, we selected only the samples collected on 
day 7 following the dose of the round. 
 
The relationship between the age and the dose of piperaquine per kg body weight and the 
drug concentration measured on day 7 was assessed using plots (groups of age against the 
dose in mg per kg and the age against the day 7 piperaquine concentration). 
 
Then the concentration of piperaquine measured on day 7 were plotted against the dose 
administrated in mg per kg will be plotted to assess the relationship between these parameters 
(concentration on day 7 in Y axis and the doses in mg per kg in X axis).  
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To assess the incidence of malaria in relation to the day 7 piperaquine concentrations 
(duration of protection of one round of SMC), the follow up time was restricted from 
October. 
 
October corresponded to the last administration of the SMC but the follow up continued up to 
the first two weeks of january; more episodes were expected on this period exceeding one 
month after the last dose of the SMC. 
For the relationship between day 7 concentration and incidence of malaria analysis (the 
duration of protection), the time of entry in the survival analysis is set to be the day 7 date.  
 
Time period to evaluate the SMC duration of protection: For the participants sampled in 
August, the exit date was the date of the first dose of September; those sampled in September 
round exited the date of the first dose in October; the exit date of children sampled in October 
was the first day of the final survey date. Attempt was made to maintain 30 days between two 
rounds of SMC in this analysis as it is planned in the interval time for the SMC delivery. 
To assess how the number of the clinical cases varies with the level of the day 7 
concentrations of piperaquine was split into four quartiles to elucidate any variation of 
incident cases between different levels. 
 
5.3 The relationship between the piperaquine administrated in milligram per kilogram 
body weight and the day 7 plasma concentration of PQ in ng/ml given with the DHA 
with the age. 
The mean dose of piperaquine was 50.5±8.1 mg per kg body weight.  
Children less than 24 months received the highest daily dose of piperaquine per kg body 
weight and the lowest in those aged more than 24 months. (Figure 5.1). In linear regression, 
each increase in one unit of age (which in fact corresponds to 1 year) increased the PQ day 7 
plasma concentration of 0.014 ng/ml, 95% CI [0.010 to 0.017], p=0.0001 
 
Children 12-23 months that had high dose of piperaquine per milligram per kilogram body 
weight appeared to exhibit low plasma concentration of piperaquine on day 7. In linear 
regression model, there is a decrease of 0.008 ng/ml in plasma concentration of piperaquine 
on day 7 for an increase in one unit of age. 
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Figure 5.1: Bar plot of the relationship between piperaquine administrated in milligram per kilogram of body weight and the day 7 
plasma concentration of PQ in ng/ml with the age group 
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5.4 The relationship between dose in mg per kilogram and plasma concentration of 
Piperaquine on day 7 
 
Figure 5.2: Relationship between dose in mg per kg and day 7 concentration of PQ 
The concentration of piperaquine on day 7 is a function of the dose of piperaquine 
administrated in milligram per kilo of body weight (figure 5.2). 
 
5.5 The incidence of clinical malaria in relation with the plasma concentration on day 7 
Fifty five children were sampled; sixteen experienced clinical malaria through the whole 
period of the surveillance. Most of the cases occurred in the first quartile representing the 
lowest concentration of piperaquine as measured on day 7; the third quartile had the second 
largest number of cases (table 5.1).  
 
Table 5.1: Incidence rate of malaria per quartile PQ concentration 
 Mean 
ng/ml 
Concentration 
 range ng/ml 
Cases N Days at 
risk 
Rate 95% CI 
<40 23.4 7.79 to 32.1 6 12 1103 0.005 2.10
-3
 to 12.10
-3
 
40 - 50 44.3 40.5 to 49.5 3 10 911 0.003 10
-3
 to 10
-2
 
50 -70 59.7 49.7 to 70.5 5 18 1648 0.003 10
-3
 to 7.10
-3
 
> 70 96.47 71.3 to 163 2 15 1376 0.001 4.10
-4
 to 6.10
-4
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The delay appearance of first case of malaria in this group ranged from 30 days to 77 days 
following the administration of the drug (Table 15). Among the recurrent 16 cases, 7 children 
had a dose in mg per kg body weight less than the targeted dose of 18 mg/kg; none had 
vomited the drug. The lower doses ranged from 13.3 mg/kg a 5 years old boy to 16.9mg/kg in 
5 years old boy (table 5.2). 
 
Table 5.2: List of patients with day 7 piperaquine concentration measured presenting 
clinical malaria after the last SMC in October 
Patient 
Day of malaria 
occurrence 
(day) 
PQ 
concentration 
ng/ml 
 
PQ doses  
Mg/kg 
Vomiting  
within 30 
minutes 
R0379-5 30 18.8 18.46 No 
R0318-9 54 25.7 13.3 No 
R0450-5 54 28.8 14.55 No 
R0450-5 30 28.8 14.55 No 
R0336-2 63 29.9 20.5 No 
R0317-7 54 31.8 18.9 No 
R0394-0 47 41.9 18.8 No 
R0374-2 45 47.2 16.2 No 
R0447-4 59 48.1 15.1 No 
R0315-3 49 50.5 16.9 Yes 
R0499-6 67 56 15.4 No 
R0403-1 53 56.6 19.8 No 
R0400-4 79 59 16 No 
R0323-9 75 69.1 19.8 No 
R0393-5 47 76.6 14 No 
R0448-8 77 163 18.9 No 
 
5.6 Kaplan-Meier estimate of the cumulative incidence of malaria in four quartiles of 
PQ concentration on day 7 
The cumulative incidence risk of malaria is significantly higher in children whose day 7 
concentration of PQ was below 40 ng/ml, the better protection was achieved with more than 
70 ng/ml of plasma concentration.  The delay in the appearance of the cases increases as the 
day 7 concentration is high (figure 5.3). 
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Figure 5.3: Incidence of malaria in relation to piperaquine concentration measured on 
day 7, in 55 children treated DHA-PQ 
 
5.6 Duration of protection after the last round of SMC in SPAQ and DHAPQ groups  
The duration of protection estimated from the day 7 date of sampling was maximal in SPAQ 
treated patients; up to 4 weeks the protection persisted up to more than 70% and decreased 
rapidly to 50% by day 35. This proportion was reduced to 40% between day 35 and 42 and 
weak protection was avaiblable after 6 weeks; more than 80% of the children are again at 
risk. The decrease in the protection with the DHAPQ followed a similar trend but was more 
marked during the first four week and suddenly fell thereafter. By seven weeks after the SMC 
dose no protection was observed for all groups (figure 5.4). 
P value for a test for trend of survivor functions with PQ dose group was P=0.0873. 
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A smoothed estimate of the hazard ratio was obtained using regression splines using the 
method of Lambert and Royston (2009), the efficacy (1-hazard ratio) with 95% confidence 
band is plotted against time since the final round of SMC. 
 
 
Figure 5.4: Duration of protection (malaria with any parasitemia). 
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5.7 Summary 
Plasma disposition of piperaquine on day 7 is an important indicator of the efficacy of 
dihydroartemisinin-piperaquine administered during this SMC study. Children less than 24 
months of age received high dose of piperaquine administrated in miligram per kilogram. 
Plasma concentration of PQ on day 7 was dose in milligram per kilogram dependent. The 
duration of protection for all regimen was maximal over 3 to 4 weeks and then decreased 
steadily.  Very low protection was seen from week 5 and none from week 7 onwards. The 
drug concentration after 4-5 weeks was not enough to provide a substantial protection but 
persisted up to 7 weeks. This persistance of low concentrations of antimalarial may lead to 
the exposure of survival parasites to very low concentration of the drug and offer a scope for 
selection of drug resistance which will be investigated in more details in the next chapter.  
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Chapter 6 Drug resistance and SMC with DHAPQ or SPAQ 
 
6.1 Introduction 
The present chapter 6 will investigate any possible evidence of selection by either SMC 
regimen of molecular makers to sulfadoxine-pyrimethamine (dhfr N51I, C59R, S108N, dhps 
S436A/F, A437G, A613S), to chloroquine  of resistance pfmdr-1PfMDR-1 N86Y, Y184F, 
D1246Y, pfcrt haplotypes CVMNK & CVIET at positions 72_76. The analysis was done in 
the first instance on first episodes samples by passive cases detection prior to the clinical case 
was treated with artemether-lumefantrine; then subsequent episodes were analysed  
The chapter is organised in accordance with the objectives set in the fourth paragraph of the 
literature review chapter:  
(i) The comparison prevalence of mutations of interest at baseline among the groups. 
(ii) The comparison of the above mutations among the groups in all episodes detected by 
passive case detection.   (iii) The comparison of the selection profile of these markers 
between the first and subsequent weeks following the administration of SMC. 
 (iv) The comparison of mutations of interest at the end of the transmission season survey 
among groups.  
(v) The comparison of the prevalence of different combination of mutations or new identified 
mutations among the groups (exploratory analysis). 
(vi) The comparison of key markers on pre and post intervention. 
 
6.2 Baseline prevalence of key molecular markers 
 
These data were provided by Mr Somé for inclusion in the analysis. Of 360 samples tested in 
San Francisco, 260 were found to be PCR positive: 90 in the DHAPQ, 87 in the SPAQ and 
83 in the untreated groups (table 6.1). 
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Table 6.1: Baseline proportion of molecular markers prior to SMC round in 260 PCR 
positive participants 
  
DHAPQ SPAQ Non SMC 
Total 
(PCR positive)  
90 87 83 260 
  Proportion (%) carrying the mutant alleles 
dhfr 
51-Ile 55.6 55.2 63.9 58.1 
59-Arg 56.7 50.6 57.1 55 
108-Asn 77.8 89.7 80.7 82.7 
dhps 
436-Ala 34.8 30.3 40.5 35.1 
437-Gly 59.6 52.3 58.3 56.8 
pfmdr-1 
Y86 29.2 33.7 24.1 29.1 
F184 53.9 61.6 60.2 58.5 
Y1246 7.9 8.1 7.1 7.7 
pfcrt CVIET 78.7 67.8 58.3 68.5 
pfcrt CVIET+Pfmdr1 Y86 25.5 25.3 16.7 22.6 
dhfr (51/59/108) 20 10.3 16.9 15.8 
 (triple dhfr+dhps G437) 12.2 5.7 12.1 10 
All baseline data kindly provided by Mr Somé 
 
At baseline, the prevalence of molecular markers of antifolate and chloroquine resistance were 
commonin the intervention area. The prevalence of the pfcrt CVIET haplotype was quite high  in 
the study area which could be an indication of CQ pressure in this population. Parasites carrying 
multiple mutations were however less frequent. The prevalence of the quadruple mutant pfdhfr/ 
pfdhps  was rare not exceeding 20% irrespective of the treatment group. 
 
6.3 Prevalence of molecular markers in the first episode after SMC administration 
DNA for malaria genotyping was extracted for 42.7% (149/349), 35.6% (116/326) and 36.7% 
(81/221) in the DHAPQ, SPAQ and non SMC groups respectively. Incident episodes were 
compared between groups using the odds ratio. 
 
Genotype results: The proportion of participants carrying the mutant allele either in pfmdr-1 gene 
or pfcrt haplotype CVIET haplotype thought to be Piperaquine resistant related mutations was 
similar in all groups. There was no association with their selection and Piperaquine treated clinical 
resistance. The odds ratio for patients treated with SPAQ carrying the single mutation in pfdhfr 51-
Ile, 59-Arg, 108-Asn, the pfdhps 437-Gly, was higher compared to the untreated group (table 6.2).  
The triple mutant in dhfr or the quadruple in dhfr plus dhps were commonly reported in the 
participant treated with Sulfadoxine-Pyrimethamine compared to the untreated group.  
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Table 6.2: Prevalence of molecular markers of resistance among samples from malaria cases (first episode) 
 Genotype DHAPQ SPAQ Non SMC Odds ratio 95% CI 
SPAQ  DHAPQ 
Odds ratio 95% CI 
DHAPQ Non SMC 
Odds ratio 95% CI 
SPAQ Non SMC 
 Proportion (%) carrying the mutant allele    
pfcrt CVIET 62.9 61 61.5 0.9 (0.5 to 1.7), p=0.79 1.1 (0.5 to 2.4), p=0.88 0.98 (0.4 to 2.3), p=0.97 
pfmdr-1 Y86 33 44.4 30.4 1.6 (0.8 to 3.3), p=0.14 0.7 (0.3 to 1.5), p=0.33 1.8 (0.9 to 3.9), p=0.08 
pfmdr-1 F184 36.4 32.3 39.2 1.2 (0.6 to 2.5), p=0.6 0.9 (0.5 to 1.7), p=0.7 0.7 (0.3 to 1.6), p=0.3 
dhfr 51-Ile 40.6 64 51.3 2.6 (1.5 to 4.6), p<0.001 0.7 (0.4 to 1.2), p=0.1 1.6 (0.9 to 3.2), p=0.08 
dhfr 59-Arg 43.6 71 53.75 3.2 (1.8 to 5.7), p<0.001 0.7 (0.4 to 1.2), p=0.15 2.1 (1.1 to 4.1), p=0.01 
dhfr108-Asn 58.3 27 70 0.3 (0.1 to 1.5), p<0.001 0.6 (0.3 to 1.1), p=0.08 0.2 (0.1 to 0.3), p<0.001 
dhps G437 63.4 84 75 3 (1.5 to 6.1), p<0.001 0.6 (0.3 to 1.2), p=0.10 1.8 (0.7 to 4.1), p=0.15 
dhpsS613 6.5 6.9 13.6 1.1 (0.3 to 3.3), p=0.9 0.4 (0.1 to 1.3), p=0.09 0.5 (0.4 to 1.5), p=0.1 
pfmdr-1 Y86 + pfcrt CVIET 3.3 6 1.2 1.8 (0.5 to 7.6), p=0.29 2.8 (0.3 to 133), p=0.33 5.3 (0.6 to 234), p=0.09 
Dhfr  (I51/R59/S108) 30.9 53.2 33.9 2.5 (1.4 to 4.6), p=0.001 1.1 (0.6 to 2.4), p=0.68 2.1 (1.1 to 4.6), p=0.01 
dhfr (I51/R59/S108) + G437 19.5 41.5 23.7 2.9 (1.5 to 5.6), p<0.001 0.8 (0.3 to 1.8), p=0.5 2.3 (1.1 to 5.1), p=0.02 
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6.5 Molecular markers profile of the episodes following SMC rounds 
We aimed at investigating the molecular markers profile of the clinical episodes occurring 
early after the SMC administration (within three weeks) during the follow up period. We first 
identified the number of episodes which occurred per round; then the episodes per round 
were split into weeks (first, second third, fourth and fifth). We defined the weeks as the 
period elapsing between the date the episode occurred and the day the patient received the 
next dose of SMC or artemether-lumefantrine. Preliminary analysis found few episodes 
within the first three weeks; therefore we categorised the period into two intervals, before and 
after three weeks. 
6.5.1 Clinical episodes per round of SMC 
Fewer cases of clinical malaria occurred during the first three weeks of each round in the 
intervention groups compared to the Non SMC group. These proportions were 14.1% (9/64) 
and 13.8% (10/72) in September for SPAQ and DHAPQ groups respectively and 27.8% in 
the Non SMC group. The risk of malaria occurrence was significantly higher in the Non SMC 
group compared to the SPAQ (OR=2.3, 95% CI 1.1 to 5.6), p=0.02) and to the DHAPQ 
group (OR=2.4, 95% CI 1.1 to 5.4), p=0.01. A similar trend was observed in October where 
there were more significant cases in the Non SMC group (table 6.3). 
Episodes of malaria occurring in the first weeks following SMC administration in each 
treatment round were identified to investigate their molecular marker profile as they were 
expected to be resistant strains of parasites.  
Table 6.3: Number of clinical cases within 3 weeks after the SMC per round 
Rounds Malaria episodes DHAPQ SPAQ Non SMC 
August 09 Number of cases 47 36 - 
Number within 3 weeks 20  10 - 
September 09  Number of cases 72 64 329 
Number within 3 weeks 10 9 91 
October 09 Number of cases 66 59 114 
Number within 3 weeks 13 8 70 
November 09 Number of cases 41 29 71 
Number within 3 weeks 0 0 34 
December 09 Number of cases 237 232 41 
 Number within 3 weeks 0 0 0 
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6.5.2 Molecular markers profile of incident cases per round 
6.5.2.1 First round in August 09 
A total of 20 episodes of  malaria occurred within 3 weeks following the SMC administration 
in August (round 1) in the DHAPQ group Among these episodes, 10 samples were 
successfully genotyped and their profile is listed in table 6.4. None of these samples carried 
triple mutant pfdhfr or quadruple mutant pfdhfr/ pfdhps . In the SPAQ treated participants, 
only 10 recurrent episodes were recorded of whom 6 were successfully genotyped (table 6.4). 
 
Table 6.4: Molecular markers profile of the cases occurring within 3 weeks of SMC 
initiation in August 09 
ID  pfmdr-1 pfcrt dhfr dhps Dhfr (irn) 
 y86 f184 y1246 cviet i51 r59 n108 a436 g437 s613  
Dihydroartemisinin-piperaquine 
R1020-2 1 0 0 - 1 0 0 0 0 0 0 
R0630-0 0 1 0 1 1 1 1 1 1 0 - 
R0311-8 0 0 0 0 - - - - - - - 
R1496-5 0 1 0 1 0 0 1 1 1 0 0 
R1452-6 0 1 0 - 0 0 1 0 1 0 0 
R0943-9 0 1 0 1 - - - 1 1 0 - 
R1320-4 - - 0 1 - - - - - - - 
R0942-2 0 0 0 - 0 0 1 1 0 0 0 
R0193-3 0 1 0 1 - - - 0 1 0 - 
R0948-0 1 1 1 - 0 0 1 0 1 0 0 
R1081-2 0 1 0 1 1 1 0 1 0 0 1 
R1019-5 0 0 0 - 0 0 1 1 0 0 0 
Total 2 7 1 6 3 2 6 6 6 0 2 
Sulfadoxine-Pyrimethamine plus Amodiaquine 
R0401-5 0 1 0 1 - - - 1 1 0 - 
R0140-6 0 1 0 0 - - - - - - - 
R0894-8 0 0 0 - - - - - - - - 
R0156-4 1 - 1 0 - - - - - - - 
Total 1 2 1 1 - - - - - - - 
6.5.2.2 Second round in September 09 
In September, 10 and 9 episodes occurred within the first three weeks in the DHAPQ and 
SPAQ groups respectively. All samples from the episodes were successfully genotyped 
except 2 samples in the DHAPQ group. The triple mutant dhfr (I51/R59/S108) and the 
quadruple mutant dhfr (I51/R59/N108) and dhps G437 were found in two samples in the 
SPAQ group and only in one sample in the DHAPQ treated participants (table 6.5). 
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Table 6.5: Molecular markers profile of the cases occurring within 3 weeks of SMC 
initiation in September 09 
ID pfmdr-1 pfcrt dhfr dhps   
 y86 f184 y1246 cviet i51 r59 n108 a436 g437 s613 
Triple 
dhfr 
dhfr 
+dhps 
Dihydroartemisinin-piperaquine 
R0615-8 1 0 0 - 0 0 1 1 1 0 0 0 
R0786-3 0 1 0 1 1 1 1 1 1 0 - - 
R1019-5 0 1 0 1 1 1 0 0 1 0 - - 
R1120-5 0 0 0 1 1 1 1 0 1 0 - - 
R1147-0 1 1 0 - 0 0 1 1 1 0 0 0 
R1189-9 0 1 0 1 1 1 0 0 1 - 1 1 
R1244-1 0 1 0 - 0 1 0 1 0 0 0 0 
R1247-6 0 0 0 1 0 0 1 1 0 0 0 0 
R1461-9 0 1 0 - 0 1 0 0 0 1 0 0 
Total 2 6 0 5 4 6 5 5 6 1 1 1 
Sulfadoxine-Pyrimethamine plus Amodiaquine 
R0342-9 0 1 0 - 0 0 1 1 1 0 0 0 
R1134-7 0 1 0 - 1 1 0 0 1 0 1 1 
R1135-0 0 1 0 1 0 0 1 1 0 0 0 0 
R1241-2 0 0 0 1 1 0 1 0 1 0 0 0 
R1349-8 0 1 0 1 1 1 1 1 1 0 - - 
R1365-9 0 1 0 - 1 0 1 1 1 1 0 0 
R1388-6 0 1 0 - - - - 1 1 0 - - 
R1431-2 0 1 0 1 1 1 0 1 1 0 1 1 
Total 0 7 0 4 5 3 5 6 7 1 2 2 
 
6.5.2.3 Third round in October 09 
The molecular marker profile of the recurrent cases in October in the intervention groups did 
not reveal significant association between mutations in the recurrent cases (table 6.6).  
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Table 6.6: Molecular markers profile of the cases occurring within 3 weeks of SMC 
initiation in October 09 
ID  pfmdr-1 pfcrt  dhfr dhps   
 y86 f184 y1246 cviet i51 r59 n108 a436 g437 s613 Dhfr(irn) Irn+g 
Dihydroartemisinin-piperaquine 
R0022-3 - - - 0 1 1 0 1 0 0 1 0 
R0164-4 - - - 0 1 1 0 0 1 0 0 0 
R0265-9 - - - 0 0 0 1 0 1 0 0 0 
R0489-7 - - - 1 - - - - - - - - 
R0795-1 - - - 0 0 0 1 0 1 0 0 0 
R0837-1 - - - 0 0 0 1 0 1 0 0 0 
R0948-0 - - - 0 0 0 1 1 1 0 0 0 
R1020-2 - - - 1 0 0 1 1 1 0 0 0 
R1147-0 0 0 1 - 1 1 0 1 0 0 0 0 
R1189-9 - - - 1 1 1 1 1 1 0 - - 
R1238-7 - - - 0 1 1 0 1 0 0 0 0 
Total 0 0 1 2 5 5 6 6 7 0 1 0 
Sulfadoxine-Pyrimethamine plus Amodiaquine 
R0031-7 - - - 1 0 0 1 0 1 0 0 0 
R0034-4 - - - - - - - - - - - - 
R0087-2 1 1 0 - - - - 0 1 0 - - 
R0489-7 - - - 0 - - - - - - 0 0 
R0959-1 - - - 0 0 0 1 0 1 0 0 0 
R1203-0 - - - 0 1 1 0 0 1 0 1 1 
Total 1 1 0 1 1 1 2 0 4 0 1 1 
 
 6.6 Exploratory analysis 
The direct sequencing of the blood spot gave the opportunity to explore points of mutations 
not yet detected in the study area. The mutations in dhps K540E and A581G and dhfr I164L 
were not found in any of the samples. Overall, 8.9% (57/644) of the samples carried dhps 
613S mutation irrespective of the number of malaria episodes. Specifically, its prevalence 
was 8% (19/237), 8.3% (17/204) and 10.3% (21/203) in the DHAPQ, SPAQ and untreated 
groups respectively (table 6.7).  
The dhps 613S mutation was associated with the single mutations in low proportion in the 
intervention arms but more in the non SMC arm. 
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 Table 6.7: Association with 613S mutation per intervention arm after the first episode 
 DHAPQ SPAQ Non SMC 
613S+51I 3.1% (4/129) 3.2% (3/95) 6.1% (4/66) 
613S+59R 3.9% (5/129) 4.2% (4/95) 6.1% (4/66) 
613S+108S 2.3% (3/128) 3.2% (3/95) 4.6% (3/66) 
436A+613S 1.5% (2/134) 4% (4/100) 6.1% (4/66) 
437G+613S 1.5% (2/132) 4% (4/99) 6.2% (4/64) 
51/59/108+613S 2.5% (3/120) 2.2% (2/89) 8% (4/50) 
51/59/108/437+613S 0.9% (1/120) 1.1% (1/89) 6% (3/50) 
 
6.7 End of the transmission season survey The prevalence of parasitemia at the end of 
transmission by microscopy was 12% (88/722) in the DHAPQ, 12% (89/731) in the SPAQ 
and 36% (88/247) in the non SMC group. To perform the molecular analysis of the 
mutations, 120 samples were randomly selected from each group for PCR. Positive samples 
from PCR were used for the prevalence assessment. At the end of the transmission season, all 
positive cases harboured the studied mutations. The proportions of molecular markers 
remained high in particular for the pfcrt CVIET haplotype in all treatment groups as well as 
the pfmdr-1 (Y86, 184F). The triple mutant dhfr and quadruple mutant dhfr/dhps  were 
particularly high in the anti-folate containing regimen. To evaluate the evolution of key 
mutation between baseline and the post intervention, we selected key mutations dhfr 51I, 
59R, dhps 437G, pfcrt CVIET, the triple mutant dhfr and quadruple mutant dhfr/dhps in each 
of the treatment group. Histograms of the key mutations before and after intervention gave an 
informative view on the trend of selection in each group (figures 6.1, 6.2 & 6.3). 
 
Figure 6.1:  Selection of mutations of interest at baseline and at the end of the 
transmission season survey in the SPAQ treatment group 
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In the SPAQ group, all selected molecular markers increased in frequency between the pre 
intervention and the end of the transmission season survey, one month after the 
administration of the last dose of SMC (figure 6.1). The increase in the dhfr 59 R, the triple 
mutant dhfr and quadruple dhfr/dhps was statistically significant between the post 
intervention and pre intervention groups (dhfr 59 R, OR=3.6, p<0.001, triple mutant dhfr, 
OR=11.5, p<0.001 and quadruple mutant dhfr/dhps OR=12.3, p<0.001). 
Figure 6.2:  Selection of mutations of interest at baseline and at the end of the 
transmission season survey in the DHAPQ group 
 
In the DHAPQ group, there was a significant decrease in the prevalence of pfcrt CVIET 
haplotype (OR=0.4, p=0.01). For all paired comparison of the selected mutations, there was a 
slight increase (non-significant) in comparison to baseline proportion (figure 6.2). In the non 
SMC group, selected mutations slightly increased but none was significant in comparison 
with the baseline. The mutations in dhfr 59 R and 51 I decreased while others increased 
slightly (figure 6.3).  
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Figure 6.3:  Selection of mutations of interest at baseline and at the end of the 
transmission season survey in the non SMC group 
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The mutations in the dhfr 59 R, 108 S, the pfcrt CVIET, the pfcrt CVIET plus pfmdr-1 Y86, the triple mutant dhfr and quadruple mutant 
dhfr/dhps were significantly associated with the selection in the SPAQ treated children compared to those who received DHAPQ or Non SMC 
(table 6.8). 
Table 6.8: Final survey molecular markers selection profile 
Mutations 
DHAPQ SPAQ Non SMC 
OR, 95% CI 
SPAQ DHAPQ 
OR, 95% CI 
DHAPQ Non SMC 
95% CI 
SPAQ Non SMC 
 Proportion carrying the mutant allele    
pfcrt CVIET 61.5 78.7 62.8 2.3 (1.1 to 5.1), p=0.02 0.9 (0.5 to 1.9), p=0.8 2.2 (1.02 to 4.7), p=0.02 
pfmdr-1Y86 28.2 39.5 31.4 0.6 (0.3 to 1.2), p=0.1 0.9 (0.4 to 1.8), p=0.6 1.4 (0.7 to 2.9), p=0.2 
pfmdr-1F184 60.3 56.6 67.4 0.9 (0.4 to 1.7), p=0.6 0.7 (0.4 to 1.5), p=0.3 0.6 (0.3 to 1.3), p=0.1 
pfmdr-1Y1246 2.6 2.6 8.1 1 (0.1 to 14.5), p=0.9 0.3 (0.02 to 1.6), p=0.1 0.3 (0.03 to 1.6), p=0.1 
dhfr 51-Ile 52 65.8 59.3 1.77 (0.9 to 3.6), p=0.08 0.7 (0.4 to 1.5), p=0.3 1.3 (0.7 to 2.7), p=0.4 
dhfr 59-Arg 48.7 79 45.4 3.9 (1.8 to 8.6), p<0.001 1.1 (0.6 to 2.2), p=0.6 4.5 (2.1 to 9.7), p<0.001 
dhfr 108-Asn 50.6 78.7 52.3 0.3 (0.1 to 0.6), p<0.001 0.9 (0.5 to 1.8), p=0.8 3.3 (1.6 to 7.2), p<0.001 
dhps A436 40.3 38.7 32.6 0.9 (0.5 to 1.9), p=0.8 1.4 (0.7 to 2.8), p=0.3 1.3 (0.6 to 2.6), p=0.4 
dhps 437G 72.7 70.7 62.8 0.9 (0.4 to 1.9), p=0.7 1.5 (0.7 to 3.1), p=0.2 1.4 (0.7 to 2.9), p=0.2 
dhps 613 S 13.7 27.1 12.2 0.4 (0.2 to 1.1), p=0.04 1.1 (0.4 to 3.4), p=0.7 2.7 (1.04 to 7.3), p=0.02 
pfmdr-1 Y86 + pfcrt CVIET 34.4 57.1 24.1 2.5 (1.2 to 5.6), p=0.01 1.6 (0.7 to 4), p=0.2 4.2 (1.8 to 9.9), p<0.001 
dhfr (51I/59R/108N) 26.6 42.9 17.2 2.1 (0.9 to 4.7), p=0.05 1.7 (0.7 to 4.7), p=0.2 3.5 (1.4 to 9.1), p=0.002 
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6.8. Overall prevalence of the mutant allele in the study population  
Despite an apparent increase in the proportion of parasites carrying the mutant strains at the end of 
the transmission season, the overall prevalence of these parasites was low in the study population. 
The prevalence the parasitemia at the end of the transmission season was significantly reduced to 
12% in each treatment group. For example, the proportion of children carrying the triple mutant in 
dhfr in the SPAQ treatment group was 57.1%, 79% for the dhfr 59R and 70.7% for the dhps 437G. 
At the end of the transmission season survey, the proportion of parasitemic participant was 12% in 
this group; overall, when we multiplied the proportion of  carrying the mutants by the prevalence of 
parasitemic participant, we found respectively9% and 8.5% the prevalence of the mutant alleles in 
the whole studied population. 
 
Caution should be applied when interpreting the relevance of the selection of mutant allele’s data to 
avoid misleading presentation of high proportion of mutant alleles while the overall prevalence of 
the parasitemic patient is significantly reduced.  
 
Figure 6.4 Prevalence of molecular markers in children with malaria, then prevalence of 
parasitemia at the end of the transmission season survey, and in the study population 
 
 
6.9 Incident cases of clinical malaria in subsequent episodes of malaria 
Among the subsequent cases, the trend of the selection differed from that of the first episode. 
Indeed the mutation in the dhfr 51I was significantly selected in the SPAQ group compared to the 
DHAPQ and Non SMC group while the dhfr 108N was mostly selected by the DHAPQ and SPAQ 
compared to the Non SMC group. The risk of selection of the dhfr 51I/59R /108N and the 
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quadruple mutations (dhfr 51I/59R /108N plus dhps 437G) was significantly associated with SPAQ 
in comparison with DHAPQ and the Non SMC groups (table 6.9). 
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Table 6.9: Prevalence of molecular markers of resistance among samples from malaria cases (subsequent episode) 
Genotype DHAPQ SPAQ Non SMC Odds ratio 95% CI 
SPAQ  DHAPQ 
Odds ratio 95% CI 
DHAPQ Non SMC 
Odds ratio 95% CI 
SPAQ Non SMC 
 Proportion carrying the mutant allele 
   
pfcrt CVIET  63.4 50.7 48.8 0.6 (0.3 to 1.2), p=0.1 1.8 (0.9 to 3.6), p=0.06 1.1 (0.5 to 2.1), p=0.8 
pfmdr-1 Y86 18.3 11.6  21.1 0.6 (0.2 to 1.7), p=0.2 0.8 (0.4 to 1.9), p=0.6 0.5 (0.2 to 1.2), p=0.09 
pfmdr-1 F184 47.4 50.7 40.1 1.1 (0.5 to 2.5), p=0.7 1.3 (0.7 to 2.6), p=0.3 1.5 (0.8 to 2.9), p=0.1 
dhfr  51-Ile 35.8 51 43.5 1.9 (1 to 3.4), p=0.03 0.7 (0.4 to 1.3), p=0.2 1.4 (0.8 to 2.3), p=0.2 
dhfr  59-Arg 43.4 53.1 49.4 1.5 (0.8 to 2.7), p=0.1 0.8 (0.5 to 1.4), p=0.3 1.2 (0.7 to 2.0), p=0.5 
dhfr  108-Asn 57.8 45.8 71.4 0.6 (0.3 to 1.1), p=0.1 0.5 (0.3 to 0.9), p=0.02 0.3 (0.2 to 0.6), p<0.001 
dhps 437G 60.2 71 72.5 1.6 (0.9 to 3.1), p=0.1 0.6 (0.3 to 1.04), p=0.04 0.9 (0.5 to 1.7), p=0.7 
dhps 613 S 10.2 8.8 8.3 0.9 (0.3 t o2.7), p=0.9 1.3 (0.6 to 3.4), p=0.6 1.1 (0.4 to 2.9), p=0.8 
pfmdr-1 Y86 + pfcrt CVIET 0.9 0.9 1.3 1 (0.01 to 80.7), p=0.9 0.7 (0.01 to 13.9), p=0.7 0.7 (0.01 to 14.2), p=0.7 
dhfr (51I/59R/108N) 27.2 39.3 25.9 1.7 (0.9 to 3.5), p=0.09 1.1 (0.5 to 2.1), p=0.8 1.9 (1 to 3.5), p=0.04 
dhfr (51I/59R/108N) + 437G 13.6 29.2 12.9 2.6 (1.1 to 6.4), p=0.01 1.1 (0.4 to 2.6), p=0.8 2.8 (1.3 to 6.1), p=0.003 
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Figure 6.5. Molecular markers carriage in the study groups The upper figure shows the proportion of 
clinical cases carrying mutations associated with resistance to amodiaquine, sulfadoxine and 
pyrimethamine, in untreated children and in children receiving SMC with SPAQ or DHAPQ. The lower 
figure shows, on the left, the relative incidence rate in children who received SMC with SPAQ or 
DHAPQ relative to untreated controls, and then for each marker, the relative incidence rate in each 
group. Clinical malaria cases are more likely to carry the triple and quadruple mutations if the child 
has received SPAQ, but there are far fewer clinical cases if children receive SMC with SPAQ than in 
untreated children. The net effect is that SMC reduces the incidence of cases carrying these 
mutations. For example, 24% of cases in the untreated group carried the quadruple mutation, 
whereas in children receiving SMC with SPAQ, 42% of cases carried the quadruple mutation, but the 
relative incidence rate was 1 in the untreated group to 0.2 in the SPAQ group , so the overall 
incidence of the quadruple mutation is 0.42:0.2x.42 or 1:0.35, a reduction of 65%.  
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Chapter 7 Discussion 
7.1 Key findings 
Efficacy of SMC was slightly higher with SPAQ, reflecting the advantage of using a 
combination of two long-acting drugs. Both regimens were well tolerated, and both regimens 
were highly efficacious. The incidence of adverse events decreased in each successive month 
which may reflect gradual tolerisation. There was a very high level of protection lasted 
approximately 4 weeks. In children treated with DHAPQ, protection was associated with the 
PQ dose received, and this emphasise the importance of maintaining a 4-week interval 
between SMC doses and avoiding under-dosing. Among children with parasitaemia at the end 
of the transmission season, the proportion carrying markers of resistance to SP was increased 
in the SPAQ group, but the overall prevalence of these markers was low due to the low 
prevalence of parasitaemia in children who received SMC. There is a potential risk of 
resistance to PQ developing as SMC with DHAPQ exposes parasites to monotherapy with 
PQ.  
There was an enormous burden of malaria in untreated children. 250 children experienced 338 
malaria episodes in 2 months, 229 with parasite density >3000/µL. SMC with SP+AQ 
reduced the number of malaria cases by 84%.  SMC with SPAQ should be introduced for 
children in Burkina Faso without delay. 
 
7.2 Limitations of these results 
One limitation of this study was the absence of a proper randomised control. By the time the 
protocol was drafted in the second semester of 2008, a control group was included. 
While the protocol was finalized, the preliminary results about the additional benefit of ITNs 
use and SMC and other results from Senegal and The Gambia (Konate et al., 2011, Cisse et 
al., 2009, Bojang et al., 2010) have added substantial evidence on the benefit of the SMC and 
therefore, randomizing a group of children not to receive the intervention would be unethical. 
However the need of data on the incidence of malaria in the study area was critical. To 
overcome the ethical constraint and obtain data on the incidence of malaria, we did recruit a 
sample of 250 children filling similar criteria for study entry as the randomized group. To 
minimize the differences in the baseline characteristics, the untreated group was recruited in 
one of the SMC site and followed on the same fashion than the intervention group; this cohort 
was recruited one month after the start of the intervention trial due to late ethical clearance 
approval following the revision of the protocol. We did not perform a comparison of baseline 
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characteristics between the three arms and no safety data was collected for the control group. 
For the efficacy analysis, we considered only the period from when the untreated group was 
recruited up to one month after the end of the intervention. 
A minor limitation was the absence of quality test (test of dissolution of the tablets). We 
received the DHAPQ tablets from the Holley Cotec Limited Company, Beijing China along 
with a Good Manufacturer Practice. The AQ sirup (Flavoquine® Parkin Davis) and SP 
(Fansidar® Roche) tablets were bought from a central drug provider who insured that the 
storage, the transports were done in conformity with the manufacturer’s recommendations.  
 
7.3 Overall interpretation 
7.3.1 Efficacy of SMC with SPAQ and DHAPQ against clinical malaria 
In this study, seasonal malaria chemoprevention resulted in a high level of protection against 
the clinical attacks of malaria. The intervention achieved 79% and 84% reduction of malaria 
with more than 3000 Plasmodium falciparum parasites per micro-litre respectively in SPAQ 
and DHAPQ group. The protective effect remained substantial even for the case definition of 
malaria with any parasite density. The protective efficacy reported in this study for DHAPQ 
was lower than that reported in Senegal, The Gambia, in Uganda and Thailand (Bojang et al., 
2010, Cisse et al., 2009, Lwin et al., 2012, Nankabirwa et al., 2010 ); the protective effect for 
SPAQ was lower compared to The Gambia and Senegalese studies but higher than of the 
Ugandan study.  
 
In this study likewise in Senegal and The Gambia, the transmission of malaria is seasonal; the 
intervention targeted the high transmission period and was given monthly over three months 
(August September and October) when the cases were at their peak.  
In Uganda and Thailand, the transmission was less seasonal and the population targeted 
differed from the population treated in West African reports (the present report included); the 
population was school children in Uganda (over 5 years old in general) and adult male in 
Thailand. In these studies, the intervention was given once and followed up for 28 days in 
Uganda and given either monthly or bimonthly in Thailand.  
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The main reason explaining the differences in the protective efficacy in the reports in West 
Africa compared to the present outcome relied on the baseline incidence of clinical malaria in 
the different sites. Despite the absence of reliable data collected in routine of from the 
National Malaria Control Program, results from research studies showed the incidence of 
clinical malaria remains high in Burkina Faso. Indeed, this incidence was 2.88 person year at  
risk in Bousse (Konate et al., 2011) and 0.92 per child per month in the present study 
compared to the situation in The Gambia where field data combined with statistical modelling 
of trends confirmed significant decline over time in the slide positivity (Ceesay et al., 2010) 
and Senegal (Trape et al., 2012). 
Our results differed with the findings from Uganda and Thailand, the most plausible 
explanation stained to two aspects: The age range of the intervention participant; In Uganda 
and Thailand, patients over 5 years old at least and adults were enrolled. While recent studies 
provided evidence data on the low efficacy of DHAPQ in young children and arguing for the 
revision of the dosage in these classes of age (Tarning et al., 2012) and the unacceptably high 
rate of clinical failure of SP and AQ in Uganda combined with the presence of key molecular 
markers establishing the resistance to SP and AQ finished to explain to low efficacy of SPAQ 
(Dorsey et al., 2007) and the better protection of DHAPQ. 
 
The protective outcome reported in our project was similar to that observed in 2011 in a 
previous study to evaluate the additional benefit of ITNs use in children receiving SMC in the 
centre of Burkina Faso. The protective efficacy was 70% for a malaria definition of fever plus 
5000 P.f parasites per micro litre of peripheral blood and we would expect the reduction of 
malaria cases to increase as the malaria definition came to a similar parasite density threshold 
than this study. Despite high protective efficacy in the overall trials referred in this thesis, to 
which extent could we still continue with these regimens: 
Sulfadoxine-pyrimethamine plus Amodiaquine 
SPAQ in opposite to the ACTs combines two “old” drugs which have been in use over the 
past two or three decades for the treatment for uncomplicated falciparum malaria when 
chloroquine fails or was ot well tolerated. Consequently, there was a long and sustained 
pression on these regimens so they have started to lose their efficacy at least when used in 
mootherapy in areas such as West Africa and had even lose any efficacy in East Africa. 
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Efficacy trials reported that SPAQ efficacy was extremely low in East Africa but retained 
some efficacy in areas of West Africa and recent SMC trials in Senegal (Cisse et al., 2009), 
The Gambia (Bojang et al., 2010), Burkina Faso (Konate et al., 2011) and Mali (Dicko et al., 
2011) revealed that the drug could still be used to prevent malaria in children less than 5 years 
old. Despite these results, mention should be made that the efficacy of individual drug is 
probably continuously decreasing as part of its use either in combination with an artemisinin 
derivative (Amodiaquine – Artesunate) for the first line therapy of uncomplicated falciparum 
malaria or as the dedicated monotherapy used for the intermittent preventive treatment of 
malaria in infancy and pregnancy (sulfadoxine-pyrimethamine). In the light of these 
evidences, we could argue that the remaining useful lifespan of the combination appeals for 
the investigation of alternative possibilities.  
Dihydroartemisinin-Piperaquine  
This ACT evaluated in this project was highly effective for the SMC in children as 
demonstrated in previous trials in Senegal (Cisse et al., 2009), The Gambia (Bojang et al., 
2010), in Uganda (Dorsey et al., 2007) and in Thailand (Lwin et al., 2012). It combines the 
very short acting artemisinin derivative eliminated within two hours and the long acting 
Piperaquine; therefore, DHAPQ does not seem to be an adequate regimen for the SMC 
thought the combination becomes a mono therapy with Piperaquine after two hours with a 
scope for drug resistance selection.  Piperaquine is an effective and suitable regimen for SMC 
in combination with a partner drug, but to date the only available co-formulated combination 
and licenced containing the Piperaquine is the DHAPQ. Luckily SMC is given over three 
rounds and stopped at the end of the transmission season when only few cases are susceptible 
to occur; DHA is highly effective and would clear most of the parasites including any 
Piperaquine resistant strain on the next round of the SMC; therefore there is a scope for 
DHAPQ use for SMC if the intervention is correctly given up to the end of transmission 
season and all measures taken to insure a high efficacy of the intervention with the DHAPQ. 
7.3.2 Efficacy against Plasmodium falciparum infection 
Thirty days after the last dose of SMC in November 2009, a cross sectional survey was 
conducted to determine the prevalence of Plasmodium falciparum infection among the 
participant in the intervention and untreated cohorts. SMC with SPAQ and DHAPQ reduced 
significantly the Plasmodium falciparum infection by respectively 73% and 72%. This 
reduction is similar to that seen for the clinical malaria. This achievement is an additional 
benefit for the SMC as the intervention is clearing the reservoir of parasites while allowing 
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continued building of the immunity considering the continued exposure of the children to the 
infective bites and the discontinuation of the intervention after three to four months of 
administration; furthermore it reduces the potential of transmission of resistant parasites. 
7.3.3 Impact on the gametocyte carriage 
The prevalence of gametocytes was low prior the initiation of the intervention and was even 
low at the end of the transmission season survey. Gametocytes carriage was reduced 
significantly between the onset and the end of the intervention, at least 93% reduction in each 
treated group and only 80% in the untreated cohort; this reduction in the untreated cohort was 
probably due to the close surveillance of the enrolled children which allowed a diagnostic of 
clinical case on time hence the administration of the effective ACT namely the artemether-
lumefantrine (Coartem®). More generally, the substantial reduction in the gametocytes 
carriage contributed to lower the transmission potential of the disease. The reduction in the 
gametocytes carriage was found in Senegal at the end of the transmission season survey in 
both groups of treatment (Cisse et al., 2009). 
7.3.4 Impact on anemia and nutritional status 
Haemoglobin was not measured upon enrolment and systematic treatment of anaemia was not 
given; therefore any change in the level through the follow up could not be measured. 
Anaemia has multifactorial causes and malaria could be a major contributor; it is anticipated 
that effective control of malaria could improve the haemoglobin level. Previous studies have 
reported an improvement but DHAPQ use has been associated with a slight drop in 
haemoglobin level in Senegal and in the present study. 
The Z scores height for age, weight for age and weight for height were computed using the 
reference population defined by the WHO in 2006. Based on their parameters, the nutritional 
status of the children in the intervention cohort has improved greatly and the proportion of 
stunted and underweighted decreased at the end of the transmission survey; however the 
proportion of the wasted increased slightly without any obvious explanation.  
7.3.5 Clinical tolerability 
While considering a drug regimen for SMC, tolerability should be regarded as a key 
component of the choice. SPAQ was as tolerated as DHAPQ and this tolerance has improved 
over the three rounds of SMC administration; vomiting within 30 minutes following the drug 
administration was rare and similar in the two groups. Furthermore the concern over the use 
of SPAQ holds on the poor tolerance of amodiaquine due to its bitter taste and this has 
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resulted in more frequent vomiting but also pruritis. Indeed in this report SPAQ was well 
tolerated and most of the adverse events were mild; importantly, vomiting which has been the 
most common side effect in previous SMC studies (Cisse et al., 2009, Bojang et al., 2010) 
with SPAQ was not more frequent in the present study as compared to the DHAPQ group. 
The better tolerance was mainly due to the paediatric formulation (sirup improved 
significantly the tolerability especially in younger children) used but also the precise dose 
given based on the weight rather than based on age as did the study by Cisse et al. in Senegal 
(Cairns et al., 2010). In this study, the remaining two doses were given at home under the 
supervision of the field workers; none of the mothers refused to administer the drug to a child 
for any reason.  
Serious adverse events recorded in this trial did not seem to be drug related as detailed in the 
result section. Deaths were due to respiratory disorders and severe malnutrition. 
 However how enough care will be made in the handling of paediatric formulation and correct 
weighting of the children is a matter of consideration when malaria endemic countries will 
come to a large scale implementation of the strategy even in settings where the basic logistics 
(scales) is missing. At least a pharmaco-vigilance component could be set to monitor closely 
any adverse events which will occur as part of the large implementation of SMC given ad 
tablets and based on the age to stick with logistic limitations.  
 
7.3.6 Biological safety 
Biological safety of repeated doses of drug as it is the case in the SMC has been less 
investigated. This study aimed to assess the potential effect on the haematological and 
biochemical parameters over debate on artemisinin derivative and haemolysis (WHO, 1998). 
Reluctance of the mother for the repeated blood sampling has limited our evaluation. 
However our data confirmed the findings of previous study in Senegal where a drop in 
haemoglobin level was seen with DHAPQ (Cisse et al., 2009). Conversely children treated 
with SPAQ had a better haemoglobin recovery over the three rounds of SMC. Further 
investigations may be needed to evaluate the biological safety of the SMC. Surprisingly over 
4400 patients received full course of DHAPQ or SPAQ over three rounds in Burkina Faso, 
Senegal and The Gambia totalising 39600 doses of DHAPQ or SPAQ closely monitoring 
without clinical complaints which had revealed a biochemical or haematological parameter 
failure; therefore, does it matter to investigate asymptomatic and transient perturbation of 
biological parameters? If further investigations are needed, the challenge will be to obtain 
venous blood samples on repeated occasions (optimal interval) in young children; the interval 
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of 7 days following the drug intake was a reasonable interval but the adherence of the mothers 
will remain difficult. An alternative would be either to conduct the evaluation in older 
children (around 48-59 months) and expect a possible inference to the youngest or to enlarge 
the interval between samples; sample size of such evaluation will account for the vulnerability 
of the study population and should stick to the possible minimum of children. 
7.3.7 Relationship between dose – day 7 concentration and duration of protection 
SMC achieved its objective through mainly a prophylactic effect of the drug regimen 
highlighting the crucial contribution of long half-life drugs. In the present study, the drugs 
were given 30 days apart but the protection lasted approximately four weeks. Other monthly 
SMC studies reported higher efficacy as compared to more than 30 days interval (Lwin et al., 
2012, Dicko et al., 2008); in Senegal, Cisse et al. gave the intervention at exactly 4 weeks 
apart and reported a high protective efficacy (Cisse et al., 2009). In the present study, the 
Kaplan Meier estimates of the cumulative incidence of malaria of any parasitemia showed an 
increase in the incident cases around the next round (before the intervention was given) 
confirming the weakness of the protection after four weeks so, 30 days between two doses 
might be longer and contribute to explain our less effective outcomes.  
Day 7 piperaquine concentration was predictive of the efficacy of DHAPQ and was a function 
of the dose given in mg per kg per body weight, though children with higher day 7 
concentration were less likely to experience the recurrence of malaria.  
In this study, younger children (1-2 years) received high dose of Piperaquine in mg per kg per 
body weight but end up with the lower day 7 concentration of Piperaquine hence the 
intervention was less effective in this sub-population. The lower efficacy of the SMC in this 
group was already reported in a previous study (unpublished); it has been suggested that 
CYP450 contributing to the metabolism of Piperaquine is not fully mature until the age of 10 
years (Johnson et al., 2006) 
Our SMC findings were also consistent with population pharmacokinetics studies (either for 
Sulfadoxine-Pyrimethamine or Piperaquine) which reported in young children the low 
exposure of the parasites to the drugs (Barnes et al., 2006, Tarning et al., 2012, Creek et al., 
2013). In this group of patients, arguments have been made about the necessity to revise the 
current dosage in order to deliver more drugs given in mg per kg so that a higher Cmax 
(maximum concentration) can be achieved and therefore a better exposure of parasites. Beside 
the need to optimize the dosage, sufficient care should be made to insure an accurate dosing 
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and the adherence to the full course of the treatment over three days; these are key point to 
maintain, improve or optimize the efficacy of these drugs but also a need to protect the 
regimen from development of tolerance by the parasite and ultimately the apparition and 
spread of resistant strains and shorten the lifespan of these useful drugs. Of note the main 
parameter seen susceptible to affect the day 7 concentration of Piperaquine was the young age 
due to the immaturity to metabolise the CYP450 which intervene in the transformation of the 
drug; children presenting with vomiting or diarrhoea were withdrawn from the population 
pharmacokinetics study. As mentioned in the tolerability section, the intervention presented 
well tolerated profile which improved over the rounds and after adjustment, mild vomiting 
and diarrhoea which occurred during the course of the population pharmacokinetics study did 
not affect the day 7 concentration of the drug. 
7.3.8 Drug resistance selection during the SMC intervention 
The selection of resistant parasite with chemotherapy has been one of the challenges endemic 
countries are being faced as the prompt treatment of malaria cases with effective drug is a key 
component of the control programs. As SMC uses drugs, there is a fear over the possible 
increase in drug pressure and consequently the loose of their efficacy. The present data on 
drug resistance showed either on incident or end of the transmission survey cases the 
association of key mutations in dhfr and dhps with the SPAQ regimen but the selection was 
not strong. Nonetheless SPAQ still retained a good efficacy meaning their presence does not 
sign an established lack of efficacy of the drug though the mutations with strongest 
association with high failure rate (dhps 540E, dhps 581G, dhps L164) were not found in this 
study and even the high prevalence of quintuple mutation in dhfr/dhps was associated with 
high protection of infant receiving SP for IPTi in Mozambic (Mayor et al., 2008). This 
epidemiology of SP resistance is common in West Africa in general where SP remains 
effective either in efficacy or preventive studies (Cisse et al., 2006, Sokhna et al., 2008, Dicko 
et al., 2008, Cisse et al., 2009). While key mutations establishing the resistance to SP were not 
found in the study area, a new one already detected in other parts of Africa (Mberu EK, 2002) 
but not Burkina Faso was revealed, the DHPS S613. The contribution of this mutation to the 
drug resistance either as a single mutation or in combination seemed limited as despite the 
detection of this mutation, SP efficacy remained high during this SMC study. 
Up to now, no firm molecular marker was associated with an artemisinin derivative resistance 
and the very short action combined with the high efficacy of the DHA put this drug less at 
risk of selection. However the partner drug Piperaquine reduced to a mono-therapy will be 
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more exposed and offers a scope for drug resistance selection. The pfcrt CVIET haplotype 
and pfmdr-1 gene are potent markers for selecting Piperaquine resistance but this study did 
not identify any selection by Piperaquine.  
Overall, all regimen were highly effective resulting in at least 70% reduction of clinical 
malaria, over 90% of asymptomatic infection and gametocytes carriage. What would be the 
impact of resistance selection for regimen which achieved massive reduction in the parasite 
biomass? The massive reduction in the gametocytes carriage is likely to limit the transmission 
of resistant parasite; furthermore, a study by Diakite et al. 2010 reported that some resistant 
parasites were cleared by their host (Diakite et al., 2010).  
It therefore can be argued that the beneficial effect of SPAQ in the overall reduction of 
malaria burden when used for SMC outweighed the slight selection of resistance markers 
meanwhile any use of DHAPQ will surely exert a selective pressure but we unfortunately 
don’t have the right markers (to Piperaquine) to assess the magnitude of this selection . 
Nonetheless a close eye should be kept on the evolution of the key known molecular marker 
along with the identification of gene conferring the resistance to Piperaquine and especially 
those not yet reported so far in order to detect the level of resistance and to alert the National 
Malaria Control Programs authorities for immediate actions to be taken. Monitoring of 
resistance to these drugs where SMC is used will require direct measurement of efficacy, 
through case control studies.   
7.4 SMC, an opportunity for malaria control in Burkina Faso?  
SMC with SPAQ in children 3 to 59 months as per the World Health Organisation 
recommendation suits to the Sahel and Sub-Sahel regions with high seasonal transmission of 
malaria where at least 70% of the clinical cases occurred within 3-4 months. The case 
definition of areas susceptible to benefit from the SMC is not unique and depending on which 
criteria were considered, most of West African countries will be covered by SMC and even 
parts of East Africa could be included(Cairns et al., 2012). 
Burkina Faso as most of the Sahel and Sub-Sahel countries is one of these areas susceptible to 
benefit from the seasonal prevention of malaria. 
The epidemiology of malaria in Burkina Faso is characterised by three transmission areas: 
- A short transmission area over three months in the North and extreme North  
- A medium transmission area over 4-6 months in the middle 
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- A longer transmission area over 6 months. In all these settings the transmission is highly 
seasonal and most of the cases occur within the rainy season. This description of malaria 
situation in Burkina Faso is rather old; yet there is no reliable parasitological confirmed data 
country wide to guide the definition of areas which could benefit from the SMC. Data 
provided by the National Malaria Control Program is incomplete and generally most of the 
cases reported were unconfirmed. In addition to that, the age group definition is unclear since 
a majority of children do not have birth certificate and ended up with a best guest to estimate 
their age with possible underestimation or overestimation; in children in these cases could 
under or over dosed and consequently more adverse events or inefficacity of the treatment. 
Owing these limitations, the criteria to set the SMC scope will rely on this old classification of 
the country into the three epidemiology settings for malaria transmission. 
The short and medium transmission areas cover two third of the country and is likely to be 
suitable for SMC and even the long transmission area might be covered upon reconsideration 
of some criteria. Populations in the low income countries are characterised by a large majority 
of young persons and the children less than 5 years old are well represented. They are most at 
risk of malaria and are susceptible to benefit from SMC.  
The situation described above justified that the Ministry of Health through the National 
Malaria Control Program introduced SMC with SPAQ in their strategic plan from 2011 to 
2015 to fight malaria (earlier than WHO recommendation to introduce SMC). Before a large 
scale implementation, the NMCP initiated a pilot introduction of the strategy in 6 health 
districts during the 2013 high transmission period (NMCP, 2013). The selected health districts 
are: 
- The district of Seguenega in the North 
- The district of Zorgho in the centre 
- The district of Sebba at the Sahel region 
- The district of Bogande in the East 
- The district of Nouna in the North-West 
- The district of Kaya in the centre-North;  
There has been a tentative to cover the country rather than a random selection. The objective 
of this pilot was to reduce the incidence of malaria in children 3-59 months by 60% in 2013 
compared to the situation of 2012 and to learn how best to proceed for the large scaling up 
(step wise or full deployment once). The project aimed at covering the population of 3-59 
months living within the 6 selected districts  
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and 90% of compliance by mothers. SMC with SPAQ is expected to be delivered over four 
days of mass drug administration per month by a pair of community health workers trained 
for this purpose. The intervention was scheduled to last four months (July to October) but up 
to the end of August no start has been made though the resources were not yet available.  
In the implementation process, a concise plan for training, supervision and evaluation is in 
place to insure the success of the pilot. The budget of this pilot, approximately 1 million US 
dollars was submitted for funding to international bodies such as UNICEF, WHO, Plan, etc...  
The application went through a first round of selection and was shortlisted; the final decision 
of funding is expected at the end of 2013 or early in 2014. It is therefore confirmed that SMC 
pilot implementation in Burkina Faso is postponed for the next 2014 transmission season. 
Furthermore, worse than postponing the pilot study, there is no firm plan in 2014; all plans 
being subject to funding availability either from the government or from the donors. In the 
best of the options of fund secured, does it stand to conduct a pilot implementation or should 
the NMCP go straight for national scaling up program? This might be the best option to avoid 
a waste of time in scaling up the strategy. 
7.5 Challenges surrounding the large scale deployment of the SMC in the Sahel region:  
Whatever suitable part of Africa for SMC strategy, several challenges are foreseen: 
- Endemic and low income countries of Africa need to get ready to translate this SMC 
recommendation of WHO into a policy. Political commitment is highly sought to lead large 
campaign of information and guidelines redaction to facilitate adequate training of the staff in 
the field and to support any modest additive running costs. Such commitment includes also 
sustainable provision of high quality of drug to cover the number of treatments needed in a 
timely manner. 
- The delivery of SMC unlike in the IPTi is not supported by any existing channel but can be 
achieved at cost effectively in clinical trial settings or in areas with existing community health 
workers in Ghana and in The Gambia (Bojang et al., 2011, Kweku et al., 2009). The 
challenges (a) and (b) necessitate financial resources which may be beyond the states 
capacities; multilateral donors and NGOs are therefore welcomed to sustain the states through 
the Ministry of Health but how far these donors can support such strategy will be a matter of 
negotiation and the states should ultimately take the responsibility and raise fund internally. 
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- The evaluation of SMC impact. We would expect a dramatic decrease of the burden of 
malaria in children after the implementation of SMC as a public health tool but how to assess 
the impact when there is no reliable data prior the introduction of the strategy. A part limited 
data provided by clinical studies, most of the data on malaria are from the routine collection in 
the health facilities and compiled in the National Malaria Control Programs annual report to 
WHO. We believe that pre SMC main activity should be a robust collection of routine data in 
the health facilities (irrespective of the cause of consultation or admission); in this respect the 
Data Surveillance System (DSS) or similar but less costly systems are urgently needed along 
with staff (physicians, nurses but also field/community health workers) training and simple 
data collection forms.  
Confirmation of malaria cases through the use of the rapid Diagnostic Tests (RDTs) or 
microscopy if available should be the rule in the health facilities; again this calls for a 
sustainable provision of the RDTs to avoid shortage and absence of reliable data.   
Having set these variable aspects, the impact evaluation has two components: - Assessment of 
drug efficacy and selection of resistance through case control studies, - the assessment of the 
whole program impact on malaria related morbidity/mortality parameters: incidence of 
clinical cases, prevalence of anaemia of any grade, proportion of admission and death due to 
malaria, prevalence of infection and of gametocyte carriage. 
- Future of SMC. There is a real hope that SMC in conjunction with the available and 
foreseen tools (ITNs, IRS, effective treatment of the clinical cases, vaccine) can curve the 
course of malaria in endemic countries and improve the survival of population at risk 
especially children and pregnant women. We foresee the future of SMC in three angles: 
 SMC is maintained till the elimination of malaria in a given area. When malaria 
related morbidity and mortality parameters fell significantly, the main question 
becomes it is efficient to provide SMC to all children under five when few of them 
remain at risk? Probably the approach needs to be rethought. 
 SMC is stopped when the incidence of malaria falls below a certain cut-off in a given 
area 
It is anticipated that SMC will impact significantly the incidence of clinical malaria and other 
morbidity parameters. Therefore any discontinuation of SMC might create a gap and offer a 
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scope of return back to higher level. If when and where to introduce SMC seems quite well 
defined, the time of its discontinuation is more difficult to determine. 
 SMC is switched to an intermittent screening and treatment when a cut-off in the 
incidence of malaria is reached. The concept of SMC is the administration of a full 
course of treatment to a subject irrespective of its parasitological status. As SMC goes 
and is effective, the number of treated children who are slide negative and unlikely to 
acquire malaria will increase. From such point of time, it is worth asking if whether 
SMC should continue in that format. Our conviction is to switch from the SMC to an 
intermittent screening and treatment of positive cases; this is justified in the sense that 
negative slide are really likely to be negative as the impact on asymptomatic infection 
and gametocytes carriers is huge. At this stage, the challenge will be the adequate 
diagnostic of malaria cases either by microscopy or RDTs, thought more sensitive 
RDTs are needed to pick up even the very low parasitemia. Although children bore the 
high burden of malaria, there is still a reservoir in adults but it is anticipated that an 
indirect effect of the effective SMC along with the direct effect of the other measures 
(ITNs, IRS, and effective treatment of clinical cases) will be a decrease in the 
reservoir in adults. Overall if direct and indirect effects of SMC curved significantly 
the burden, we can argue the extension of the intermittent screening and treatment to 
the whole population. The advantages of targeted treatment at this phase reduction of 
drug consumption, which in turn reduces the cost of the strategy but it also put less 
drug pressure susceptible to generate parasite mutations hence the appearance and 
widespread of drug resistance. Intermittent screening and treatment could ultimately 
be part of the malaria elimination/eradication agenda.  
Despite the challenges and other difficulties, SMC remains a serious tool susceptible to 
change the course of the ever disastrous infectious disease over the past century.  
Malaria parasites exist in the nature in equilibrium with other pathogens. Other diseases will 
emerge to fill the gap caused by the declining malaria such as bacterial diseases, viral 
infections which can bring up the mortality in young groups.  
7.6 Areas for future research 
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This thesis has explored an alternative, effective and safe drug regimen for SMC. However 
several research questions remain and call for further investigation: 
1) The monitoring and evaluation of the impact of SMC as it is introduced, including 
pharmaco-vigilance studies and monitoring of drug resistance.  
2) The evaluation of child-friendly formulations, dispersible formulations and taste-masked 
formulations. 
3) In some countries SMC may be given to a wider age range, (it is currently given to children 
up to 10yrs in Senegal), safety and efficacy of DHAPQ could therefore be evaluated 
in a wider age range. In areas of seasonal malaria in South East Africa, SMC with DHAPQ 
could potentially be used; a superiority trial of the safety and efficacy of DHAPQ compared to 
SPAQ in these areas should be conducted as a priority.  
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Chapter 8 Conclusion and recommendations 
The time has more than ever come to curve the course of malaria as several effective tools are 
accessible at once to made available to the policy makers, the funders, the patients and finally 
to the scientists working on malaria. More than ever, the challenge has come to implement in 
an integrated manner and settings specific epidemiology the strategies to fight malaria. 
As part of my PhD program, we undertook to investigate different drug regimens for chemo-
prevention of malaria from August 2009 to January 2010. We designed a non-inferiority 
clinical trial described in the chapter 3 to primarily determine if whether efficacy of DHAPQ 
is non-inferior to that of SPAQ. We also determined the incidence of malaria in the study area 
and investigated how day 7 Piperaquine concentration is related to the level of protection. 
Secondary endpoints of the study included biological safety assessment, the prevalence of 
adverse events, malaria infection, carriage of gametocytes, anemia and the profile of drug 
resistance selection due to each drug regimen over the follow up period and again at the end 
of the transmission season. A total of 1499 children 3-59 were randomly assigned to receive 
either monthly full treatment dose of SPAQ or DHAPQ; an untreated and non-randomized 
cohort of 250 children in the similar age range was recruited in one of the site where the 
randomized cohort was selected. The study took place in Satiri, Balla and Kadomba in the 
Lena Health district at approximately 30 miles from the capital city of Bobo-Dioulasso; the 
intervention was given over three (3) months in August, September and October. Sub-studies 
for day 7 Piperaquine concentration measurement and the biological safety assessment were 
undertaken beside the main trial. An epidemiological survey was carried out in November for 
the randomized cohort and in December for the untreated cohort. Tolerability assessment was 
set on day 3 and fourth nightly following each round of the intervention administration. 
The main results were reported in the chapters 4, 5 and 6. SMC with SPAQ or DHAPQ led to 
a reduction of 84% and 79% in the incidence of malaria with 3000 parasites per microliters 
and above. The incidence of malaria was 229 episodes in the untreated cohort, a mean of 0.92 
episodes per child per month. 
 
The other relevant findings of this study included: 
(i) The adverse events were moderate and common in all regimen and decreased over 
the rounds of SMC administration; no serious adverse event did appear to be drug 
related 
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(ii) The day 7 Piperaquine concentration was dose related and a predictor of the 
intervention outcome; the young children had a lower protective efficacy (low day 
7 Piperaquine concentration). 
 
(iii) The prevalence of asymptomatic malaria infection and gametocytes carriers were 
dramatically reduced (over 93% in the treated groups). 
(iv) The use of SPAQ exerts a selective pressure; however, the overall prevalence of 
molecular markers to this regimen was low due to the massive reduction of the 
prevalence of parasitemia at the end of the transmission season. 
(v)  The selection pressure of DHAPQ use was not assessed due to the absence of firm 
gene conferring the resistance to Piperaquine but it is anticipated that its use will 
increase the presence of resistant parasite to the Piperaquine.  
 
A full assessment of the suitability of a drug regimen to consider for the Seasonal 
Chemoprevention of Malaria relies not only on the efficacy, but rather include the tolerability 
and ease of use by the mothers, the potential impact on the hematological and biochemistry 
parameters and ultimately balancing the drug efficacy and its potential to select resistant 
parasites. On these grounds, SPAQ stands to be suitable drug for the SMC as recommended 
by the World Health Organization.  
The concept of SMC has proven to be effective in reducing the incidence of clinical malaria; 
its targets the high risk period in the Sahel and Sub-Sahel regions of Africa. Successive and 
step wise exploration of the efficacy, the number of doses, the interval between doses and the 
timing have demonstrated that monthly administration of a full course of an effective drug is 
the optimum combination to obtain the maximum of efficacy. The potential for SPAQ and 
DHAPQ has been investigated in Senegal, The Gambia, Ghana, Burkina Faso and finally the 
present study (Cisse et al., 2009, Bojang et al., 2010, Konate et al., 2011). Although the 
incidence of malaria was low in Senegal and The Gambia to yield solid conclusion, the 
findings in the present study along with that reported in the centre of the country (Konate et 
al., 2011) have definitively confirmed the benefit of SMC for malaria prevention among 
children. Studies on how SMC could be delivered since there is no previous channel for 
delivery have concluded that SMC can be delivered successively through systems outside the 
health facilities at a cost effective way; community health workers or villages strikers in The 
Gambia have delivered SMC even better than the health facility based strategy. For all aspects 
considered, SMC as a potent in clinical trials setting to reduce clinical malaria. 
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Time has come to translate the hope into the really in the communities of the Sahel region; 
this is a big challenge for public health policy makers. Since SMC recommendation by WHO 
in March 2012, countries are moving into implementation phase at different speed depending 
on how they faced and overcome the challenges; Senegal has formally adopted SMC and is in 
an implementation stage; Togo is also piloting SMC in selected health districts in 2013. In 
Mali SMC is ongoing in an MSF (Médecin Sans Frontière) site, Koutiala (500 km from 
Bamako). In Burkina Faso the process hasn’t start yet; a technical guide on SMC introduction 
in 6 selected districts exists but the fund was not available.  
SMC is an advocated tool which can along with other measures contribute to a sensible 
reduction of the burden of malaria. For the perspective of large scaling up and to maintain the 
efficacy of the strategy as tool, the following recommendations can be drawn: 
1. A political will to commit them for a sustainable support of the program. SMC 
introduction requires substantial financial resources, infrastructures and logistics. 
2.  SMC with SPAQ was adopted in a context where SP retained some efficacy 
especially in West Africa but could rapidly decline as SPAQ is used in children and 
SP alone for the intermittent preventive treatment in pregnancy. We recommend a 
close monitoring of the drug efficacy to guide any change of regimen 
 
3. New drug regimens are needed. While monitoring the efficacy of the current drugs, 
new components should be evaluated to allow a switch when the current drug will fail. 
The evaluation will include the determination of the pharmacokinetic and the 
biological safety profile. Pediatric formulation are welcome to be evaluated as they 
contribute to lower the adverse events 
4. Molecular markers studies are needed to follow the change in the markers profile; they 
will inform about the efficacy before the clinical stage. 
5. The measurement of SMC impact. This measure is critical but is challenging in view 
of lack of reliable data on malaria morbidity in health facilities prior SMC 
implementation. 
6. More research is needed to guide the future of SMC as its implementation progresses 
and the incidence and other morbidity parameters of malaria are decreasing. It that 
pertinent to establish trend of cut off values of the malaria morbidity parameters from 
which SMC should be rethought?  
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7. Careful designed studies to evaluate the impact of SMC on the transmission of 
malaria. In the present report, the gametocyte carriage has decreases but the proportion 
of children with gametocyte was low and could not yield any significant conclusion on 
SMC potential for transmission reduction. 
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Appendixes 
 
 
Appendix 1 Information sheet and informed consent forms (randomized & untreated cohorts) 
FICHE D’INFORMATION DU PATIENT 
TRAITEMENT PREVENTIF INTERMITTENT SAISONNIER DU PALUDISME 
CHEZ LES ENFANTS DE 3 A 59 MOIS A BOBO DIOULASSO, BURKINA FASO: 
UN ESSAI CLINIQUE RANDOMISE ET CONTROLLE 
Le paludisme est un problème très préoccupant dans notre pays des recherches ont  montré en 
Afrique que la prise d’un médicament contre le paludisme une fois par mois (IPT) peut 
diminuer le risque de contracter le paludisme chez les enfants de moins de 5 ans. Ici nous 
voulons savoir quel est le meilleur médicament pour cela. Si vous acceptez que votre enfant 
participe à l’étude nous allons vous demander d’amener votre enfant au centre de santé une 
fois par mois (en Août, Septembre et Octobre) ; le docteur va examiner votre enfant et 
l’infirmier lui donnera le médicament (flavoquine® plus du fansidar® ou duocotexcin®) au 
dispensaire, et vous remettra le restant pour lui donner à la maison pour les deux jours 
suivants. Ces médicaments sont efficaces, bien tolérés et utilisés au Burkina Faso pour le 
traitement du paludisme simple. Un agent vous visitera deux fois par semaine à la maison 
pour s’assurer que vous avez donné le médicament à l’enfant mais aussi demandera si l’enfant 
va mieux et s’il n’a pas de plaintes depuis la prise du médicament.  Si votre enfant a la fièvre, 
l’agent va faire un examen sanguin pour voir s’il a le paludisme pour commencer rapidement 
le traitement, mais vous devez emmener l’enfant au dispensaire. Environ 1500 enfants 
rentreront dans cette étude. Pour comprendre comment les médicaments agissent et sont 
efficaces,  nous allons faire des prélèvements sanguins chez votre enfant au début et en fin 
d’étude. Votre enfant aura des prélèvements sanguins au bout du doigt ou au pli du coude (de 
très petites quantités de sang) deux fois au jour 2 et 7 er parfois au jour 30. Nous vous dirons 
si votre enfant est concerné. Vous pouvez amener votre enfant à la formation sanitaire chaque 
fois que vous sentez qu’il est malade ou si vous avez des craintes sur sa santé.  Les 
prélèvements sanguins ne feront rien à votre enfant, seulement une douleur légère et 
passagère due à la piqure pour le prélèvement. Nos équipes sont bien formées et ferons de leur 
mieux pour minimiser la douleur lors du prélèvement, le matériel utilise est à usage unique. 
Les médicaments que nous donnons à votre enfant sont efficaces et bien tolérés ; des effets 
indésirables sévères (comme une réaction sévère de la peau ou du foie) peuvent être observés 
chez certains enfants mais cela est très rare. Vous êtes libre de ne pas participer à cette étude 
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et nous respecterons votre choix ; vous pouvez aussi a tout moment retirer votre enfant de 
l’étude sans avoir à vous justifier, et cela n’affectera pas la santé ou la demande de soins de 
votre enfant. Les connaissances issues de cette étude aideront le Burkina à déterminer le 
meilleur médicament pour la prévention du paludisme chez les enfants.  Les prélèvements de 
sanguins de votre enfant seront gardés à l’IRSS Bobo et pourront être utilisés plus tard pour 
des recherches sur le paludisme.  
Les données collectées sur votre enfant resteront confidentielles et ne seront accessible qu’à 
ceux qui travaillent dans le projet, le nom de votre enfant ne sera en aucun cas utilisé lors d’un 
rapport ou un écrit dans les journaux. .  
Si vous avez des questions complémentaires, vous pouvez contacter le Principal Investigateur 
du projet Dr Issaka Zongo,  téléphone 226-20-98-18-80 à l’Institut de Recherche en Sciences 
de la Santé. 
  
143 
 
TRAITEMENT PREVENTIF INTERMITTENT SAISONNIER DU PALUDISME 
CHEZ LES ENFANTS DE 3 A 59 MOIS A BOBO DIOULASSO, BURKINA FASO: 
UN ESSAI CLINIQUE RANDOMISE ET CONTROLLE 
Consentement éclairé 
 
En signant ce formulaire, vous dites à l’équipe du projet que: 
       Nous vous avons bien expliqué l’étude  
       Vous avez bien compris ce que nous demandons à votre enfant 
       Votre participation à l’étude est entièrement volontaire  
        Vous pouvez arrêter à tout moment votre participation  
      Vous avez l’occasion de poser toutes vos questions 
 
FICHE DE CONSENTEMENT 
 
Nom de l’enfant ________________________________________________ 
 
Numéro d’Identification __________________________ 
 
 
J’ai compris les explications qui m’ont été données et j’accepte que mon enfant 
participe à l’étude. 
 
 
Nom du parent ou du gardien de l’enfant        
 
Relation avec l’enfant _____________________________________________ 
 
 
Signature ou *empreinte du parent ou du gardien de l’enfant       
 
 
*Si le parent ou le gardien ne peut pas signer, un témoin signera à son nom. 
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Nom du témoin     
 
 
Signature du témoin     
 
 
 
Signature de l’investigateur administrant le consentement éclairé                        Date/Heure 
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ETUDE TRANSVERSALE SUR LA PREVALENCE DE LA PARASITEMIE ET DE 
L’ANEMIE CHEZ L’ENFANT DE 3-59 MOIS A BOBO-DIOULASSO, BURKINA 
FASO 
 
Le paludisme est un problème très préoccupant dans notre pays, les enfants de moins de 5 ans 
les femmes enceintes sont les plus susceptible de contracter la maladie. Des recherches 
menées dans beaucoup de pays africains ont montré la prise d’un médicament contre le 
paludisme une fois par mois (IPT) peut diminuer le risque de contracter le paludisme chez les 
enfants de moins de 5 ans.  
Nous voulons avoir combien d’enfants ont les microbes du paludisme dans leur sang mais 
aussi chez combien d’enfants la quantité du sang a diminué. Si vous acceptez de participer à 
cette étude, nous allons faire un prélèvement de sang au bout du doigt de votre enfant, nos 
docteurs ou infirmiers poseront des questions sur l’âge, le statut vaccinal et nutritionnel, 
l’utilisation ou non de moustiquaires (imprégnées ou pas) puis examineront votre enfant. Si 
votre enfant souffre du paludisme ou n’a pas beaucoup de sang, nous lui donneront des 
médicaments. Vous êtes libres de participer ou non à cette étude et nous respecterons votre 
volonté ; cela n’empêchera pas votre enfant d’être traité dans le centre de sante ou nous 
faisons l’étude et vous pouvez aussi arrêter votre participation à l’étude sans avoir à nous 
donner les raisons.  
Les connaissances issues de cette étude aideront le Burkina à déterminer le meilleur 
médicament pour la prévention du paludisme chez les enfants..  Les prélèvements de sanguins 
de votre enfant seront gardés à l’IRSS Bobo et pourront être utilisés plus tard pour des 
recherches sur le paludisme.  
Les données collectées sur votre enfant resteront confidentielles et ne seront accessible qu’à 
ceux qui travaillent dans le projet, le nom de votre enfant ne sera en aucun cas utilisé lors d’un 
rapport ou un écrit dans les journaux. .  
Si vous avez des questions complémentaires, vous pouvez contacter le Principal Investigateur 
du projet Dr Issaka Zongo,  téléphone 226-20-98-18-80 à l’Institut de Recherche en Sciences 
de la Santé. 
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Consentement éclairé 
En signant ce formulaire, vous dites à l’équipe du projet que: 
       Nous vous avons bien expliqué l’étude  
       Vous avez bien compris ce que nous demandons à votre enfant 
       Votre participation à l’étude est entièrement volontaire  
        Vous pouvez arrêter à tout moment votre participation  
      Vous avez l’occasion de poser toutes vos questions 
 
FICHE DE CONSENTEMENT 
 
Nom de l’enfant ________________________________________________ 
 
Numéro d’Identification __________________________ 
 
 
J’ai compris les explications qui m’ont été données et j’accepte que mon enfant 
participe à l’étude. 
 
 
Nom du parent ou du gardien de l’enfant        
 
Relation avec l’enfant _____________________________________________ 
 
 
Signature ou *empreinte du parent ou du gardien de l’enfant       
 
 
*Si le parent ou le gardien ne peut pas signer, un témoin signera à son nom. 
 
Nom du témoin     
 
 
Signature du témoin     
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Signature de l’investigateur administrant le consentement éclairé                        Date/Heure 
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Appendix 2 Screening form 
Nom : _____________________________ 
Prénom: ____________________________ 
Numéro de screening: ______________ 
 
Date de Screening: /____/_____/____/ 
Age*:_____mois   Sexe: □ M        F □   (cocher) 
Poids: /_____/.__/ kg        Taille : /__/__/./__/ 
cm 
Groupe ethnique: ______________ 
* Reporter la date exacte de naissance mentionnée dans le carnet de vaccination 
 Information sur la mere 
Nom:  
Age*:_____(année) Nom du chef de famille 
______________________________________  
CRITERED DE SELECTION Enfants entre 3- 59  mois  
CRITERES D’INCLUSION  OUI  NON 
1. Age compris entre 3 et 59 mois   
2. Intention de résider dans  le village au moins 6 mois   
3. Habilité à respecter le calendrier de suivi   
4. Provision d’un consentement éclairé   
EXCLUSION CRITERIA NON OUI 
5. 5. Allergies connue aux médicaments 
    □ Amodiaquine:____________□ DHA-P:_____________ 
□ SP:______________________  
 
 
 
 
 
6. 6. Paludisme grave/signes de danger 
7. Précisez les signes or symptomes: 
_________________________ 
  
 
8. 7. Maladies fébrile concomitantes  
9. Précisez le diagnostic: _________________________ 
  
 
8.  Existence d’affection chronique   
10. 9. Utilisation antérieure d’antimalarique (2 semaines 
précédents) 
11. □ CQ  □ AQ □ SP  □ Quinine  □ AL  □ AQ AS  
12. □ Other _________ 
13. Précisez: □ dose complète     □ Incomplète          □ NA 
  
ENROLLEMENT  
14. 10. Inclus □ 11. TPI pour le prochain mois: □ 12. □ Non inclu 
13. 13. Numéro de randomisation : |__|__|__|__|__|-|__| 
 INFORMATIONS COMPLEMENTAIRES OUI  NON 
14. 15. L’enfant a-t-il dormi sous une moustiquaire la nuit 
dernière 
  
15. 16. Combien d’enfants dorment sous cette même 
moustiquaire 
  
16. 17. L’enfant dort il d’habitude sous une moustiquaire   
17. 18. La moustiquaire est- elle intacte ? /__/ (0=non, 1=oui),  
18. Si oui décrire l’altération 
  
19. 19. La moustiquaire est-elle imprégnée   
NB : Ces informations ne sont pas des critères d’exclusion du patient 
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Appendix 3 Enrolment form 
FICHE CLINIQUE (1): 1. Numéro de randomisation: |__|__|__|__|__|-|__| 
 
Nom et prénoms de l’enfant:  
 
 
Nom Prénoms de la mère :  
5. Sexe:  M _____F _____  
2. Jour 0 Date: 
|___|___|/|___|___|/|___|___| 
  Jour           mois      années 
 
2. Date de naissance de l’enfant 
                           
: |___|___|/|___|___|/|___|___|     ou Age : |___|___| 
(Années)  
                            Jour           mois      années 
Enumérer tous les médicaments injeres les deux dernières semaines 
Médicament (si nom inconnu ,lister par des lettres – 
“Inconnu medic A”) (a) 
Dose (b) Date de la dernière 
dose (c) 
8.    Complete      Incomplete       Inconnu       
 N/A. 
 
 
9.  Complete      Incomplete       Inconnu       
 N/A. 
  
 
Cotation 0-4: absent = 0; moyen = 1; modéré = 2; sévère = 3, menace vitale = 4, N/A = ne peut être évalué 
 AOUT SEPTEMBRE OCTOBRE AUTRES JOURS IMPREVUS 
 JOU
R 0  
JOU
R 1  
JOU
R 2  
JOU
R 0  
JOUR 
1  
JOU
R 2  
JOU
R 0  
JOU
R 1  
JOU
R 2  
JOU
R.. 
JOUR
.. 
JOU
R.. 
JOU
R.. 
DATE              
12. Histoire febrile 
(O/N) 
             
13. Vomissement 
< 30 mns 
             
14. Faiblesse              
15. Moustiquaire 
(Oui/Non) 
             
16. MII (Oui/Non)              
16. Céphalées*              
17. Anorexie              
18. Nausée*              
19. Vomissement              
20. Dleur 
abdominale* 
             
21. Diarrhée              
22. Toux              
23.  Prurits              
27. 
Autres__________
____ 
             
29. Effets 
secondaires† (O/N)           
             
Initials              
*Noter seulement pour  patients > 3ans.  Pour enfants < 3 ans incapable de répondre, noter N/A.† Effet 
secondaire: si nouvellement apparu ou  aggravant et si cotation  > 2. Notifier au CE Muraz et sponsor tout  
effet secondaires grave. 
 
ICHE CLINIQUE (2):                                       Numéro de randomisation: |__|__|__|__|__|-|__| 
Nom et prénoms de l’enfant:  Nom et prénoms de la mère : 
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5. Sexe:  M _____F _____  
2. Jour 0 Date: 
|___|___|/|___|___|/|_
__|___| 
                            Jour           
mois      années 
 
2. Date de naissance de l’enfant 
                           : |___|___|/|___|___|/|___|___|   ou Age : 
|___|___| (Années)  
                            Jour           mois      années 
SIGNES PHYSIQUES  Cotation 0-4: absent = 0; moyen = 1; modéré = 2; sévère = 3, menace vitale = 4, N/A = ne peut 
être évalué 
 AOUT SEPTEMBRE OCTOBRE AUTRES JOURS IMPREVUS 
 JOU
R 0  
JOU
R 1  
JOU
R 2  
JOU
R 0  
JOU
R 1  
JOU
R 2  
JOU
R 0  
JOU
R 1  
JOU
R 2  
JOUR
.. 
JOUR
.. 
JOUR
.. 
JOUR
.. 
DATE              
30. 
Temperature 
(ºC) 
             
31. Poids (kg)              
32. Taille (cm)              
33. 
Deshydratation 
             
34. Jaunice              
35. Thorax              
36. Abdomen              
37. Peau              
39. 
Autres_______
___ 
             
40. Effets 
secondaires† 
(O/N)           
             
ABNORMAL EXAM RECORD 
En cas 
d’anomalie 
rencontrés à 
l’examen 
physique les 
décrire 
       
 
      
Initials 
 
             
* Tablet test –  > 9 mo; Heel-toe –  > 2 years; Romberg –   > 4 years.  * Suivre les guides d’évaluation et de cotation.  
Noter N/A pour les jeunes enfants et les patients non adhérents.† Enregistrer l’effet second si nouveau ou aggravation avec 
cote  > 2. .  Notifier au CE Muraz,et au  sponsor immédiatement tout effet secondaire grave. 
 
 
 
 
 
 
FICHE CLINIQUE (3):                      Numéro de randomisation: |__|__|__|__|__|-|__| 
 
Nom et prénoms de l’enfant:  
 
Nom et prénoms de la mère:  
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5. Sexe:  M _____F _____  
2. Jour 0 Date: 
|___|___|/|___|___|/|___
|___| 
                Jour           mois      
années 
 
2. Date de naissance de l’enfant 
                           : |___|___|/|___|___|/|___|___|     ou Age : 
|___|___| (Années)  
                            Jour           mois      années 
RESULTAT DE LABORATOIRE 
 AOUT SEPTEMBRE SEPTEMBRE AUTRES JOURS IMPREVUS 
 JOUR 
0  
JOUR 
1  
JOUR 
2  
JOUR 
0  
JOUR 
1  
JOUR 
2  
JOUR 
0  
JOUR 
1  
JOUR 
2  
JOUR 
.. 
JOUR 
.. 
JOUR 
.. 
JOUR 
.. 
DATE              
40. Densite 
parasitaire 
      (asexual 
parasites/ul) 
             
41. Espèces              
42. Heure 
d’administration 
du médicament 
             
Heure du 
prélèvement 
             
43. Densité 
Gametocytaire 
             
44. 
Hémoglobine*† 
(g/dL) 
          
 
   
Initials              
*(Cotation 0-4: normal = 0; mild abnormality = 1; modere = 2; severe = 3, menace vitale = 4) 
† Tx d’hémoglobine <  5g/dl mesure après le jour 0 est un effet secondaires grave.  Notifier au CE Muraz, et au sponsor 
immédiatement  tout effet secondaires grave. 
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FICHE DES EFFETS SECONDAIRES 
 
 
Numéro de randomisation: |__|__|__|__|__|-
|__| 
 
2. Jour 0 Date: 
|___|___|/|___|___|/|___|__
_| 
                              Jour         mois      
années 
 
 
 Compléter le jour du début  Compléter le jour du début et 
mettre à jour si nécessaire 
Complete on final day 
Description 
du signe 
(a) 
Date 
de 
début 
(b) 
Date de 
notification 
(c) 
Initiales 
of 
personne 
qui 
reporte  
Maximum 
sévérité* 
(d) 
Maximum 
relation† 
(e) 
Sérieux? 
‡ (Y/N) 
(f) 
Episodique? 
(Y/N) 
(g) 
Résultat 
†† (h) 
Date de 
guérison‡‡ 
(i) 
45.          
46.          
47.          
48.          
49.          
* Sévérité: cotation 1-4: moyen = 1; modéré = 2; sévère = 3, menace vitale = 4    
† Relation: cotation  0-4: aucune = 0; peu probable= 1; possible = 2; probable = 3; certaine = 4    
‡ Importance: Critères d’évaluation des effets secondaires: fatal, menace vitale, risque d’une hospitalisation prolongée, 
risque d’ un gène ou d’une incapacité importante ou persistante nécessitant une intervention médicale / chirurgicale pour 
éviter des fâcheuses issues.    
††Résultats: cotation 1-5 :guérison sans séquelle = 1; guérison avec séquelle = 2; Effets secondaires persistant jusqu’à la 
fin de l’étude / intermittents, mais avec amélioration = 3; sujet décédé = 4; inconnu = 5. Notifier à l’IRSS qui va assister 
avec la prise en charge des effets secondaires graves 
‡‡ Date de guérison: Complète à J 28 – Si  les ES continuent d’évoluer jusqu’à la fin du suivi, coter  "5=inconnu». 
 
 
 
 
 
 
 
 
 
 
 
SUIVI INCOMPLET 
  Exclu  - Si oui, motif de l’exclusion: (Cocher une raison) Dernier jour de suivi _____ 
             Utilisation d’autres antimalariques: si oui, décrire__________________________ 
             Retrait de consentement éclairé 
             Maladies febrile concomitant, si oui diagnostic_____________________ 
             Perdu de vue 
             Erreur ou violation du protocole au cours du suivi ne permettant pas l’assignement d’un 
resultat_____________________________ 
 
 153 
 
 
 
Appendix 4 Adverse event enquiry form 
 
PHARMACOVIGILANCE (SUIVI au JOUR 3-7) 
 
 
 
 
 
 
 
 
 
 
 
Expliquez aux parents, particulièrement les mères que nous voulons connaitre ce qui ne va pas ou ce qui s’est aggravé chez 
l’enfant depuis l’administration des médicaments aux enfants.  
Vous devez interroger la personne qui traitait l’enfant dans la concession.  
L’enfant est il présentement malade ou a-t-il été malade ces 3 derniers jours?  Oui |__| Non |__| Nsp |__| Température : 
|__|__|.|__|°C 
Si Oui, cochez chaque symptôme et précisez sa durée et sa sévérité: 
Symptômes Cochez* Date de début:                                      Date de notification 
Histoire fébrile (rapportée par la 
mère) 
|__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Maux de tête  |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Somnolence |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Vertiges |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Douleurs abdominales |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Perte d’appétit |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Nausées |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
vomissements |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Diarrhée  |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Toux |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Eruptions cutanées  |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Prurit (grattage) |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Ictère (yeux jaunes) |__| |__|__|/|__|__|/|__|__|                           |__|__|/|__|__|/|__|__| 
Autres:    spécifiez_________________________     |__|__|/|__|__|/|__|__| 
 
* (1=oui, 2=non, 3=ne peut être apprécié) 
L’enfant a t il vomi ce jour ou lors de ces 3 derniers jours ?  Oui |__|   Non |__|  Nsp |__|   
Si oui, combien de fois |__|__| 
Commentaires: décrivez n’importe quel symptôme, qu’il soit modéré ou sévère, présenté par l’enfant et précisez en 
détails l’action prise pour juguler le mal. 
___________________________________________________________________________________ 
Quelle action a été prise ?______________________________________________________________ 
 
Si l’enfant est malade, référer le au poste de santé et informer le médecin de terrain de projet. 
 
 
 
 
 
 
Site ____________________________________    Nom de l’agent de  terrain_____________________________________ 
Numéro de randomisation : |__|__|__|__|__|-|__|   Nom de l’enfant _________________ _______    
Date de naissance |__|__| |__|__| |__|__|__|__|   ou  Age |__|__| années     Sexe |__| M/F 
Nom de la mère ________________________________________Mois  |__| (1=Aout, 2=septembre, 3=octobre) 
Date de visite: |__|__| |__|__| |__|__|__|__|    L’enfant est-il présent ?         Oui  |__|   Non  |__| 
Si Non, précisez pourquoi il est absent ____________________________________________________________________________ 
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L’enfant a-t-il reçu du TP ce mois? Oui |__|  Non |__|  NSP |__| 
Si oui, précisez la date mentionnée sur la carte  _____/_____/_________ 
Si non, pour quelle raison l’administration n’a pas été faite ?__________________________________ 
Nous voudrions maintenant avoir vos analyses sur le TPI administré à votre enfant : 
 
 1
ere
 dose 
 
 
L’enfant a-t-il reçu la première dose du TPI 
administré?  
|__| Oui/Non/Nsp 
Si oui, l’enfant a-t-il: (cochez la réponse) 
Bien avalé le médicament ? 
Avalé le médicament mais l’a aussitôt rendu? 
Refusé de prendre le médicament? 
 
|__| 
|__| 
|__| 
L’enfant a-t-il vomi après prise du médicament ? |__| Oui/Non/Nsp 
Si oui, la dose a-t-elle été re-administrée ? 
 
|__| Oui/Non/Nsp 2
eme
 dose 
J1 (à domicile par l’agent 
de terrain) 
3
eme
 dose 
J2 (à domicile par l’agent 
de terrain) 
Avez-vous administré les 2
nd
 et 3
eme
 doses ?   |__|  Oui/Non/Nsp 
  
|__|  Oui/Non/Nsp 
 
|__| Oui/Non/Nsp 
Si non, pour quelle raison?  
(Mentionnez la raison dans la case) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Si oui, l’enfant a-t-il: (cochez la réponse) 
Bien avalé le médicament ? 
Avalé le médicament mais l’a aussitôt rendu? 
Refusé de prendre le médicament? 
L’enfant  a-t-il craché le traitement?  
 
|__| 
|__| 
|__| 
 
|__| 
  
 
|__| 
|__| 
|__| 
 
|__| 
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Appendix 5 Active malaria case detection form 
 
Projet TPI Lena2009/Diagnostic et suivi de la morbidité 
(Chaque enfant devra être visité dans un délai de 14 jours suivant l’administration du TPI) 
 
1. Identification :    Date de la visite : ____/____/______/     
 
Round du TPI : Aout : |__| Septembre |__| Octobre |__|      
 
Date : ____/____/________ / 
 
Nom de l’enfant:___________________________________  ID |___| |___|___| |___|___|___| Sexe:  |___| M /F 
Date Naissance : ____/____/________  ou Age : |___|___| années  |___|___| mois 
Nom de la Mère :        ________________________________________________________________________ 
 
2. Examen clinique et para clinique 
Température axillaire: |___|___|. |___|
o
C  L’enfant se sent-il/elle bien aujourd’hui? |__| Oui /Non/NSP 
 
Symptômes lors des dernières 48 heures: (1=oui, 2=non, 3=ne sait pas) 
      Oui/Non/Nsp      Oui/Non/Nsp 
Histoire febrile    |__| 
Toux     |__| 
Difficulté respiratoire   |__| 
Convulsions    |__| 
Vomissements    |__| 
Diarrhée    |__| 
Eruption    |__| 
Autres Symptômes
  
 
Précisez : Si l’enfant est fébrile, (température axillaire non corrigée 37.50C) ou antécédents de fièvre 
dans les 48 dernières heures, faire si possible un prélèvement.  
 
Un TDR a-t-il été fait ?  Oui/Non  |__| Si oui, indiquez le résultat : Positif/Négatif/Ininterprétable 
|__|   
Si non, pourquoi? 
___________________________________________________________________________ 
 
 
La goutte épaisse a-t-elle été faite? Oui/Non  |__| (1=oui, 2=non) 
Si oui, indiquez le résultat (nb Pf par l): __________ Si non, pourquoi? 
________________________________ 
 
Une goutte épaisse sur papier buvard a-t-elle été recueillie ? Oui/Non  |__| (1=oui, 2=non) 
 
EN CAS DETDR NEGATIF, EN PRESENCE DE FIEVRE OU D’HISTOIRE FEBRILE, REFERER 
L’ENFANT A LA FORMATION SANITAIRE IMMEDIATEMENT 
Le traitement à administrer en cas de TDR positif est le Coartesiane sirop (La posologie du Coartesiane 
sera conforme à la fiche posologique contenue dans votre kit. 
 
 
L’enfant a-t-il/elle été référé(e) au centre de santé ?  Oui/Non  |__| (1=oui, 2=non) 
 
5. Nom et fonction du personnel soignant : ______________________________________________ 
 
Préciser aux parents que l’enfant doit être ramené au poste de santé si son état ne s’améliore pas. 
  
  
 
Appendix 6 Guide for signs, symptoms and biological results cotation 
Guide pour la cotation des symptômes, signes physiques et résultats de laboratoire 
Tableau A. Guide pour la cotation des symptômes du patient. 
 Grade 1 
MOYEN 
Grade 2 
MODERE 
Grade 3 
SEVERE 
Grade 4 
MENACE VITALE 
Histoire fébrile N/A Présent (Oui) N/A N/A 
Faiblesse Légère baisse de l’activité, 
asthénie pour les enfants, 
mais continue à jouer 
Diminution modérée de 
l’activité, asthénie et 
limitation des activités 
pour les enfants 
Non participation aux 
activités habituelles, 
Incapacité de jouer pour 
les enfants 
Prostration 
Douleur 
musculaire/ 
articulaire 
Plaintes moyenne et/ou 
localisée 
Douleur diffuse  Asthénie profonde, 
limitation des activités 
N/A 
Cephalees* Moyenne, ne nécessite pas de 
traitement 
Transitoire et modéré 
mais nécessite un 
traitement 
douleur sévère, constant; 
requiert un traitement 
narcotique 
Douleur très sévère nécessite 
un traitement narcotique 
régulier 
Anorexie Baisse de l’appétit mais 
accepte les aliments solides 
Baisse plus importante 
de l’appétit, admet les 
aliments liquides et 
évite les solides 
Appétit très diminué, 
refuse le lait évite les 
aliments liquide et solide 
(< 2 ans < 12 h; > 2 ans < 
24 h) 
Appétit très diminué, refuse 
le lait évite les aliments 
liquide et solide (< 2 ans > 
12 h; > 2 ans > 24 h) 
Nausée* Moyenne, transitoire, 
sensation d’envie de vomir. 
Peut toujours prendre les 
aliments 
Modérée et/ou envie 
constant de vomir, 
baisse de la prise 
alimentaire 
Sévère, constante envie de 
vomir avec baisse 
importante de la prise 
alimentaire 
N/A 
Vomissement 1 épisode par jour 2-3 épisodes par jour Hypotension  orthostatique 
ou réhydratation par voie 
veineuse 
Collapsus cardio vasculaire, 
requiert une réhydratation 
par voie intra veineuse 
Douleur 
abdominale * 
Moyenne (1-3 sur une échelle 
de 1 à 10) 
Modérée (4-6 sur une 
échelle de 1 à 10) 
Modérée à sévère (> 7 sur 
une échelle de 1 à 10 
Severe – nécessite un 
traitement 
Diarrhée Transitoire 3-4 selles liquides 
par jour 
5-7 selles liquides par 
jour 
Hypotension orthostatique 
ou > 7 selles liquides par 
jour ou nécessite de 
réhydratation intra 
veineuse 
Collapsus cardio vasculaire, 
requiert une réhydratation 
par voie intra veineuse 
Toux Transitoire / intermittent Persistent / constant Incontrôlée Cyanoses, stridor, baisse 
sévère de la capacité 
respiratoire 
Prurit Prurit transitoire Prurit perturbant le 
sommeil 
Prurit constant insomniant N/A 
Acouphènes* Mild, transient ringing or 
roaring sound 
Moderate, persistent 
ringing or roaring sound 
Severe ringing or roaring 
sound with associated 
hearing loss 
N/A 
Changement du 
comportement 
Difficulté de concentration, 
légère confusion ou agitation 
sans perturber les activités 
quotidienne ne requérant pas 
de traitement 
Confusion ou agitation 
modérées, limitation des 
activités quotidiennes, 
requiert un léger 
traitement 
Confusion sévère ou 
agitation; Besoin 
d’assistance pour les 
activités quotidiennes, 
nécessite un traitement 
Psychose toxique; Requiert 
hospitalisation pour prise en 
charge 
“Rhinite”  
(IRA viral) 
Légère congestion nasale, 
rhinorrhée moyenne 
Congestion nasale et 
rhinorrhée modérées 
N/A  N/A  
Reaction 
allergique 
N/A N/A Urticaire urticaire severe   
choc anaphylactique, 
angioeodeme 
Convulsion N/A N/A Crises localisées ou 
généralisées 
Crises épileptiformes 
* Evaluer seulement pour les enfants de plus de 3 ans.   N/A pour les moins de 3 ans ou incapable de répondre 
 
Référence – Base sur l’échelle de toxicité de l’OMS pour déterminer la sévérité des effets secondaires 
  
 
Table B. Guide pour les signes physiques 
Déshydratation Apprécier l’état de la peau, les muqueuses, les globes oculaires, la fontanelle, le pouls, et les urines 
Jaunice Rechercher une coloration jaune de la sclera, les conjonctives les téguments et la peau 
Thorax Apprécier la respiration: rythme, profondeur, et un éventuel effort respiratoire. Rechercher une cyanose. 
Rythme respiratoire maximal acceptable selon l’âge: < 2 mois = 60, 2-12 mois = 50, 1-5 ans = 40, > 5 ans = 30. 
Inspecter le cou pour apprécier la position de la trachée, une éventuelle rétraction supra claviculaire et une 
contracture du muscle sterno mastoïdien ou des autres muscles respiratoires accessoires. 
 Inspecter a la recherche d’une déformation évidente, palper a la recherche d’une crépitation neigeuse et percuter 
a la recherche de zones d’hyper sonorité. 
Ausculter la région antérieure et postérieure du thorax a la recherche de bruits respiratoires normaux et tout autre 
bruit surajoutés: Râles crépitant, sous crépitant, sibilants, ronchus.   
En cas d’anomalies évaluer le degré  
Abdomen Inspecter et ausculter l’abdomen.  Rechercher les bruits (borborygmes) avant toute palpation. Listen for bowel 
sounds in the abdomen before palpating it.  Palper tous les quadrants de l’abdomen superficiellement et 
profondément. Evaluer la taille du foie et de la rate. 
Rechercher des signes d’inflammation ou d’irritation péritonéale: Baisse de la mobilité intestinale, une défense 
abdominale, une contracture localisée ou généralisée ou une rigidité.  
Peau Inspecter la peau: couleur, rougeur, lésion évidente. En présence de lésions noter leur localisation, distribution 
(localisée ou diffuse), type (macules, papules, vésicules) et leur couleur.   
Tablet test Pour les enfants > 9 mois, demander à l’enfant de prendre un objet posé sur une surface plane avec le pouce ou 
l’indexe (bic par exemple).  Ce test pour apprécier la coordination des extrémités distales évalue la fonction 
motrice, le système vestibulaire (coordination des yeux et des mouvements du corps), le cerceau et le système 
sensoriel.  Attention : Pendant ce test soyez attentif car l’enfant a tendance à tout emporter à la bouche 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
Table C.  Grading Physical Examination Findings 
 Grade 1 
MOYEN 
Grade 2 
MODERE 
Grade 3 
SEVERE 
Grade 4 
MENACE VITALE 
Temperature* 
(axilaire) 
37.5-37.9C 38.0-39.5C > 39.5C Fièvre continue, >  40.0C 
pendant plus de 5 jours 
Déshydratation Less than 2 of the 
following: 
Restless, irritable 
Sunken eyes 
Drinks eagerly, thirsty 
Skin pinch goes back 
slowly 
2 of the following: 
Restless, irritable 
Sunken eyes 
Drinks eagerly, thirsty 
Skin pinch goes back 
slowly 
Deux des signes suivants: 
Léthargie ou inconscience 
Yeux secs (enfoncement 
des globes oculaires) 
Incapacité de boire ou 
boisson très limitée. 
Pli cutané s’effaçant très 
lentement 
Deux des signes suivants  + 
choc: 
Léthargie ou inconscience 
Yeux sec avec enfoncement 
des globes oculaires 
Incapacité de boire ou boisson 
très limitée. 
Pli cutané s’effaçant très 
lentement 
Jaunice Légère coloration jaune 
des conjonctives et de la 
sclère 
Coloration jaune modérée 
de la sclère, des 
conjonctives et des 
téguments 
Ictère flamboyant des 
conjonctives et de la 
sclère, coloration jaune de 
la peau 
N/A 
Thorax Légère augmentation de 
la fréquence respiratoire 
(pour l’âge, 
température), bruits 
anormaux transitoires 
ou localises 
Augmentation modérée 
de la fréquence, 
persistance de bruits 
anormaux diffus 
Fréquence respiratoire 
rapide (< 2 mois > 60, 2-
12 mois > 50, 1-5 ans > 
40, adultes > 30)* 
mouvement des ailes du 
nez 
Cyanose 
Abdomen Bruits normaux, 
réaction abdominal 
localisée et/ou foie 
palpable a 2-4 cm au 
dessous de rebord costal 
droit et/ou une rate 
palpable et/ou une 
hernie ombilicale 
Bruits normaux ou 
légèrement anormaux, 
réaction abdominale 
modérée, hépatomégalie 
modérée (4-6 cm sous le 
rebord costal droit) et/ou 
une splénomégalie palpée 
a mi chemin entre 
l’ombilic et la symphyse 
pubienne 
Contracture abdominale 
Signes évidents 
d’irritation péritonéale 
avec une hépatomégalie 
importante (> 6 cm sous 
le rebord costal droit) 
et/ou une rate en dessous 
d’une ligne passant a mi 
chemin entre l’ombilic et 
la symphyse pubienne 
Absence de mouvements 
intestinaux. Rigidité 
abdominale 
Peau† Rash cutané localisé, 
érythème ou prurit 
Reaction maculo 
papuleuse diffuse, peau 
desquamant 
Présence de vésicules, 
desquamation cutanée 
plus importante, 
ulcération cutanée. 
Dermatose exfoliative ou 
érythème multiforme ou 
suspicion de syndrome de 
Stevens-Johnson ou nécrose 
nécessitant une intervention 
chirurgicale 
 
 Grade 1 
MOYEN 
Grade 2 
MODERE 
Grade 3 
SEVERE 
Grade 4 
MENACE VITALE 
Audition < 4 ans: N/A 
> 4 ans: Baisse de 
l’audition au niveau d’une 
oreille 
< 4 ans: N/A 
> 4 ans: Baisse de 
l’audition au niveau au 
niveau des deux oreilles 
ou baisse sévère au 
niveau d’une oreille 
< 4ans: Pas d’évidence 
de baisse de l’audition 
> 4 ans:  Baisse très 
importante de l’audition 
au niveau des deux 
oreilles 
N/A 
Tablet test Difficulté à prendre 
l’objet mais parvient 
quand même à le prendre 
Incapable de prendre un 
objet sans qu’il ne 
retombe  
Incapable de prendre un 
objet 
N/A 
Autres signes 
cliniques 
Ne nécessite pas un 
traitement; surveillance 
du signe 
Besoin de traitement Besoin de traitement et 
d’une éventuelle 
hospitalisation 
Requiert une intervention 
médicale active, voire une 
hospitalisation 
Référence – The Harriet Lane Handbook, 15th edition, 2000 
† Référence – Echelle de cotation de la sévérité des effets secondaires de l’OMS 
 
 
  
  
 
 
TABLE D.   Guide pour la cotation des anomalies de Laboratoire (taux d’hémoglobine) 
 Grade 1 
MOYEN 
Grade 2 
MODERE 
Grade 3 
SEVERE 
Grade 4 
MENACE VITALE 
Hémoglobine 
(g/dL) 
9.0 – 9.9 7.0 – 8.9 5.0 – 6.9 < 5.0 
 
 
Critères de paludisme grave/Signes de Danger 
 
Paludisme grave 
 Coma (si après convulsions, > 30 min) 
 Convulsions répétées (> 2 en 24 h) 
 Anemie sévère (Hb < 5.0 g/dL) 
 Détresse respiratoire (dyspnée de repos) 
 Ictère coloration jaune des yeux) 
 
Signes de danger 
 Convulsions récentes (1-2 en 24 h) 
 Altération de la conscience  (confusion, delirium, psychose) 
 Léthargie 
 Incapacité de boire ou de téter 
 Vomissements incoercibles 
 Incapacité de s’assoir / se tenir debout du fait  de l’asthénie 
 
  
  
 
Appendix 7 Weight based dose of the study drugs 
Amodiaquine (AQ) 
Poids par kg Nombre de cuillères mesures par jour   
5.0-5.6 1cuillere mesure + ¼ 
5.7-7.5 1cuillere mesure + ½ 
7.6-8.7 1cuillere mesure + ¾ 
8.8-10 2 cuillere measures 
10.1-10.7 2 cuillères-mesures + ¼ 
10.8-12.5 2 cuillères-mesures + ½ 
12.6-13.7 2 cuillères-mesures + ¾ 
13.8-15 3 cuillères-mesures 
15.1-15.7 3 cuillères-mesures + ¼ 
15.8-17.5 3 cuillères-mesures + ½ 
17.6-18.7 3 cuillères-mesures + ¾ 
18.8-20 4 cuillères-mesures 
20.1-20.7 4 cuillères-mesures + ¼ 
20.8-22.5 4 cuillères-mesures + ½ 
22.6-23.7 4 cuillères-mesures + ¾ 
23.8-25 5 cuillères-mesures 
25.0-25.7 5 cuillères-mesures + ¼ 
25.8-27.5 5 cuillères-mesures + ½ 
27.6-28.7 5 cuillères-mesures + ¾ 
28.8-30 6 cuillères-mesures 
30-30.6 6 cuillères-mesures + ¼ 
30.7-32.5 6 cuillères-mesures + ½ 
32.6-33.7 6 cuillères-mesures + ¾ 
33.8-35.0 7 cuillères-mesures 
35.1-35.6 7 cuillères-mesures + ¼ 
35.7-37.5 7 cuillères-mesures + ½ 
37.6-40.0 5 cuillères-mesures 
 
 
 
 
 
 
 
 
  
  
 
Sulfadoxine-pyrimethamine (SP) 
Poids en kg Nombre de comprimés 
5.0-7.4 ¼ 
7.5-12.4 1/2 
12.5-17.4 3/4 
17.5-22.4 1 
22.5-27.4 1 1/4 
27.5-32.4 1 1/2 
32.5-36.2 1 3/4 
 
Dihydroartemisinin-Piperaquine (DHAPQ) 
Poids en kg Nombre de comprimés par jour 
5-7.1 1/4 
7.2-11.9 1/2 
12.0-16.6 3/4 
16.7-21.4 1 
21.5-26.1 1 1/4 
26.2-30.9 1 1/2 
31.00-35.70 1 3/4 
35.8-36.2 2 
 
  
 
Appendixe 8 Pharmacokinetics of sulfadoxine 
A clinical study was carried out to assess the pharmacokinetics of Sulfadoxine-pyrimethamine 
and amodiaquine when used for SMC. Drug measurement was done using HPLC for sulfadoxine 
(Appendix 8) but no peak of drug was detected for Amodiaquine. 
1 Baseline characteristics of the enrolled patient. 
 
A total of 150 children were enrolled and followed up over 28 days; the percentage of 
compliance at each scheduled visit was very high: 98.7% (148/150) for the second sample visit, 
94.7% (142/150) for the third and 90% (135/150) for the last visit. The study was conducted in 
May-June 2011 in an area of low incidence of malaria and no slide was positive for Plasmodium 
falciparum. Other characteristics are described in the table 27. 
 
Table 0-1: Characteristics of patients treated with SP at entry  
 6 months 6-11 months 12-23 
months 
24-35 
months 
36-47 
months 
48-59 
months 
Population 10 21 40 17 43 19 
Male n (%) 6 (60%) 13 (62%) 16 (40%) 8 (47%) 21 (49%) 12 (63%) 
Mean temperature 
(°C) 
36.4 36.6 36.5 36.5 36.4 36.7 
Mean Weight in 
kilogram (sd)  
7.2 8.6 9.1 10.9 12.0 14.0 
Mean Height in cm 
(sd) 
66.2 71 75.9 86.2 91.6 98.1 
Dose in mg/kg 
(Mean) 
33.4 
(25-41.7) 
31.8 
(25.41.7) 
29.6 
(24.8-41.7) 
28.9 
(24.5-41.7) 
29.3 
(23.8-34.1) 
28.7 
(24.2-34.1) 
 
2 Treatment dosage characteristics in different groups of age 
Table 28 Treatment characteristics 
 
Mean dose Median 
dose 
IQR Range Under-dosed  
(<25mg/kg/day) 
Target range  
(25-70 mg/kg/day)  
Age group      N % N % 
<=6 months 33.4 35.7 13.5 16.7 0                   0% 10    100% 
7-11 months 31.8 31.3 5.6 16.7 0    0% 21 100% 
12-23 months 29.6 28.1 3.4 16.9 1       2.5% 39     97.5% 
  
 
24-35 months 28.9 28.8 6.0 17.2 3       17.6% 14 82.4% 
36-47 months 29.3 28.8 4.5 10.3 4 9.3% 39 90.7% 
48-59 months 28.7 28.8 5.4 9.9 1 5.3% 18 94.7% 
Total 29.9 29.2 4.5 17.9 9           6%    141                 94% 
 
The mean dose of SP administrated was 29.9 mg per kilogram body weight; the targeted dose is 
25-70 mg per kilogram body weight; only 6% of the children were under-dosed (table 28).  
 
3 The dosage given in mg per kg and the age 
Children aged 6 months received the higher dosage of drug in mg per kg and this dosage was 
slightly less in those aged 24 to 36 months; but overall none was over-dosed (figure 16).  
 
Figure 16 Distribution of dose in mg per kg and the group of age in months 
4 Relationship between Sulfadoxine concentration in mg/ml and the age in months 
 
Sulfadoxine concentration on days 1-5 was higher in old age group (24-35 months and 48-59 
months) and lower in the participant 7-11 months. The same pattern was seen with the next 
window of sampling but the concentration was lesser in the 12-24 months children. Over the last 
window, the drug concentration was almost null in two age groups, those under 6 months and 
those in the 24-35 months group (figure 17). 
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Figure 17 Distribution of sulfadoxine concentration and age groups 
 
5 Sulfadoxine concentration in mg/ml and dose in mg per kg 
6 Measure of amodiaquine 
Samples were collected for deshetylamodiaquine concentratiom measurement. 
Unfortunately no drug was detected during the analysis with the HPLC.  
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Appendixe 9: Alternative drug regimen for SMC 
1. Sulfadoxine-Pyrimethamine plus Piperaquine (SP+PQ) 
This combination is ideal for SMC in regard of the long half-life of the two partners and the 
objective of the SMC which is to clear the existing parasites while preventing the acquisition of 
new ones (prophylactic effect). SPPQ has been trialled in Senegal and in The Gambia (Bojang et 
al. 2010) and in Senegal (Cisse et al., 2009). The combination was as effective as or even better 
than SPAQ and better tolerated. The disadvantages of this regimen are that (i) it does not exist as 
co-formulated and (ii) the partner SP suffers from loss of efficacy in areas of East Africa. Future 
research are needed to investigate the efficacy of co-formulated regimen ideally given as a single 
dose (like SP) to maximise the efficacy, the adherence and protect each of the component as 
longer as possible.  
2. Artemether-Lumefantrine  
Artemether-Lumefantrine is another ACT not primarily suitable for use in SMC for similar 
reasons as for the DHAPQ. Artemether-lumefantrine is a highly effective anti-malarial as 
demonstrated in efficacy trials through endemic countries of Africa and Asia (Katrak et al., 
2009, McGready et al., 2008, Nambozi et al., 2011). However the post treatment prophylactic 
effect is very limited due to the relatively short half-life of Lumefantrine (14 days) allowing 
recurrence of parasites few weeks following the initiation of a therapy with artemether-
lumefantrine (Zongo et al., 2007b) AL might be used for SMC only in areas of low transmission 
and probably the timing would be reduced to every three weeks owning most frequent adverse 
events.  
3. Mefloquine-artesunate (AS-MQ) 
AS-MQ is a combination used for the first line treatment of malaria in the Cambodia border 
since 2000 at the dose of 12 mg per kg of Artesunate and 20 mg/kg of mefloquine or a maximum 
total of 600 mg of Artesunate and 1000 mg of mefloquine; by 2002 emergence of resistance 
restricted its use to the in Eastern Cambodia and in Thailand (Carrara et al., 2009, Rogers et al., 
2009). With the introduction of ACTs in the treatment of malaria there was renew of interest in 
the combination Mefloquine plus Artesunate (MQ-AS) and series of studies in Asia reported the 
combination is effective for the treatment of uncomplicated falciparum malaria owning more 
frequent adverse events (Mayxay et al., 2006, Smithuis et al., 2006). An efficacy study 
conducted in patients with uncomplicated falciparum malaria in Benin showed a high efficacy of 
MQ-AS with a good tolerance profile (Massougbodji A, 2002). Mefloquine in monotherapy is 
  
 
now being considered as a possible alternative to the failing monotherapy with sulfadoxine-
pyrimethamine for the intermittent preventive treatment of malaria in pregnancy (Denoeud-
Ndam L, 2012). Artesunate is safe in the second and third trimester of the pregnancy and its use 
in combination with mefloquine may be an option to protect mefloquine; of note Artesunate 
appears to decrease the maximum mefloquine concentration and its half-life (Karbwang et al., 
1994).  From there we can argue for the investigation of MQ-AS for a possible replacement of 
SPAQ for the SMC in children less than 5 years old in the Sahel and Sub-Sahel region. 
4. Mefloquine plus Sulfadoxine-Pyrimethamine (MQ-SP) 
An old study comparing the efficacy of MQ-SP (Fansimef®) and SP (Fansidar®) in Zambian 
adults with symptomatic malaria reported better efficacy with MQ-SP compared to SP alone and 
the side effects was common in both groups(Ekue JM, 1987); in a phase I safety and tolerance 
study of mefloquine adult Brazilian adverse events included dizziness, nausea, vomiting that 
were mild and did not require specific care (de Souza JM, 1987). These studies are precursors 
and may serve a baseline for further investigation about the potential of this combination for the 
SMC in replacement to SPAQ. 
The alternative drug regimen to consider in a given area should account for the current lines for 
the treatment of acute malaria and avoid being the similar regimen as this will increase the drug 
pressure and may contribute to speed the spread of drug resistance. Furthermore, the potential 
replacement should be easier of use, preferably as a single dose once, finally very well tolerated 
and accessible.  
 
